Download REFERENCES
Transcript
614 Christopher C. Hardwick et al. Table 5. Compound RB LC 2KF 4KF FMF RB and photoproducts in normal, untreated blood Concentration (nM) average (range) 23.9 11.4 2.0 1.2 5.0 (8.6â79.6) (0.0â75.3) (0.9â3.4) (0.5â2.4) (1.7â11.5) Hustad has reported a value of 6.9 nM (2.7â42.5 nM) for RB concentration in plasma (n 5 63) (37). In a later report, Hustad reported the average RB concentration in the plasma of 124 senior citizens as 15.3 nM (5.4â28.4 nM) (25). Capo-chichi reported in 2000 that the median concentration of RB in 10 infants and 10 adolescents to be 20.9 nM (12.7â53.4) and 18.5 nM (8.2â57.8), respectively (25). We now report for n 5 30, an average value of 23.9 nM (8.6â79.6 nM) (Fig. 3). The higher mean value observed in this study might be a reflection of the fact that no additional protein precipitation or extraction step was required in this procedure resulting in higher retention of starting levels of RB, or might be due to partial leakage of erythrocytes still present in the buffy coat platelet products. Photolysis of RB during the MIRASOL process results in the formation of four photoproducts: 2KF, 4KF, FMF and LC. These four photoproducts were found to be present in apheresis platelets that had not undergone any photochemical treatment, although at a much lower concentration (Table 5, Fig. 4). It is also important to note in this context that the concentrations measured in the platelet products will be diluted by a factor of 16- to 20-fold upon infusion of the products into a patientâs blood stream, thus lowering the difference between concentrations determined in these products and the levels naturally circulating in blood. The demonstration of the existence of these agents in naturally occurring blood products suggests that the introduction of a RB-based PRT process will not introduce new agents into the blood supply, which are not already present to some extent. The consequence of increased levels of these agents in blood products resulting from this process is being evaluated in separate toxicology studies, which include short-term and long-term exposure to each of the agents described and Figure 4. HPLC photochemical profile generated during treatment of 50 lM RB in apheresis platelet concentrates (MIRASOL-treated apheresis platelet concentrates) overlaying the photochemical profile generated by direct measurement of a sample of untreated apheresis platelets. characterized in this study (38â45). The presence of these agents in our blood, the ubiquitous nature of RB exposure, its presence in our diets and our ability to metabolize it and manage its inherent photochemistry suggests a low risk profile for this product. These features in combination with the pathogen reduction capacity of this system have the potential to greatly enhance the safety of blood products presently offered in routine clinical practice. AcknowledgementsâThe authors acknowledge support in part by the following: Laboratories at Bonfils, Inc. (717 Yosemite Street, Denver, CO 80230) for the collection of apheresis platelets; Gambro BCT (10811 West Collins Avenue, Lakewood, CO 80215); Dr. Donald B. McCormick, Ph.D., Fuller E. Callaway Professor of Biochemistry, Department of Biochemistry, School of Medicine, Emory University, Atlanta, GA 30322-3050. Kristin E. Bjorgo, Navigant Biotechnologies, for help in preparing the manuscript. REFERENCES 1. Curran, J. W. and D. N. Lawrence (1984) AIDS associated with transfusion. N. Engl. J. Med. 310, 69â75. 2. Warburg, O. and W. Christian (1932) Uber das neue oxydationsferment. Naturwissenschaften 20, 980. 3. Speck, W. T., S. Rosenkranz and H. S. Rosenkranz (1976) Further observations on the photooxidation of DNA in the presence of Riboflavin. Biochim. Biophys. Acta 435, 39â44. 4. Kuratomi, K. and Y. Kobayashi (1977) Studies on the interactions between DNA and flavins. Biochim. Biophys. Acta 476, 207â217. 5. Olsen, J. H., H. Hertz, S. K. Kjaer, A. Bautz, L. Mellemkjaer and J. D. Boice Jr. (1996) Childhood leukemia following phototherapy for neonatal hyperbilirubinemia (Denmark). Cancer Causes Control 7, 411â414. 6. Sisson, T. R., N. Kendall, E. Shaw and L. Kechavarz-Oliai (1972) Phototherapy of jaundice in the newborn infant. II. Effect of various light intensities. J. Pediatr. 81, 35â38. 7. Sisson, T. R. (1987) Photodegradation of Riboflavin in neonates. Fed. Proc. 46, 1883â1885. 8. Sisson, T. R., B. Slaven and P. B. Hamilton (1976) Effect of broad and narrow spectrum fluorescent light on blood constituents. Birth Defects Orig. Artic. Ser. 12, 122â133. 9. Boadi, W. Y., L. Thaire, D. Kerem and S. Yannai (1991) Effects of dietary supplementation with vitamin E, Riboflavin and selenium on central nervous system oxygen toxicity. Pharmacol. Toxicol. 68, 77â82. 10. Webster, R. P., M. D. Gawde and R. K. Bhattacharya (1996) Modulation of carcinogen-induced DNA damage and repair enzyme activity by dietary Riboflavin. Cancer Lett. 98, 129â135. 11. Bates, C. J. (1987) Human Riboflavin requirements, and metabolic consequences of deficiency in man and animals. World Rev. Nutr. Diet 50, 215â265. 12. Corbin, F. III. (2002) Pathogen inactivation of blood components: current status and introduction of an approach using Riboflavin as a photosensitizer. Int. J. Hematol. 76(Suppl. 2), 253â257. 13. Goodrich, R. and M. S. Platz (1997) The design and development of selective, photoactivated drugs for sterilaization of blood products. Drugs Future 22, 159â171. 14. Ruane, P. H., R. Edrich, D. Gampp, S. D. Keil, R. L. Leonard and R. P. Goodrich (2004) Photochemical inactivation of selected viruses and bacteria in platelet concentrates using Riboflavin and light. Transfusion 44, 877â885. 15. Treadwell, G. E., W. L. Cairns and D. E. Metzler (1968) Photochemical degradation of flavins V. Chromatographic studies of the products of photolysis of Riboflavin. J. Chromatogr. 35, 376â388. 16. Cairns, W. L. and D. E. Metzler (1971) Photochemical degradation of flavins. VI. A new photoproduct and its use in studying photolytic mechanism. J. Am. Chem. Soc. 93, 2772â2777. 17. Oka, M. and D. B. McCormick (1985) Urinary lumichrome-level catabolites of Riboflavin are due to microbial and photochemical events and not rat tissue enzymatic cleavage of the ribityl side chain. J. Nutr. 115, 496â499. 18. Smith, E. C. and D. E. Metzler (1963) The photochemical degradation of Riboflavin. J. Am. Chem. Soc. 85, 3285â3288. 329 Photochemistry and Photobiology, 2004, 80 19. Song, P. S. and D. E. Metzler (1967) Photochemical degradation of flavins-IV. Studies of the anaerobic photolysis of Riboflavin. Photochem. Photobiol. 6, 691â709. 20. Halwer, M. (1951) The photochemistry of Riboflavin and related compounds. Dissertation 73, 4870â4874. 21. Speek, A. J., F. van Schaik, J. Schrijver and W. H. Schreurs (1982) Determination of the B2 vitamer flavinâadenine dinucleotide in whole blood by high-performance liquid chromatography with fluorometric detection. J. Chromatogr. 228, 311â316. 22. Ichinose, N., K. Adachi and G. Schwedt (1985) Determination of B2 vitamers in serum of fish using high-performance liquid chromatography with fluorescence detection. Analyst 110, 1505â1508. 23. Zempleni, J., J. R. Galloway and D. B. McCormick (1996) The identification and kinetics of 7 alpha-hydroxyriboflavin (7-hydroxymethylriboflavin) in blood plasma from humans following oral administration of Riboflavin supplements. Int. J. Vitam. Nutr. Res. 66, 151â157. 24. Zempleni, J. (1995) Determination of Riboflavin and flavocoenzymes in human blood plasma by high-performance liquid chromatography. Ann. Nutr. Metab. 39, 224â226. 25. Hustad, S., M. C. McKinley, H. McNulty, J. Schneede, J. J. Strain, J. M. Scott and P. M. Ueland (2002) Riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose Riboflavin supplementation. Clin. Chem. 48, 1571â1577. 26. Lopez-Anaya, A. and M. Mayersohn (1987) Quantification of Riboflavin, Riboflavin 59-phosphate and flavin adenine dinucleotide in plasma and urine by high-performance liquid chromatography. J. Chromatogr. 423, 105â113. 27. Capo-chichi, C. D., J. L. Gueant, F. Feillet, F. Namour and M. Vidailhet (2000) Analysis of Riboflavin and Riboflavin cofactor levels in plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 739, 219â224. 28. Floridi, A., C. A. Palmerini, C. Fini, M. Pupita and F. Fidanza (1985) High performance liquid chromatographic analysis of flavin adenine dinucleotide in whole blood. Int. J. Vitam. Nutr. Res. 55, 187â191. 29. Johansen, K. and P. O. Edlund (1990) Determination of water-soluble vitamins in blood and plasma by coupled-column liquid chromatography. J. Chromatogr. 506, 471â479. 30. Roughead, Z. K. and D. B. McCormick (1990) Flavin composition of human milk. Am. J. Clin. Nutr. 52, 854â857. 31. Roughead, Z. K. and D. B. McCormick (1990) Qualitative and quantitative assessment of flavins in cowâs milk. J. Nutr. 120, 382â388. 32. Oka, M. and D. B. McCormick (1985) Urinary lumichrome-level catabolites of Riboflavin are due to microbial and photochemical events and not rat tissue enzymatic cleavage of the ribityl chain. J. Nutr. 115, 496â499. 330 615 33. Zempleni, J., G. Link and W. Kubler (1992) The transport of thiamine, Riboflavin and pyridoxal 59-phosphate by human placenta. Int. J. Vitam. Nutr. Res. 62, 165â172. 34. Zempleni, J., J. R. Galloway and D. B. McCormick (1996) Pharmacokinetics of orally and intravenously administered Riboflavin in healthy humans. Am. J. Clin. Nutr. 63, 54â66. 35. Fall, H. F. and H. G. Petering (1956) Metabolite inhibitors. I. 6,7dimethyl-9-formylmethylisoalloxazine, 6,7-deimethyl-9-(29-hydroxyethyl)-isoalloxazine and derivatives. J. Am. Chem. Soc. 78, 377â380. 36. [USP] United States Pharmacopeia (2003) MD Validation of Compendial Methods. In USP-NF26. (Edited by USP Compendial Committee), pp. 2439-2442. USP, Rockville, MD. 37. Hustad, S., P. M. Ueland and J. Schneede (1999) Quantification of Riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in human plasma by capillary electrophoresis and laser-induced fluorescence detection. Clin. Chem. 45, 862â868. 38. Piper, J., S. Murphy, R. Schuyler, R. Haynes and A. Wilson (2002) Assessment of the acute toxicity and genotoxicity risks associated with lumichrome, the primary photoproduct of Riboflavin. Vox Sang. 83, 192. 39. Piper, J. T., S. E. Murphy, R. S. Schuyler, R. Haynes and A. Wilson (2001) Evaluation of the acute toxicity and genotoxicity risks associated with the Riboflavin photoproduct lumichrome. Transfusion 41, 90S. 40. Piper, J., E. Hansen, M. Woolum, D. Gampp, L. Goodrich and G. Goodrich (2001) Evaluation of the genotoxicity and acute toxicity risks associated with a Riboflavin based pathogen inactivation process. Int. J. Toxicol. 20, 404. 41. Piergiorgio, P. and A. Calatroni (1982) Hydrolysis of Riboflavin nucleotides in plasma monitored by high performance liquid chromatography. J. Chromatogr. 229, 445â449. 42. Baeckert, P. A., H. L. Greene, I. Fritz, D. G. Oelberg and E. W. Adcock (1988) Vitamin concentrations in very low birth weight infants given vitamins intravenously in a lipid emulsion: measurement of vitamins A, D, and E and Riboflavin. J. Pediatr. 113, 1057â1065. 43. Chastain, J. L. and D. B. McCormick (1987) Clarification and quantitation of primary (tissue) and secondary (microbial) catabolites of Riboflavin that are excreted in mammalian (rat) urine. J. Nutr. 117, 468â475. 44. Chastain, J. L. and D. B. McCormick (1988) Characterization of a new flavin metabolite from human urine. Biochim. Biophys. Acta 967, 131â134. 45. Chastain, J. L. and D. B. McCormick (1987) Flavin catabolites: identification and quantitation in human urine. Am. J. Clin. Nutr. 46, 830â834. æç®23 Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation Heather L. Reddy, Anthony D. Dayan, Joy Cavagnaro, Shayne Gad, Junzhi Li, and Raymond P. Goodrich The Mirasol PRT System (Gambro BCT, Lakewood, CO) for platelets and plasma uses riboflavin and UV light to reduce pathogens and inactivate white blood cells in donated blood products. An extensive toxicology program, developed in accordance with International Organisation for Standardisation (ISO) 10993 guidelines, was performed for the Mirasol PRT system. Test and control articles for most of the reported studies were treated (test) or untreated (control) blood products. For some studies, pure lumichrome (the major photoproduct of riboflavin) or photolyzed riboflavin solution was used. Systemic toxicity was evaluated with in vivo animal studies in the acute and subchronic settings. Developmental toxicity was evaluated with an in vivo animal study. Genotoxicity and neoantigenicity were evaluated with in vitro and in vivo tests. Hemocompatibility and cytotoxicity were assessed with standard, in vitro assays. The pharmacokinteics, excretion, and tissue distribution of 14 C-riboflavin and its photoproducts was evaluated with an in vivo animal study. The possible presence of leachable or extractable compounds (from the disposable set) was evaluated with novel assays for measuring these compounds in blood. No treatment-related toxicity was observed in any of the studies. C 2008 Elsevier Inc. All rights reserved. HE COLLECTION, SEPARATION, and transfusion of red blood cells, platelets, plasma, and fractionated plasma components are essential medical practices, often required for the preservation of life and for the treatment of disease. Although the transfusion of these components is a vital therapy, transfusions are still associated with some risk for transmission of disease to the patient. Bacteria, viruses, and parasites are all potential sources of infection that have been transmitted by allogeneic transfusions.1 Residual donor white blood cells (WBCs) can cause a series of severe immune responses in a transfusion recipient, resulting in the failure of the transfusion or other complications as a result.2-4 Prion-transmitted diseases are also a recent and growing concern owing to the potential transfusion-mediated transmission of variant Creutzfeldt-Jakob disease (vCJD).5-8 A number of safety measures have been taken to reduce the risk of disease transmission. They include increased diligence in preparing the donor's arm before donation and diversion of the first portion of blood from the donor to decrease the risks of bacterial contamination of the blood product.9 Decreasing the risk of bacteria-related morbidity and mortality in recipients was also the driver for the reduction in storage time for platelets from 7 to 5 days.10 Additional approaches to prevent disease transmission include the use of questionnaires to screen donors and thereby minimize the risks of collecting blood with viral or other diseases, the use of antibody testing and nucleic acid testing to detect viruses, and the use of culture techniques to detect bacteria.1,11 γ-Irradiation has been used to reduce the possibility of transfusionassociated graft-vs-host disease (GVHD) in susceptible patient populations.12 Leukoreduction has also been adopted in some parts of the world to reduce the possibility of prion transmission.13 Despite the use of the various approaches, as outlined, transfusion-transmitted infection from agents such as HIV, hepatitis B virus, hepatitis C virus, and bacteria continue.14-16 In part, these events arise from the inability of available tests to detect agents in blood at low levels, which are nonetheless infectious, or during a latent period. Risks related to transfusion-associated GVHD remain, primarily because γ-irradiation of blood components is not universally used. There are some infectious agents for which screening tests are not routinely used, notably Parvovirus B19; cytomegalovirus; and the causative agents of parasitic diseases such as Chagas disease, malaria, babesiosis, and leishmaniasis.17-19 The recent entry of West Nile virus (WNV) into the blood supply in North America is an example of the emergence of a new T From Navigant Biotechnologies, Inc, Lakewood, CO; Access BIO, Boyce, VA; and Gad Consulting Services, Cary, NC. A.D.D. is an Independent Consultant in London, UK Current affiliation for J.L.: Thermogenesis, Sacramento, CA. Address reprint requests to: Raymond Goodrich, PhD, Navigant Biotechnologies, Inc, 1215 Quail Street, Lakewood, CO 80215. Current affiliation for J.L.: Thermogenisis, Sacramento, CA. E-mail: ray.goodrich@navbio.com 0887-7963/08/$ - see front matter n 2008 Elsevier Inc. All rights reserved. doi: 10.1016/j.tmrv.2007.12.003 Transfusion Medicine Reviews, Vol 22, No 2 (April), 2008: pp 133-153 331 133 134 REDDY ET AL Table 1. Reported Toxicity Findings After Riboflavin Administration Species Route Results Acute Study type Mouse SC Acute Mouse IP Acute Acute Acute Acute Acute Subacute 4 d Subchronic 4-6 wk Rat Rat Rat Mouse Dog Mouse Rat IP SC Oral IV Oral SC Oral Chronic 22 mo Rat Oral Chronic 140 d Chronic 5 mo Developmental Rat Dog Rat Oral Oral Oral Reproduction Rat Oral Carcinogenicity Rat Oral Mouse Mouse Human CHL E coli TA1535, TA1537, TA1538, TA98, TA100 ± S9 activation TA100, TA102, TA98, TA97A; ± S9 activation, cecal cell-free extract Human IP Perioral Perioral Preincubation Preincubation Preincubation 1200 mg/kg: slight reduction in body temperature 2400 mg/kg: neuromuscular effects and mortalities LD50 = 340 mg/kg LD0 = 750 mg/kg LD50 = 560 mg/kg LD0 N 5000 mg/kg LD50 N 10000 mg/kg LD50 N 50 mg/kg NOAEL of 2000 mg/kg 2/6 Mortalities at 1000 mg × kgâ1 × dâ1 Increased liver enzymes at 2.0 mg × kgâ1 × dâ1 Mild liver cell hypertrophy at 1.5 mg × kgâ1 × dâ1 50 mg × animal × dâ1, no adverse effects 25 mg × kgâ1 × dâ1, no adverse effects During pregnancy and lactation NOAEL of 40 mg × kgâ1 × dâ1 3 Generations, NOAEL of 50 mg × animal × dâ1 1.5 mg × kgâ1 × dâ1 for 22 mo, no evidence of carcinogenicity Four doses at 1000 mg/kg, negative 100 mg/kg, negative 200 mg × kgâ1 × wkâ1 for 1 y, negative Negative Negative 10 ÎŒmol/plate, negative results Preincubation 25-100 ÎŒg/mL, negative results Micronucleus Micronucleus Micronucleus (oral mucosa) Clastogenesis Gene mutation Ames test S typhimurium Ames test S typhimurium Pharmacokinetics IV 11.6 mg/subject in bolus (242 mL) Cmax = 1209 nmol/L Disposition t1/2 = 0.1006 h Renal clearance t1/2 = 0.7385 h Ref 27 28,29 27 27 27 30 27 28 31 32 27 27 33 27 32 28 34 35 36 37 38 39 40 Abbreviations: SC, subcutaneous; IP, intraperitoneal; LD50, lethal dose at which 50% of the test population survives; LD0, lethal dose at which none of the test population survives; NOAEL, no observable adverse effect level; CHL, Chinese hamster lunch fibroblast cell line; Cmax, maximum concentration in the bloodstream; t1/2, time to reduction in concentration by 50%. agent for which testing was not readily available. Since the appearance of WNV in the United States, several cases of transfusion-related WNV infections have occurred.20 The low levels of WNV present in blood during a subject's subclinical viremia makes its detection difficult even with the most sensitive of the available nucleic acid testing technologies.21 Pathogen reduction via a chemical or photochemical process has also been used as a blood safety measure. Methylene blueâtreated and solvent/detergent-treated plasmas have been used as transfusion products, such as fresh frozen plasma (FFP), and in the manufacture of fractionated and purified blood-derived products such as factor VIII concentrate. These treatments are effective against enveloped viruses and yield only slight reductions in protein quality.22,23 Recently, a technology using a psoralen compound and UV light has been developed for the reduction of pathogens as well as the inactivation of leukocytes in platelets and in plasma.24-26 Similarly, the Mirasol PRT System (Gambro, BCT, Lakewood, CO) was developed to provide reduction of a wide variety of pathogens and inactivation of leukocytes. This device uses UV light and riboflavin to reduce pathogens. Riboflavin was chosen as a photochemical sensitizer because of its well-documented safety profile, as evidenced by 332 TOXICOLOGICAL REVIEW OF MIRASOL PRT 135 Fig. 1. Diagram of the steps involved with the use of the Mirasol PRT System. Platelets or plasma product in an illumination/storage bag is combined with riboflavin solution to achieve approximately 50 ÎŒmol/L and then exposed to 6.2 J/mL UV light. The treated product is then ready for clinical use or blood bank storage. Riboflavin remains in the treated blood product, no removal device is used. the reports referenced in Table 1. It is an essential nutrient for all living organisms, including humans. The novel nature of this pathogen reduction treatment (PRT) required comprehensive toxicological evaluation to prove that use of this technology to treat blood components would not introduce new hazards. The strategy, nature, and results of these toxicological studies are the subject of this review. or plasma product volumes ranging from 170 to 365 mL and platelet product cell concentrations ranging from 1100 to 2100 × 103/mL. The Mirasol PRT System reduces the infectivity of pathogens by 3 combined mechanisms. The first is the direct damage of nucleic acids of pathogens with the UV light source used in this system. The second is the damage of pathogen nucleic acids, proteins, and membranes by reactive oxygen species generated when riboflavin absorbs light and interacts with dissolved oxygen in solution. The Mirasol process was designed to minimize the contributions of this mechanism because of its nonspecific nature. The third is the damage of pathogen nucleic acid by the interaction of riboflavin with nucleic acids. Exposure of riboflavin to light when it is associated with or in proximity to nucleic acids leads to a Type I photochemical reaction that can induce oxidation of guanine residues and strand breaks. The result of this chemistry is irreversible damage to the nucleic acid.41 MIRASOL PRT SYSTEMâDESCRIPTION The Mirasol PRT System consists of an illuminator, the illumination/storage bag, and riboflavin solution (Fig 1). The Illumination/Storage bag is made of biocompatible materials and is adapted from the container used to collect and store platelet products obtained with the Trima automated blood collection device (Gambro, BCT). The sterile riboflavin solution contains riboflavin (500 ÎŒmol/L) in a 0.9% sodium chloride (NaCl) solution with pH adjusted with hydrochloric acid to be in the range of 4.0 to 5.0. A volume of 35 ± 5 mL of this solution is added to a blood component product to produce a final concentration of approximately 50 ÎŒmol/L. The illuminator delivers the necessary dose of UV light (6.2 J/mL) to the contents of the illumination bag based on product volume (derived from weight) and measured flux rate. Robustness studies demonstrated that the system is suitable for use with initial platelet MIRASOL PRT PHOTOCHEMISTRY Photolysis of riboflavin during treatment results in the formation of 4 major, quantifiable photoproducts: 2â²-ketoriboflavin, 4â²-ketoriboflavin, formylmethylflavin, and lumichrome. Several minor components are present in negligible quantities and 333 136 REDDY ET AL Table 2. Concentration of Riboflavin and Photoproducts in Treated and Untreated Platelets42 Untreated platelets (n = 30) Mirasol PRT platelets â (n = 30) Pretreatment â (ÎŒmol/L) Riboflavin Lumichrome 2-Ketoflavin 4-Ketoflavin Formylmethylflavin 48.33 ± 1.13 N (47.1-50.4) ¶ 0.23 ± 0.08 (0.1-0.3) ND ND ND Posttreatment â¡ (ÎŒmol/L) 38.68 2.90 1.27 0.53 1.99 ± ± ± ± ± 0.68 0.30 0.17 0.03 0.24 (38.0-39.9) (2.5-3.0) (1.10-1.49) (0.48-0.58) (1.63-2.32) Day 5, treated § (ÎŒmol/L) 39.65 3.60 0.71 0.16 1.72 ± ± ± ± ± 1.22 0.30 0.12 0.04 0.22 (37.0-41.3) (3.2-4.1) (0.59-0.90) (0.11-0.22) (1.42-2.07) nmol/L 23.9 # (8.6-79.6) 11.4 (0.0-75.3) 2.0 (0.9-3.4) 1.2 (0.5-2.4) 5.0 (1.7-11.5) Abbreviation: ND, not detected. â All studies for treated products were performed with and without γ-irradiation. No significant difference (Student t test, P b .05) was observed. â Platelet product with Mirasol riboflavin solution, before UV light exposure. â¡ Platelet product with Mirasol riboflavin solution, immediately after UV light exposure. § Platelet product with Mirasol riboflavin solution and UV light exposure, stored for 5 days at room temperature with agitation. N Mean ± 1 SD. ¶ Range of measured concentrations. # Mean. represent less than 1% of the total photoproduct peak areas. These minor components have been identified as isomers of the major components by analysis using high-pressure liquid chromatography followed by 2 stages of mass spectroscopy. Each of these 4 major photoproducts is a normal metabolite of riboflavin, and each has been detected in untreated apheresis platelets (Table 2), although at much lower concentrations than observed in Mirasol PRTâtreated platelets.42 The concentrations measured in Mirasol PRTâtreated blood products are diluted by a factor of 16- to 20-fold upon infusion of the products into a patient's blood stream (based on 250-300 mL infused into a subject of 5600 mL blood volume on average), thus reducing the concentrations toward the levels naturally circulating in the bloodstream. The existence of these photoproducts in freshly donated, nonilluminated blood products shows that a riboflavin-based PRT system will not introduce new chemicals into the blood supply. These photoproducts have been examined in earlier studies of riboflavin photolysis in various solutions. After exposure to light, decreased reactivity of the solutions was demonstrated.43-45 The results clearly show that conversion of riboflavin from its native form into the photoproducts leads to decreased reactivity of the solution owing to decreases in the extinction coefficients of the resulting solution (photobleaching). nonenveloped viruses as well as gram-negative and gram-positive bacteria.46 Prevention of GVHD due to WBC inactivation by the Mirasol PRT System has been studied both in vitro and in vivo.47,48 Parasite reduction studies have been conducted in collaboration with the Walter Reed Army Institute of Research and are the subject of separate publications.49,50 The results of these studies with bacteria, viruses, parasites, and WBCs demonstrate broad efficacy and capacity for the process in the reduction of pathogenic agents in blood components. Blood components treated with riboflavin and UV light exhibit satisfactory quality, as assessed by in vitro measurements.46,51,52 Initial studies on protein quality after treatment demonstrated adequate retention of coagulation factors, coagulation inhibitors, and immunoglobulins, all at levels required for therapeutic efficacy.53,54 Some platelet quality indices were reduced in treated products in comparison with untreated controls but remained within acceptable transfusion limits.46,51,52 These studies were repeated after γ-irradiation of the products and showed no significant additional effect (C. Hardwick and R. Goodrich, unpublished data, 2003). Despite the differences in in vitro measurements, Mirasol PRTâtreated platelets exhibited normal function in models of adhesion, aggregation, and thrombus formation.55 Data from a clinical trial in healthy human subjects illustrated that Mirasol PRTâtreated platelets exhibited decreased recovery and survival time in comparison with untreated platelets. Nevertheless, recovery values and cell quality indices for Mirasol PRTâtreated platelets remained well MIRASOL PRT SYSTEMâEFFICACY Pathogen reduction with the Mirasol PRT System has been tested with a wide variety of enveloped and 334 TOXICOLOGICAL REVIEW OF MIRASOL PRT 137 within the acceptable range for clinical utility of platelet products currently licensed and in routine use.56,57 Additional studies involving evaluation of the efficacy of treated platelet products in the clinical setting with thrombocytopenic patients are in progress. riboflavin photochemistry-induced deficit, riboflavin (3 mg/kg perioral) is conventionally given to infants during the phototreatment regimen. Concern was once expressed about the toxic potential of riboflavin with direct phototherapy of newborns, based on theoretical consideration of its possible effect on DNA in the presence of light and on the results of experiments in simplified in vitro systems,70,71 but there have been no reports of adverse effects in the clinical setting. This includes results from large retrospective analyses, which directly evaluated potential tumorigenic consequences in more than 50 000 infants undergoing the therapy for more than 10 years after phototherapy.70 This type of therapy continues in wide clinical use today.72 There are a few claims of uncertain quality in individual subjects of âsensitizationâ and possible enhancement of epileptiform seizures after several months of high daily doses of riboflavin (eg, N5 mg · kgâ1 · dâ1 for N6 months), but those reports remain unsubstantiated.61,62 In no other reports of high oral and parenteral doses of riboflavin in humans have toxic effects been described,73-78 probably because of its physiologic nature and the rapid excretion of an excessive dose.40 There is an abundance of references on the toxicity of riboflavin administered by various routes. These data support its use in total parenteral nutrition regimens. Table 1 summarizes representative published toxicity data for oral, subcutaneous, perioral, intraperitoneal, and IV exposures to riboflavin. Although the safety of riboflavin has been extensively studied, there were no reports that directly supported its use in the Mirasol PRT System. Therefore, Navigant Biotechnologies, Lakewood, Colo, conducted a comprehensive preclinical safety evaluation program in support of the Mirasol PRT System, designed to investigate all potential sources of concern. The work was done in compliance with International Organisation for Standardisation (ISO) 10993.79 THERAPEUTIC USE AND TOXICITY OF RIBOFLAVIN IN HUMANS Riboflavin was chosen as the photosensitizing agent for this pathogen reduction process because it can be photoactivated to damage pathogens; it has a substantial history of safe clinical use; and it is both a naturally occurring vitamin (B2) and an essential dietary nutrient. The latter features afforded it the advantage of a well-known and well-characterized safety profile on which to base its evaluation in transfusion medicine. The metabolic role of riboflavin has been well characterized, principally as a source of the essential coenzymes flavin adenine mono- and dinucleotides. The recommended daily intake of riboflavin is about 1.3 mg/d for the average adult58-60 and up to 1.6 mg/d for the lactating woman. Riboflavin is administered in medical practice by the oral, intramuscular, and intravenous (IV) routes to treat deficiency states, and it is widely taken orally as a dietary supplement. Recommended therapeutic doses by any route are up to 30 mg/d for an adult,61 but there are records of people taking up to 200 mg/d or more orally for 6 months with no adverse effect.59,62 Riboflavin is very widely used as a permitted food coloring in the United States, where it has âgenerally regarded as safeâ status,63 and in Europe, where it has been approved by the Scientific Committee on Food.64 The Joint Food Agriculture Organization/ World Health Organization (FAO/WHO) Expert Committee on Food Additives has reviewed its use in food and it has been given a value for acceptable daily intake (ADI) of 0 to 0.5 mg · kgâ1 · dâ1, which is a maximum ADI of 35 mg/d for a subject of average weight (70 kg).58 Riboflavin is given to newborn babies undergoing phototherapy for neonatal jaundice.65,66 Administration of supplemental riboflavin to these vulnerable patients has become standard practice because the treatment-accelerated clearance of bilirubin via phototherapy could also make them at least temporarily deficient in riboflavin owing to overlap of the light absorption spectra of riboflavin and bilirubin.66-69 To avoid the risk of the potential METHODS Test Article Definition To establish the safety of Mirasol PRTâtreated blood products, in vivo animal toxicity studies were performed with treated platelets (and in some instances with treated plasma), as well as with pure lumichrome, and with photolyzed riboflavin in 335 138 REDDY ET AL Table 3. Studies of Systemic Toxicity Acute toxicity Mirasol PRTâtreated rat platelets Subchronic toxicity Mirasol PRTâtreated dog platelets Photolyzed riboflavin solution Mirasol PRTâtreated dog plasma No. of animals/group 10 Male rats 10 Female rats 4 Male dogs 4 Female dogs 10 Male rats Duration of study 14 d; dosing on d 1 14 d; dosing on day 1 9 d; dosing on day 1 Dose route Group 1 Dose material Dose frequency IV injection via tail vein IV infusion via catheter IV injection via tail vein 6 Male dogs; 2 in recovery 6 Female dogs; 2 in recovery 13 wk with 4 wk for recovery group; dosing daily, 6 d/wk IV infusion via catheter Untreated rat platelets Three 2.0-mL injections, 2 h apart Untreated dog platelets Three 40-mL infusions, 2 h apart Sterile 0.9% NaCl Three 2.0-mL injections, 2 h apart Untreated dog plasma Daily 40-mL injections via catheter Mirasol PRTâtreated rat platelets Three 2.0-mL injections, 2 h apart Mirasol PRTâtreated dog platelets Three 40-mL infusions, 2 h apart Photolyzed riboflavin solution Three 2.0-mL injections, 2 h apart Mirasol PRTâtreated dog plasma Daily 40-mL injections via catheter Mirasol PRTâtreated, γ-irradiated rat platelets 2.0-mL injections Mirasol PRTâtreated γ-irradiated dog platelets 40-mL infusions Photolyzed riboflavin solution 2.0-mL injections NA Mirasol PRTâtreated, γ-irradiated rat platelets Three 2.0-mL injections, 2 h apart Mirasol PRTâtreated γ-irradiated dog platelets Three 40-mL infusions, 2 h apart NA NA Group 2 Dose material Dose frequency Group 3 Dose material Dose frequency Group 4 Dose material Dose frequency Abbreviation: NA, not applicable. the absence of platelets and plasma. The Mirasol PRT System parameters used to prepare test articles were always within the range verified for clinical use of the device. Wherever possible, Mirasol PRTâtreated platelets in autologous plasma were used as the test article so that any toxicity from the individual components and any interaction between them (storage bag, riboflavin, light, blood product) would be detected. The doses used in the in vivo studies were designed to maximize exposure while minimizing volume-associated effects and discomfort to the animals. In some cases, pure compounds were used to yield higher doses of the compounds of interest in a study (such as lumichrome and photolyzed riboflavin). In certain animal studies, such as embryo-fetal development in rats and subchronic repeated-dose test in dogs, the volume of animal platelets required to prepare test and control articles for the study would have been very large and would have been required over many weeks. To obtain a consistent test article in as humane a fashion as possible for those studies, species-specific plasma was used rather than platelets. The photochemistry of riboflavin yields equivalent photoproduct profiles in plasma products and in platelet products (which consist mainly of plasma). The absence of platelets eliminates the possibility of detecting toxic alterations to the platelet surface; however, that issue was addressed in the neoantigenicity and 14Criboflavin binding studies. Therefore, when necessary and appropriate, plasma was regarded as an appropriate substitute for platelets and was used as the test article. Treatment of plasma with the Mirasol PRT System is identical to the treatment of platelets. Sample Size Determination, Statistics, and Data Analysis Sample size determination for studies was based on historical experience or published requirements where appropriate. In all cases, data were maintained in validated databases allowing archiving and analysis of data. All studies, assays, and data analysis were performed at accredited contract testing laboratories in accordance with Good Laboratory Practice (GLP) requirements, except 336 TOXICOLOGICAL REVIEW OF MIRASOL PRT 139 where noted. Comparisons of data between study groups were analyzed using Student t test, Wilcoxon distributions and other suitable analyses as appropriate for the particular study data being analyzed. and mortality, outward signs of toxicity (behavioral and physical examinations), clinical chemistry of blood and urine, hematologic indices, body weights and food consumption, and pathologic and histopathologic evaluation of tissues. Test and control article administration is described in Table 3. The daily dose (40 mL) was equivalent to the human dose; the range of doses relative to body weight was 4.7 ± 0.3 mL/kg in the first week of dosing and 4.1 ± 0.3 mL/kg in the last week of dosing for the males and 5.6 ± 0.5 mL/kg in the first week of dosing and 4.8 ± 0.4 mL/kg in the last week of dosing for the females. On days 0 and 86 of the study, blood samples were removed from the animals to measure riboflavin and lumichrome and thereby assess any accumulation of riboflavin or photoproduct during the course of this experiment. Two animals per sex per group were observed for a 4-week recovery period after the 13-week dosing regimen. At the end of the terminal and recovery periods, complete necropsies were performed. Organ weights were recorded, and select tissues were microscopically examined for the nonâ recovery group animals. Systemic Toxicity Studies Acute toxicity. Two acute toxicity studies, 1 in rats and 1 in dogs, evaluated the acute toxicity of Mirasol PRTâtreated, species-specific platelet products, with or without γ-irradiation. In those studies, both males and females were used, to reveal any sexdependent effects. In addition, an acute toxicity study of photolyzed riboflavin in saline was performed to test the toxicity of higher doses of riboflavin and its photoproducts than are attainable in a blood product. The dose volume used in all rat studies (2.0 mL) corresponded to a range of doses per body weight (mean dose of 9.0 ± 0.7 mL/kg for males and 11.5 ± 1.3 mL/kg for females in the study of treated rat platelets and 9.4 ± 0.3 mL/kg for the male rats in the study of photolyzed riboflavin). The dose volume used in the acute dog studies (40 mL) yielded mean doses per body weight of 3.9 ± 0.3 mL/kg for males and 5.1 ± 0.4 mL/kg for females. Table 3 provides a summary of the number of animals and of the dose frequency, route, and material for the acute toxicity studies. Each study was performed in accordance with ISO 1099380,81 and International Conference on Harmonization guidelines.82 These studies evaluated any immediate, systemic toxicity due to administration of Mirasol PRTâtreated platelet products by observations of mortality, clinical signs of toxicity, hematology, clinical chemistry, food consumption, general behavior, and weight gain. Complete necropsies were conducted for all animals, and macroscopic observations were made. In the study performed with dogs, electrocardiographic examinations were conducted before randomization, at the conclusion of dosing, and before necropsy. The studies provided observations of effects on major physiologic systems, such as functioning of the nervous, cardiovascular, and respiratory systems, to exclude any pharmacologic effects of test article administration. Subchronic toxicity. The repeated dose study for subchronic toxicity was done in the dog to support more prolonged and repeated administration of Mirasol PRTâtreated platelets to patients, some of whom may require intermittent transfusions over several weeks. Parameters evaluated in the repeated dose toxicity study included morbidity Reproductive Toxicity Study Embryo-fetal development in rats exposed to Mirasol PRTâtreated products. The developmental toxicity potential of rat plasma treated with the Mirasol PRT System was evaluated in female Sprague-Dawley rats (mean gestation interval = 22 days). Time-mated, pregnant animals in the test and control groups (n = 25 for control, n = 24 for test group) were given IV PRT-treated or untreated products, respectively, at a dose of 2.0 mL per animal (7.7 ± 0.4 mL/kg on the first day of dosing, 6.0 ± 0.3 mL/kg on the last) on gestation days 6 through 17. The animals were observed over the course of the study for clinical signs, body weight, and food consumption. On gestation day 20, the animals were necropsied, and the ovaries and uterus were investigated for the total number of implantations, total number of corpora lutea, early and late resorptions, and viable and nonviable fetuses. Individual body weights and sex of the fetuses were noted. Gravid uterine weights were recorded, and adjusted body weight changes were calculated. All fetuses were given an external examination and processed for visceral or skeletal examination, and malformations and developmental variations were recorded. 337 140 REDDY ET AL Table 4. Mammalian Erythrocyte Micronucleus Test No. of mice/sex used for bone marrow collection after dose administration Dose (20 mL/kg) No. of mice/sex dosed 24 h 48 h Vehicle control: 0.9% NaCl for injection Negative control: untreated human platelets Test article: Mirasol PRTâtreated platelets Low dose (diluted in saline 1:3) Middle dose (diluted in saline 1:1) High dose (undiluted) Positive control: cyclophosphamide (50 mg/kg) 10 10 5 5 5 5 5 5 10 5 5 5 5 5 0 0 5 0 Genotoxicity Studies chromosome aberration test. The assay was performed using Chinese hamster ovary (CHO) cells.85-87 Based on the findings from the preliminary toxicity assay, the doses chosen for the chromosome aberration assay using the test article (Mirasol PRTâtreated platelets) and negative control (untreated platelets) ranged from 0.005 to 0.1 mL/mL for all 3 exposure groups. The test and control articles were soluble in saline at a concentration of 1 mL/mL, the maximum concentration used. Both test and control article were tested in the absence and the presence of an Aroclor-induced S9 activation system. The CHO cells were exposed to test or control article for 4 and 20 hours in the nonactivated test system and for 4 hours in the S9 activated test system. All cells were harvested 20 hours after treatment initiation. Selection of doses for microscopic analysis was based on toxicity of the test article (the lowest dose with at least 50% reduction in cell growth and 2 lower doses) in all harvests. Mammalian erythrocyte micronucleus test. Mirasol PRTâtreated platelets and control, untreated platelets were tested to assess clastogenicity in vivo with the mammalian erythrocyte micronucleus test.88-90 An increase in the frequency of micronucleated polychromatic erythrocytes is expected in the bone marrow of animals exposed to genotoxic compounds. The assay was performed in 2 phases. In the pilot toxicity study, neat test article was administered intraperitoneally to 5 male and 5 female mice at a volume of 20 mL/kg (the highest optimal single-dose volume). No mortality was observed during the course of the study. All mice were observed for clinical signs of toxicity after dose administration and daily for 3 days afterward. Body weights were recorded before dose administration, 1 day after, and 3 days after dose administration. Results from the pilot study were Three different tests were performed to evaluate the genotoxicity of Mirasol PRTâtreated human platelet products: an in vitro test for gene mutations in bacteria, an in vitro test for clastogenicity in mammalian cells, and an in vivo bone marrow micronucleus test. Bacterial reverse mutation assay (Ames test). Mirasol PRTâtreated, day 5 platelets (with and without γ-irradiation) and control, untreated day 5 platelets were tested using Salmonella typhimurium tester strains TA98, TA100, TA1535, and TA1537 and Escherichia coli tester strain WP2 uvrA in the presence and absence of rat-liver derived S9, prepared by the contract research organization. The assay was performed in 2 phases, using the plate incorporation method and normal saline as the diluent. The first phase established the dose range for the confirmatory mutagenicity assay and provided a preliminary mutagenicity evaluation. In the first phase, the dose levels tested were 0.33, 1.0, 3.3, 10, 33, 100, 333, and 1000 ÎŒL per plate. The second phase, the confirmatory mutagenicity assay, was used to evaluate and confirm the mutagenic potential of the test article with dose levels of 3.3, 10, 33, 100, 333, and 1000 ÎŒL per plate.83,84 The in vitro test for gene mutations in bacteria (Ames test) was also performed with lumichrome, the major product of riboflavin photolysis. The in vitro mutagenicity of lumichrome was evaluated in the dark to test its mutagenic potential in the absence of light activation. The maximum concentration tested was at the limit of solubility of lumichrome. Chromosomal aberration in Chinese hamster ovary cells. Mirasol PRTâtreated platelet products and control, untreated platelet products were tested to assess potential clastogenicity (chromosome breakage) in vitro with the mammalian 338 TOXICOLOGICAL REVIEW OF MIRASOL PRT 141 riboflavin to albumin. 95 Reports of additional studies, carried out in nonphysiologic conditions, including the use of artificial media preparations, anaerobic conditions, and nonphysiologic pH values, claimed to demonstrate the formation of riboflavin-protein adducts via tryptophan residues in the protein.95 This work also extended further to show the formation of possible antibodies against such complexes. 97 Other studies with human plasma samples were unable to reproduce these results and instead showed riboflavin interactions to occur primarily with immunoglobulins, which act as natural carriers for the compound in vivo and are a potential source of claims for antibody generation.98,99 The studies of 14C-riboflavin binding before and after photolysis were thus undertaken to assess the potential for adduct formation under the specific conditions used for Mirasol treatment of blood products. To determine the distribution of riboflavin and its photoproducts after Mirasol PRT treatment, a known amount of radiolabeled riboflavin (14C) was added to unlabeled riboflavin solution, and the resulting solution was used to treat platelet products from 6 different donors with the Mirasol PRT System. Preillumination samples from each platelet product were used as controls, and test articles were postillumination samples. Cell concentrations, protein-associated radioactivity, and protein concentrations were determined for all samples. The method was sensitive enough to determine differences of less than 1% in binding of 14C-labeled compound, at micromolar concentrations per milligram of protein, if such effects were occurring. Given prior reports of the levels and extent of photochemical modification of proteins under specific conditions of treatment, if such modifications were occurring with Mirasol treatment, this method would be able to detect it.96,97 Evaluation of nonimmunologic alterations. To assess the potential for nonimmunologic alterations to cells that could subsequently induce an immunologic response, another test, the Capture-P assay, (Immucor, Inc, Norcross, GA) was used to evaluate the binding of immunoglobulin G to Mirasol PRTâ treated platelets, and to untreated platelets, after exposure to allogeneic and autologous plasma. Platelet products, and the associated plasma, from 2 different donors were used to provide the test and control articles for this study. Platelets were tested with the Capture-P assay after 1 and 5 days of used to assess toxicity of the test article and to set dose levels for the definitive study. In the definitive micronucleus study, 1 intraperitoneal injection was administered to the male and female mice in each group. The animals were observed for clinical signs of toxicity after dose administration. Table 4 describes the study groups, the number of animals per group, and test or control articles given to each group, as well as the sacrifice times. Immediately after sacrifice, bone marrow was aspirated from the femurs into a syringe. Two slides of bone marrow suspension were prepared and fixed for each mouse. The slides were analyzed for the presence of micronuclei in bone marrow cells, polychromatic erythrocytes, and normochromatic erythrocytes. Neoantigenicity Studies The potential for Mirasol PRTâtreated platelets to exhibit neoantigenicity (the production of new antigenic determinants due to the treatment) was evaluated with 2 in vitro and 1in vivo test. Because the photoproducts associated with the Mirasol PRT System are the same as metabolites, catabolites, and photoproducts of riboflavin normally present in humans under routine conditions, there was no reason to consider that they might themselves affect the immune system, and there were no indications of any such effect in the toxicity tests. 14 C-riboflavin binding evaluation. The potential for neoantigen formation was first assessed in vitro by measuring the binding of radiolabeled riboflavin to platelets and plasma proteins after Mirasol PRT treatment and comparing the results with those obtained with untreated controls. This method assesses binding of a radiolabeled compound to proteins and cellular membranes. The presence of covalently bound compounds on cellular membranes or proteins indicates that chemical modification has occurred. This modification could be seen as foreign in the bloodstream and result in an immune response. Immune responses to antibiotics, bound to the surface of red blood cells, have been observed.91 Quinacrine mustard, which binds to proteins and blood cells, also results in the production of antibodies.92-94 If Mirasol PRT treatment were to lead to chemical modification of blood constituents in vitro, the in vivo generation of an immune response might be possible. Prior studies have identified the potential for binding of 339 142 REDDY ET AL storage. This study was non-GLP but was welldocumented, performed in a respected clinical laboratory, and included appropriate controls. Neoantigenicity evaluated with the Ouchterlony assay. The formation of new antigens was evaluated in vivo by comparing the immune response between animals given control (untreated) human platelets and animals given Mirasol PRTâtreated human platelets. Rabbits were immunized with control article or with 1 of 2 test articles (Mirasol PRTâtreated, day 5 human platelets, with or without γ-irradiation). The immunizations occurred on days 0, 21, and 42 of the in-life portion of the study. On day 49, sera from the immunized animals in the test and control groups were collected and tested for antibody production. Antibodies were collected and used in the Ouchterlony assay to incubate with either control or test article. Lines of immunoprecipitation were examined to determine reactions of identity, partial identity, or nonidentity. Partial identity immunoprecipitation lines would indicate neoantigenicity if the test article contained new antigens arising as a result of the treatment. Sensitivity of the assay was evaluated with chicken albumin and serum from rabbits immunized with that compound. The chicken albumin could be detected by weak precipitin lines at 0.15 ÎŒg/40 ÎŒg plasma protein and at 0.15 ÎŒg/200 ÎŒg plasma protein, with antibody present at 10, 15, 20, or 25 ÎŒg per well in the assay plate. atmosphere containing 5% ± 1% carbon dioxide. The negative control article (negative control plastic) and the positive control article (natural rubber) were prepared and exposed similarly to the test and control articles. The extent of decolorization was evaluated at times 0, 24, and 48 hours. Minimal essential medium elution study. The minimal essential medium elution study100 was conducted to evaluate the potential cytotoxicity of Mirasol PRTâtreated human platelets. The test was designed for the evaluation of test article extracts with assessment of biologic reactivity of a mammalian cell culture (L929). Aliquots of test article (Mirasol PRTâtreated human platelets) and control article (untreated human platelets) were centrifuged, after which the resulting platelet pellets were mixed with the extraction medium (minimal essential medium) and incubated at 37°C ± 1°C for 24 ± 2 hours. After extraction, the medium was removed and applied to an L929 cell culture. The L929 cultures were incubated for 48 hours, at 37°C ± 1°C, and then evaluated for the response of the cell monolayer. Biologic reactivity (cellular degeneration and malformation) was rated on a scale of 0 to 4. In addition, the primary product of riboflavin photolysis, lumichrome, was tested for in vitro cytotoxicity by direct exposure to the indicator. The lumichrome solution, at the maximum possible lumichrome concentration, was exposed to the indicator cells. Cytotoxicity Studies Hemocompatibility Studies Agar diffusion test. Mirasol PRTâtreated human platelets and control, untreated human platelets were tested to assess cytotoxicity with the agar diffusion assay. The indicator cells for this assay were mouse fibroblast L929 cells, which are classically used for cytotoxicity studies because they demonstrate sensitivity to leachable cytotoxic compounds.100 Cultures of L929 cells were used in the assay after replacement of the liquid medium with a serum-supplemented medium/agar mixture that is stained with a vital dye, neutral red. The culture was protected from light for the duration of the assay to prevent cell damage elicited by photoactivation of the stain. The test article and control article were applied directly to a filter paper disc (surface area 100 mm2) at a volume of 100 mL and placed on the surface of the agar. All plates were incubated for 48 hours, at 37°C ± 1°C, in a humidified Hemolysis test. Mirasol PRTâtreated human platelets and control, untreated human platelets were assessed for hemolytic activity in direct contact with human blood.101-103 Fresh, whole human blood (type-matched to be compatible with test and control articles) was collected into EDTAcoated Vacutainer tubes. The positive control article solution was obtained by adding 10 mL of sterile water for injection per vial. The test and control article solutions were obtained by adding 5 g of material to 10 mL of sterile 0.9% NaCl. All vials were incubated in a 37°C ± 2°C water bath for 30 minutes, followed by addition of 0.2 mL of diluted human blood and incubation in a 37°C ± 2°C water bath for 60 minutes. After incubation, the vials were centrifuged for 5 minutes at approximately 1500g, and the absorbance of each supernatant was determined against an NaCl blank 340 TOXICOLOGICAL REVIEW OF MIRASOL PRT 143 Table 5. Summary of Samples for Pharmacokinetic Study Group no. 1 (Intact) 2 (Intact) Urine â Feces â Cage rinse Cage wash and wipe Blood â Tissues â¡ Predose, 0-12 h, 12-24 h, 24-h intervals to 144 h NA Predose, 24-h intervals to 144 h 24-h intervals to 120 h 144 h 144 h 144 h NA NA NA 1 h, 8 h, 24 h, 48 h, 96 h 1 h, 8 h, 24 h, 48 h, 96 h â Urine and feces collected on wet ice. Urine assayed directly by liquid scintillation chromatography (LSC). Remaining urine saved for analysis of metabolites. â Blood collected from all animals in groups 1 and 2 predose and at designated time points. Prep and assay plasma by LSC. Remaining plasma saved for analysis of metabolites. â¡ Tissues collected include the following: group 1âresidual carcass, pelt (hair and skin with underlying fat layer), and tail skin; group 2âsmall intestine, large intestine, spleen, kidneys, liver, lymphatics (lymph nodes, includes splenic, inguinal, and popliteal), and femur bone marrow (right and left). at 540 to 545 nm. Test and control articles were tested in triplicate. Platelet function studies. Platelet function and the thrombogenicity of Mirasol PRTâtreated platelets were directly evaluated in a series of non-GLP experiments. The hemostatic activity and thrombogenicity of treated platelets were measured in an ex vivo model in which Mirasol PRTâ treated human platelets were mixed with whole blood previously depleted of platelets. The details of the experimental system are described by PerezPujol et al.55 In brief, 8 Trima apheresis platelet collections were performed to collect more than 340 mL at a concentration between 1180 and 2160 × 106 cells/mL. Half of the product volume was treated with the Mirasol PRT System. The other half was used as the paired control. Treated and control platelets were stored in a platelet storage incubator at 22°C ± 2°C for 5 days. Samples were tested using flow cytometric and perfusion methods on days 0, 3, and 5 of storage.55 The flow cytometric analysis used commercially available monoclonal antibodies, tagged with fluorescein or phycoerythrin, to detect glycoprotein (GP) IIb-IIIa, GPIb, GPIV, P-selectin, the 53-kd lysosomal membrane protein, and coagulation factor V. The exposure of aminophospholipids on the outer leaflet of the platelet membrane was also quantified using annexin V. The binding of fibrinogen and von Willebrand factor was detected with the corresponding polyclonal antibodies, and nonspecific membrane immunofluorescence was evaluated. Blood for perfusions was obtained from healthy volunteers and depleted of platelets and leukocytes by filtration. Samples taken from the test and control articles at different days were incorporated into the thrombocytopenic blood at volumes aimed to increase the platelet count in the perfusate to 150 × 109/L with a final volume of 20 mL. Perfusions were performed at 37°C in annular chambers with enzymatically denuded New Zealand rabbit aorta segments. Blood was recirculated through the chamber for 10 minutes at a shear rate of 800 sâ1. At the end of the perfusion, the segments were rinsed with 20 mL of PBS, removed from the chamber, and sliced off and washed with a fixing buffer. Platelets interacting with the subendothelium were evaluated and classified as either adhesion, contact platelets that are attached but not spread and groups of platelets that form aggregates of less than 5 ÎŒm in height, or thrombus, platelets that form aggregates of 5 ÎŒm or more in height. Coagulation proteins and complement pathway. Mirasol PRTâtreated human platelets and control, untreated human platelets were stored at 22°C for 5 days, after which samples were removed and centrifuged to isolate the plasma fraction. The plasma fraction was analyzed with function-based assays for key protein components of each hemostatic pathwayâthe contact pathway, the thrombin pathway, the fibrinolytic pathway, the complement pathway, and the coagulation pathway. Factor XI (FXI), factor XII (FXII), highmolecular-weight kininogen (HMWK), prekallikrein (PK), and activated factor XII (FXIIa) were assessed as components of the contact pathway. Prothrombin fragments 1 and 2 (F1+2), thrombinantithrombin complex, and D-dimer were assessed as components of the thrombin pathway. Plasminogen (PLG), α2-antiplasmin (A2A), and PLG 341 144 REDDY ET AL Table 6. Summary of the Results of the Systemic and the Reproductive Toxicity Studies Test Systemic toxicity Acute toxicity of photolyzed riboflavin in rats Acute toxicity of Mirasol PRTâtreated platelets in rats â Acute toxicity of Mirasol PRTâtreated platelets in dogs â Subchronic toxicity of Mirasol PRTâtreated plasma in dogs Reproductive toxicity Embryo-fetal development in rats exposed to Mirasol PRTâtreated plasma Findings ⢠No test-articleârelated changes in mortality, clinical signs, body weight, food consumption, clinical pathology, organ weights, or macroscopic pathology evaluations were observed. ⢠No test-articleârelated mortality, clinical observations, body weight changes, food consumption changes, or macroscopic changes were observed. ⢠No test-articleârelated mortality, clinical observations, body weight changes, food consumption changes, or macroscopic changes were observed. ⢠No toxicologically significant findings were observed in clinical, physical, electrocardiographic, or ophthalmascopic examinations. ⢠Macroscopic observations did not yield any test-articleâ related effects in dogs of either sex. ⢠Test-articleârelated findings for decreased body weight, increased eosinophils, increased chloride, and decrease thymus weights with associated microscopic findings were noted; however, these findings were minor and were not considered to be toxicologically significant. ⢠No test-articleârelated clinical signs of toxicity were observed during treatment period, no dam had all fetuses resorbed, and no deaths occurred during study. ⢠Treated group exhibited significant increase in gestation body weight on gestation day 18, and body weight changes were significantly increased on gestation day intervals 12-15, 6-18, and 0-20. Increase correlated with significantly increased food consumption in treated-group animals. ⢠No significant differences were observed in fetal weight (g), gravid uterine weight, adjusted weight change, postimplantation loss, nonviable fetuses/, litter size, early and late resorptions, mean no. of corpora lutea/litter, no. of implantation sites, preimplantation loss, no. of viable fetuses/letter, and sex ratio (% males/litter). ⢠No external or test-articleârelated visceral abnormalities were reported in any of fetuses examined. No significant difference in skeletal malformation and variations were observed in control and treated groups. â Indicates that study was done with and without γ-irradiation of treated blood products. activator inhibitor type 1(PAI-1) were assessed as components of the fibrinolytic pathway. CH50/ classical pathway, C3a, C5a, and C1 esterase inhibitor were assessed as components of the complement pathway, and antithrombin III, protein C (PC), and protein S (PS) were assessed as components of the coagulation pathway. Mean values for test and control articles were compared using Student t test. In addition, assays for chemotaxis (response to C5a) and assays of myeloperoxidase release from cytochalasin Bâ treated human polymorphonuclear leukocytes (response to C3a and C5a) were used to further assess physiologic relevance of any changes after treatment. Pharmacokinetics of Photolyzed in Rats 14 C-Riboflavin The in vivo pharmacokinetics and elimination of riboflavin and its photoproducts in rat plasma treated with the Mirasol PRT System were also studied. Sterile-filtered rat plasma was mixed with 500 ÎŒmol/L 14C-riboflavin, treated by the Mirasol PRT System, and administered to male CD rats by IV injection in a single dose. The study consisted of 2 treatment groups of male Crl: CD(SD) IGS BR 342 TOXICOLOGICAL REVIEW OF MIRASOL PRT 145 Table 7. Summary of the Results for the Mammalian Erythrocyte Micronucleus Study Test Findings Test for clastogenicity in mammalian cells (in vivo; mouse bone marrow micronucleus test) ⢠No mortality occurred at any dose level during course of micronucleus study. ⢠Clinical signs, noted on days after dose administration, included lethargy and piloerection in males and females dosed with untreated platelets and in all animals dosed with test article (neat and diluted). In addition, hunched position was noticed in animals at middle (1:1 dilution) and high (neat) dose. All other mice treated with vehicle or positive control articles appeared normal during course of study. ⢠No appreciable reduction in ratio of polychromatic erythrocytes to total erythrocytes was observed in groups treated with negative control or test article, relative to vehicle control groups. This suggests that negative control and test article did not inhibit erythropoiesis. No significant increase in incidence of micronucleated polychromatic erythrocytes in negative control or test-articleâtreated groups relative to respective vehicle control groups was observed, regardless of sex, dose, or bone marrow collection time. rats. A treated group of 3 rats (group 1) and a treated group of 15 rats (group 2) each received the radiolabeled test article at a target radiolabeled riboflavin dose level of 0.48 mg/kg with approximately 555,000 Bq per animal (mean actual dose levels of approximately 0.38 mg/kg and 547,600 Bq per animal). The dose volume for both groups was approximately 4 mL per animal. All animals were observed twice daily for morbidity, mortality, injury, and the availability of food and water. Urine and feces were collected from group 1 animals predosing and at intervals through 144 hours postdosing. In addition, whole blood was collected, and plasma was prepared, predosing and at the end of the experiment. The tissues collected for postmortem study were residual carcass, pelt, and tail skin, as well as small intestine, large intestine, spleen, kidneys, liver, lymphatics, and right and left femur bone marrow. The concentration of radioactivity in whole blood, plasma, urine, feces, tissues, and cage residues was determined, and analyses of the kinetics of 14C-labeled compound excretion were performed. The plasma and tissue concentrations obtained were for radioactivity associated with riboflavin and its photoproducts, rather than for individual compounds. Table 5 summarizes the samples analyzed for each group. The pharmacokinetic parameters of riboflavin and photoproduct in plasma, small intestine, large intestine, spleen, kidneys, liver, lymphatic, and femur bone marrow tissues were determined from mean concentration-time data in the test animal. Appropriate validated software was used to calculate these parameters. Measurement of Leachable and Extractable Compounds in Mirasol PRTâTreated Products In addition to standard medical device testing for plastic components, several novel methods were applied to evaluate the levels of leachable and extractable compounds in human blood products after treatment with the Mirasol PRT System. This non-GLP analysis was performed to identify and quantify compounds that might migrate directly into the platelet product as a result of treatment with the Mirasol PRT System. Untreated and Mirasol PRTâ treated products were analyzed by gas chromatography and mass spectrometry for volatile and semivolatile organic compounds, by inductively coupled plasma-atomic emission spectroscopy (ICP) for metals, and by Fourier transform infrared spectroscopy (FTIR) for polymeric materials. RESULTS In all studies of toxicity, γ-irradiated Mirasol PRTâtreated products yielded the same results as nonâγ-irradiated, Mirasol PRTâtreated products. Systemic Toxicity No toxicologically significant findings were observed in any of the studies of acute toxicity (Table 6). No toxicologically significant findings were observed in the repeated-dose toxicity study 343 146 REDDY ET AL examined for malformations and developmental variations (Table 6). No mutagenicity was observed in the Ames test (with and without S9 metabolic activating fraction) for treated or control human platelets, or for lumichrome. The in vitro and in vivo tests for clastogenicity in mammalian cells (chromosomal aberration in cultured CHO cells and micronucleus test in mouse bone marrow cells, respectively) were also performed with Mirasol PRTâtreated products. Human platelets treated with the Mirasol PRT System gave negative results in all genotoxicity experiments. Detailed results of the in vivo genotoxicity experiment are summarized in Table 7. Table 8. Clotting Factor Levels in Treated and Untreated, Control Platelet Preparations After 5 Days of Storage Treated â (n = 6) Reference range104 Control (n = 6) FXI (IU/mL) FXII (IU/mL) PK (IU/mL) HMWK (IU/mL) Antithrombin III (IU/mL) PC (IU/mL) PS (IU/mL) 0.42-1.44 0.40-1.52 0.65-1.35 â 0.65-1.35 â 0.86 ± 0.13 1.40 ± 2.0 1.11 ± 0.06 0.78 ± 0.12 0.72-1.45 0.82 ± 0.01 0.84 ± 0.11 NS 0.58-1.64 0.56-1.68 PAI-1 (IU/mL) PLG (IU/mL) A2A (IU/mL) D-D (ng/mL) 0-31 â 0.68-1.44 0.72-1.32 0-255 â FXIIa (ng/mL) F1+2 (nmol/L) TAT (ng/mL) 0-3.6 â 0.4-1.8 â 1.02 ± 0.19 0.16 ± 0.08 (3 of 6 @ b0.11) 3.6 ± 1.3 1.04 ± 0.10 0.88 ± 0.05 5/6 b110, 1 at 139 1.5 ± 0.2 0.5 ± 0.0 C3a (ng/mL) C5a (ng/mL) C1 esterase Inhibitor (mg/mL) CH50/classic pathway (U/mL) 0.0-5.0 â 0-940 â â 4.7-9.5 8.0-19.5 â 176-282 â 0.59 1.07 0.73 0.68 ± ± ± ± 0.12 0.23 0.10 0.29 b.05 b.05 b.05 NS â¡ 0.75 ± 0.8 0.13 ± 0.03 (4 of 6 @ b0.11) 17 ± 4 0.88 ± 0.08 0.82 ± 0.07 b110 b.05 NS 4.8 ± 0.9 1.0 ± 0.1 b.05 b.05 3 of 6 b0.6; 1.1 ± 0.4 0.7 ± 0.1 5510 ± 552 16 594 ± 4939 8±1 16 ± 3 11 ± 2 7±1 281 ± 56 P 21 ± 18 b.05 b.05 b.05 NA § Neoantigenicity and Cytotoxicity Results of studies using 14C-labeled riboflavin and exposure of platelets and plasma to UV light did not demonstrate any detectable binding of riboflavin or its photoproducts to platelets or to NA b.05 Table 9. Clotting Factor Levels in Mirasol PRTâTreated FFP b.05 b.05 Mirasol FFP b.05 Fibrinogen (mg/dL) FVIIIa activity (IU/mL) FII activity (IU/mL) FV activity (IU/mL) FVII activity (IU/mL) FIX activity (IU/mL) FX activity (IU/mL) FXI activity (IU/mL) FXII activity (IU/mL) Total protein (g/L) Antithrombin III (IU/mL) PC (IU/mL) PS (IU/mL) PLG (IU/mL) A2A (IU/mL) HMWK (IU/mL) Abbreviations: PC, protein C; PS, protein S; A2A, alpha-2plasmin; D-D, D-dimer; TAT, thrombin-antithrombin complexes. â Values reported for plasma from Mirasol PRTâtreated platelets are corrected for the dilution due to the addition of riboflavin. â Reference range specific to laboratory or assay kit. â¡ P N .05. § Most data below detection limit of assay. (Table 6). In the repeated-dose toxicity study, the levels of riboflavin and lumichrome in blood samples from animals receiving Mirasol PRTâ treated products were below the limits of quantification, as were the levels in blood samples from animals receiving untreated plasma. These results were consistent with the observed rapid clearance of riboflavin after IV administration, both in the literature40 and in the pharmacokinetic study with 14 C-riboflavin in Mirasol PRTâtreated products. Developmental Toxicity and Genotoxicity No developmental toxicity was observed in the embryo-fetal development study. All fetuses were Reference range104 Treated â, assayed postillumination (n = 27) 145-385 227 ± 60 216 ± 32 0.52-1.55 0.6 ± 0.2 0.9 ± 0.2 0.65-1.54 0.8 ± 0.1 0.8 ± 0.1 0.54-1.45 0.7 ± 0.1 0.62-1.65 0.9 ± 0.2 0.6 ± 0.1 0.45-1.48 0.8 ± 0.2 0.7 ± 0.1 0.68-1.48 0.8 ± 0.1 0.8 ± 0.1 0.42-1.44 0.8 ± 0.2 0.6 ± 0.1 0.40-1.52 1.0 ± 0.3 0.8 ± 0.1 48-64 57 ± 2 53 ± 3 0.72-1.45 0.8 ± 0.1 1.0 ± 0.1 0.58-1.64 0.56-1.68 0.68-1.44 0.72-1.32 0.65-1.35 1.1 0.8 0.8 1.0 0.8 0.9 ± 0.2 1.0 ± 2 0.9 ± 0.2 0.9 ± 0.1 0.7 ± 0.2 ± 0.2 ± 0.1 ± 0.2 ± 0.2 ± 0.2 Treated â, stored for 1 y (n = 27) 0.6 ± 0.1 â Values reported for Mirasol PRTâtreated plasma are corrected for the dilution due to the addition of riboflavin. 344 TOXICOLOGICAL REVIEW OF MIRASOL PRT 147 removed from platelet products stored for 5 days, statistically significant changes in PRT-treated samples were observed in FXI, FXII, PK, PC, PS, PAI-1, PLG, A2A, FXIIa, and F1+2. The activities of FXII, PK, PC, PAI-1, PLG, and F1+2 were within the reference range. The activities of the remaining proteins (FXI, PS, A2A, HMWK, and FXIIa) were outside the reference range, but the changes were not deemed to be clinically relevant compared with the levels in normal, untreated blood (Table 8). Similar studies on platelets after γirradiation yielded similar findings. Because analysis of plasma protein levels in platelet products stored at room temperature for extended periods shows degradation in protein quality due to storage alone, Mirasol PRTâtreated FFP was assessed for factor activity. Results are presented in Table 9 for samples held for 8 hours at room temperature after collection and before treatment with Mirasol PRT to simulate worst-case conditions for routine treatment of plasma products. Samples were then treated and stored frozen until analysis of factors in standard coagulation assays. Results for all samples analyzed remained within historical reference ranges based on untreated, historical, and concurrent controls. Results for Mirasol PRTâtreated FFP are representative of values obtained for plasma from Mirasol PRTâtreated platelets immediately posttreatment. The plasma from Mirasol PRTâtreated human products contained significantly more C3a desarg Table 10. Complement Test Results in Treated and Untreated, Control Platelet Preparations Sample Chemotaxis assay Enzyme release assay Reference range Positive control = 60.4 Negative control = 16.8 22.8 ± 1.8 24.2 ± 5.0 NS Positive control = 1.13 Negative control = 0.32 0.41 ± 0.03 0.45 ± 0.14 NS Control (n = 6) Treated (n = 6) P NOTE: NS, P N .05. plasma proteins. No evidence of neoantigenicity was observed with the Ouchterlony assay, indicating that no new antigens were formed during treatment with the Mirasol PRT System. Treatment with the Mirasol PRT System did not result in greater immunoglobulin G binding than what was observed in comparison with untreated controls, when assessed with the Capture-P assay. In the tests of lumichrome cytotoxicity, and of the cytotoxicity of Mirasol PRTâtreated products, no cytotoxicity was observed. Hemocompatibility In tests of hemocompatibility, no hemolysis was observed. In functional assessments, when mixed with thrombocytopenic whole blood, the function of Mirasol PRTâtreated platelets was well preserved, in comparison with controls.55 Treated platelets displayed no evidence of hyperactivation or hypercoagulability. In evaluation of plasma Table 11. Results of Pharmacokinetic Study and Test for Leachables and Extractables Test Findings Pharmacokinetics of photolyzed 14C-riboflavin in Mirasol PRTâtreated rat plasma Approximately 95% of total radioactivity administered to animals was eliminated within approximately 260-275 h postadministration Based upon observed areas under the curve, tissues exhibiting highest to lowest overall exposure were liver N kidneys N large intestine N small intestine N spleen N femur bone marrow N lymphatics Observed mean t1/2 estimates determined from radioactivity excretion rate data in urine (55.3 h) and determined from radioactivity excretion rate data in feces (55.1 h) were in excellent agreement with t1/2 estimate (52.1 h) for plasma No significant differences before and after exposure to treatment conditions No polymeric material was detected by FTIR in either treated or untreated platelet extracts All metals detected in treated-platelet extracts were present in untreated-platelet extracts in similar amounts. Assessment of leachable and extractable compounds using standard medical device biocompatibility testing Assessment of leachable and extractable compounds in Mirasol PRTâtreated human platelets and untreated human platelets Abbreviation: FTIR, Fourier transform infrared spectroscopy. 345 148 REDDY ET AL and C5a desarg (2.7- and 1.8-fold higher, respectively) and significantly lower values for C1 esterase (1.8-fold lower) and CH50 (14-fold lower) than in plasma from untreated controls (Table 8). The desarg forms of C3a and C5a are biologically inactive forms of the anaphylatoxins produced in the common pathway of complement activation. The increase in these inactive forms in treated products and decrease in the active component, CH50 (total hemolytic complement), are consistent. Little to no complement-derived activity was observed in plasma from either Mirasol PRTâ treated platelets or untreated controls, and there were no significant differences between treated and control results (Table 10). Similar studies performed on products after γ-irradiation yielded identical results (data not shown). Pharmacokinetics of Photolyzed in Rats 14 DISCUSSION The design of the Mirasol PRT device, the strategy of the investigative work, and the specific experiments that were conducted to evaluate toxicity were based first on scientific considerations and then on the need to comply with regulatory requirements. Consideration was also given to minimizing the need for animal experimentation as far as permitted by the information required and the need for reliable scientific experiments. The system design and the experimental program were intended to answer potential scientific and medical concerns and to permit a comprehensive safety assessment of the Mirasol PRT System. The design of the preclinical safety studies was also intended to conform to specific regulatory requirements in different countries, adapted to the nature of this innovative device. The official guidelines used for the study design included ISO 1099379 for medical devices and the general toxicity and pharmacokinetic guidelines for drugs of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.82,105 The nonclinical toxicity program was based throughout on studying preparations that had undergone Mirasol PRT treatment, a process shown to be effective in reducing levels of several types of infectious agents.46,49,50,106,107 The testing of treated blood products has examined the potential for toxicity resulting from the entire process (from addition of riboflavin and controlled illumination in the Mirasol illumination bag) and has examined the potential for harm to the blood products themselves. Assessments included effects on the cells and plasma proteins, the toxicity of riboflavin itself and its photoproducts, and the effects on other system components comprising the medical grade plastic connectors and bags used in this process. The results obtained have been compared with extensive literature on the effects of riboflavin and its photoproducts in animals and humans arising from its medical use as a vitamin and more widely as a food colorant or additive. The methods used have been those recommended by current official guidelines interpreted according to the special nature and properties of platelets and plasma and designed to provide as much information as possible from focused in vitro and in vivo studies. The difference in size between human patients and in vivo animal C-Riboflavin After a single IV administration of Mirasoltreated plasma containing photolyzed 14C-riboflavin, the radioactivity was well distributed from the whole blood to tissues selected for assay within the first hour postdose. Most of the excreted urinary radioactivity was recovered by 12 hours postdose, and more than half of all radioactivity was excreted in urine. Blood levels of radioactivity declined rapidly post-dose, as expected from studies of riboflavin metabolism and excretion in humans. 40 Measurements of the radioactivity associated with the 14C-riboflavinâtreated plasma indicated rapid initial apparent distribution (and/or clearance) from the systemic circulation that appeared to be complete within the first 8 to 48 hours postdose. Table 11 contains a summary of the key study results. Leachables and Extractables The leachables and extractables analyses detected no polymeric material in either test or control platelet products (Table 11). The Mirasol illumination/storage bag does not contain the plasticizer di(2-ethylhexyl)pthalate (DEHP), and testing verified that this plasticizer was not present in treated and stored products. No toxicologically relevant concentrations of metals were found. These results correlate with those from the biocompatibility testing of the Mirasol illumination/storage bag elementsâall elements are biocompatible. 346 TOXICOLOGICAL REVIEW OF MIRASOL PRT 149 test systems has restricted application of the standard toxicological strategy of administering a range of doses far exceeding the human dose to reveal possible toxic hazards. In studying Mirasol PRTâtreated blood products, the largest volumes or doses have been given consistent with maintaining the welfare of any animals used and to separate effects due to toxicities of the components from toxicities due to volume overload alone. The results of the in vivo and in vitro toxicity tests have reproduced previously reported findings (Table 1) for riboflavin and its photoproducts in animals and humans under relevant conditions, despite the special circumstances of the presence of blood cells and proteins and the use of various medical-grade plastic connectors and storage containers. There has been no indication, even after repeated administration of the maximum achievable exposure to Mirasol PRTâtreated products (6 times per week for 13 weeks in the subchronic test in the dog), of any untoward effect on the functions of the major physiologic systems or in producing any target organ toxicity. Furthermore, a variety of special tests have shown that no detectable new antigens are present on Mirasol PRT Systemâ treated cells or proteins and that such preparations did not stimulate antibody formation. The wide range of toxicity tests has also excluded any genotoxic risk and any toxic effect on pregnant animals and on embryo-fetal development. Local tolerance at the site of IV infusion has been shown to be good. The treated platelet preparations have not shown any cytotoxicity, nor did they leach unwanted substances from the containers and connectors used in the Mirasol system. These results indicate the lack of specific toxicity of Mirasol PRTâtreated products, and because of the experiments done, they give a strong indication that the same medical acceptability is likely also to apply to both human platelets and to human plasma treated in the same way. The absence of toxicity was considered likely given the extensive prior experience in humans and the laboratory experience of the safety of the chemicals involved (riboflavin, lumichrome, and the other riboflavin photoproducts), but it has been very important to confirm that prediction and to extend it to include the special cells and plasma proteins also involved in the Mirasol System. To this should be added the evidence of retention of acceptable platelet function and survival after treatment, which has been the subject of additional peer-reviewed publications.46,51,55,57 Thus, there is evidence of the safety of this process in a broad range of laboratory tests from which a qualitative extrapolation of safety in patients can be made. Quantitative prediction of safety, or at least of the margin of safety represented by the difference between the relative exposures of man and animals and the observed âno effect levelâ in the laboratory, must be more cautious, but there are relevant data on which to base some realistic predictions. The likely exposure of humans to riboflavin and its photoproducts is 0.077 mg/kg for each unit of product transfused. Likely exposure of recipients in a clinical setting was calculated on the assumption of a mean recipient weight of 70 kg, nominal riboflavin solution concentration of 500 ÎŒmol/L, mean riboflavin photoconversion of 18%, and nominal riboflavin solution volume of 35 mL. This exposure level can be compared with the lethal dose at which 50% of the population survives reported for IV riboflavin in mice (50-100 mg/kg)30 yielding a safety factor of at least 50/0.077 = 649. However, this safety margin calculation is somewhat illusory because there is no reliable indication from the clinical literature, or from appropriate animal experiments, of the toxic dose of riboflavin in man, and so, the upper bound of the âno toxic effect levelâ remains unknown. It is reasonable only to conclude that there is no reason to predict toxicity in man due to parenteral exposure to riboflavin and its photoproducts in Mirasol PRTâ treated products until much higher exposures are reached than would ever be feasible from platelet or plasma transfusions. For similar reasons, comparison of exposure from treated platelets with the ADI for riboflavin of 0 to 0.54 mg × kgâ1 × dâ1 is no less misleading because the ADI refers to life-long, daily exposure to the substance in the diet and is not an appropriate comparator for a short-term parenteral exposure even if the latter is repeated up to several times per week, at least for a few months. In these circumstances, which are not unusual for physiologically essential substances, the best that the toxicologist can offer is the prediction that riboflavin and its photoproducts have low experimental toxicity in vivo. Published work suggests that administration of the agent in the extreme may result in renal damage due to crystalluria as the most prominent toxic effect in rodents. This work is 347 150 REDDY ET AL derived from studies in which animals were given very large IV doses, and the harmful effect is very probably a consequence of the limited aqueous solubility of riboflavin. This is far removed from any circumstance associated with administration of Mirasol PRTâtreated products in the transfusion setting. There is no realistic indication that chemical toxicity will be a limiting factor in any likely course of treatment with Mirasol PRTâtreated products. Results from all genotoxicity studies with the Mirasol PRT System have been negative. This has included evaluation of all photoproducts and photolyzed platelets and plasma at the maximum tolerable or maximum soluble limits for these assays. The absence of any indication of potential tumorigenic effects in the subchronic and other tests, the lack of genotoxicity, the chemical nature of riboflavin and its photoproducts, and the lack of suspicion arising from the physiologic role and human experience of this vitamin obviated the need for further carcinogenicity testing. Prior carcinogenicity testing of riboflavin in historical studies (Table 1) is consistent with these findings and also supportive of the lack of carcinogenic potential of this compound. The Mirasol PRT System has been evaluated in an extensive preclinical safety evaluation program. The historical literature available on riboflavin and its photoproducts as well as the results of this work support its safety profile in man. The results obtained from the studies conducted and reported here are consistent with these data and indicate that the risk of toxicity due to the use of this system in the transfusion setting should be low. ACKNOWLEDGMENTS We would like to thank Mr Jon White, Dr Ali Faqi, Dr Mary Sherman, Ms Sheryl Loux, Ms Leigh Bergeron, Mr Devaki Sadhu, Dr Florence Burleson, and Dr Ramadevi Gudi for conducting the toxicology research work described in this review article. We also would like to acknowledge the work of Dr George Garratty's and Dr Patsy Giclas' laboratories for their analysis of platelet immunologic properties. We are grateful to Deanna Gampp, Nick Hovenga, Suzann Doane, Denise Gilmour, Shawn Keil, and Christopher Hardwick for their laboratory support work for Navigant's toxicology program. REFERENCES 9. Blajchman MA: Bacterial contamination of cellular blood components: Risks, sources and control. Vox Sang 87 (Suppl):98-103, 2004 10. US Food and Drug Administration. Minutes of 36th Meeting of the Blood Product Advisory Committee; 1992, May 28â29; Bethesda, Maryland. Washington (DC), USFDA; 1992 11. Yomtovian R, Lazarus HM, Goodnough LT, et al: A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 33:902-909, 1993 12. Schroeder ML: Transfusion-associated graft-versus-host disease. Br J Haematol 117:275-287, 2002 13. Saunders C, Herbert P, Rowe G, et al: In vitro evaluation of the PALL Leukotrap Affinity Prion Reduction Filter as a secondary device following primary leucoreduction. Vox Sang 89:220-228, 2005 14. Blajchman MA, Goldman M, Baeza F: Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 18:11-24, 2004 15. Cohen ND, Munoz A, Reitz BA: Transmission of retroviruses by transfusion of screened blood in patients undergoing cardiac surgery. N Engl J Med 320:1172-1176, 1989 16. Nelson KE, Donahue JG, Munoz A, et al: Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. A multicenter study of HIV-1 and HTLV-I/II infections. Ann Intern Med 117:554-559, 1992 1. Busch MP, Kleinman SH, Nemo GJ: Current and emerging infectious risks of blood transfusions. JAMA 289:959-962, 2003 2. Vamvakas EC, Blajchman MA: Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction? Blood 97:1180-1195, 2001 3. Lee JH, Klein HG: From leukocyte reduction to leukocyte transfusion: The immunological effects of transfused leukocytes. Baillieres Best Pract Res Clin Haematol 13:585-600, 2000 4. Gould DS, Auchincloss HJ: Direct and indirect recognition: The role of MHC antigens in graft rejection. Immunol Today 20:77-82, 1999 5. Llewelyn CA, Hewitt PE, Knight RS, et al: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusions. Lancet 363:417-421, 2004 6. Hewitt PE, Llewelyn CA, Mackenzie J, et al: Creutzfeldt-Jakob disease and blood transfusion: Results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 91:221-230, 2006 7. Wroe SJ, Pal S, Siddique D, et al: Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet 368:2061-2067, 2006 8. Peden AH, Head MW, Ritchie DL, et al: Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364:527-529, 2004 348 TOXICOLOGICAL REVIEW OF MIRASOL PRT 151 17. Grant IH, Gold JW, Wittner M, et al: Transfusionassociated acute Chagas disease acquired in the United States. Ann Intern Med 111:849-851, 1989 18. Leiby DA, Lenes BA, Tibbals MA, et al: Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. N Engl J Med 341:1237-1239, 1999 19. Wu DG, Mason B, Jong J, et al: Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 45:1003-1010, 2005 20. Biggerstaff BJ, Petersen LR: Estimated risk of transmission of the West Nile virus through blood transfusion in the US. Transfusion 43:1007-1017, 2002 21. Custer B, Tomasulo PA, Murphy EL, et al: Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: Analysis of 2003 data to inform 2004 decision making. Transfusion 44:1547-1554, 2004 22. Hellstern P: Solvent/detergent-treated plasma: Composition, efficacy, and safety. Curr Opin Hematol 11:346-350, 2004 23. Williamson LM, Cardigan R, Prowse CV: Methylene blueâtreated fresh-frozen plasma: What is its contribution to blood safety? Transfusion 43:1322-1339, 2003 24. Corash L, Lin L: Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 33:1-7, 2004 25. Lin L, Dikeman R, Molini B, et al: Photochemical treatment of platelet concentrates with amotosalen and longwavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 44:1496-1504, 2004 26. Lin L, Hanson CV, Alter HJ, et al: Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 45:580-590, 2005 27. Unna K, Greslin JG: Studies on the toxicity and pharmacology of riboflavin. J Pharmacol 76:75-80, 1942 28. Hayashi M, Kishi M, Sofuni T, et al: Micronucleus tests in mice on 39 food additives and eight miscellaneous chemicals. Food Chem Toxicol 26:487-500, 1988 29. Kuhn R, Boulanger P: Uber die Giftigkeit der Flavine. Hoppe Seylers Z Physiol Chem 241:233-238, 1936 30. Studer A, Zbinden G, Uehlinger E: Die pathologie der avitaminosen and hypervitaminosen, in Buchner F, Letterer E, Roulet F (eds): Handbuch der Allgemeinen Pathologie, Band II. Berlin, Springer Verlag, 1962, pp 734-987 31. Williams Jr JR, Grantham PH, Yamamoto RS, et al: Effect of dietary riboflavin on azo dye reductase in liver and in bacteria of cecal contents of rats. Biochem Pharmacol 19:2523-2525, 1970 32. Scotto JM, Stralin HG, Lageron A, et al: Influence of carbon tetrachloride or riboflavin on liver carcinogenesis with a single dose of aflatoxin b1. Br J Exp Pathol 56:133-138, 1975 33. Leclerc J: Influence of thiamine, riboflavin and vitamin B6 content in food on tissue content of these vitamins in the female lactating rat and young rats. Ann Nutr Aliment 28:11-20, 1974 34. Lim-Sylianco C: Genotoxic studies of street soils in Quezon City, Philippines, in Sumino K (ed): Environmental and occupational chemical hazards, no. 8. Proceedings of the AsiaPacific Symposium in Environmental and Occupational Toxicology, 1987, Oct 4â10; Singapore. Kobe, Japan, Kobe University School of Medicine 35. Munoz N, Hayashi M, Bang LJ, et al: Effect of riboflavin, retinol, and zinc on micronuclei of buccal mucosa and of esophagus: A randomized double-blind intervention study in China. J Natl Cancer Inst 79:687-691, 1987 36. Sugiyama M, Ando A, Nakao K, et al: Influence of vitamin B2 on formation of chromium(V), alkali-labile sites, and lethality of sodium chromate(VI) in Chinese hamster V-79 cells. Cancer Res 49:6180-6184, 1989 37. Haveland-Smith RB: Evaluation of the genotoxicity of some natural food colours using bacterial assays. Mutat Res 91:285-290, 1981 38. De Flora S: Study of 106 organic and inorganic compounds in the Salmonella/microsome test. Carcinogenesis 2:283-298, 1981 39. Kale H, Harikumar P, Nair PM, et al: Assessment of the genotoxic potential of riboflavin and lumiflavin. Mutat Res 298:9-16 40. Zempleni J, Galloway JR, McCormick DB: Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 63:54-66, 1996 41. Kumar V, Lockerbie O, Keil SD, et al: Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level. J Photochem Photobiol 80:15-21, 2004 42. Hardwick CC, Herivel TR, Hernandez SC, et al: Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology. J Photochem Photobiol 80:609-615, 2004 43. Holmstrom B: Spectral studies of the photobleaching of riboflavin phosphate. Arkiv for Kemi 22:281-301, 1964 44. Dekker RH, Srinivasan BN, Huber JR, et al: Photochemistry of flavinsâI. Conventional and laser flash photolysis study of alloxazines. J Photochem Photobiol 18:457-466, 1973 45. Koziol J: Studies of flavins in organic solventsâI. Spectral characteristics of riboflavin, riboflavin tetrabutyrate and lumichrome. J Photochem Photobiol 5:41-54, 1966 46. Ruane PH, Edrich R, Gampp D, et al: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 44: 877-885, 2004 47. Fast LD, DiLeone G, Cardarelli G, et al: Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag 2â/âgcâ/â double knockout mice. Transfusion 46:1553-1560, 2006 48. Fast LD, DiLeone G, Li J, et al: Functional inactivation of white blood cells by Mirasol treatment. Transfusion 46: 642-648, 2006 49. Cardo LJ, Rentas FJ, Ketchum L, et al: Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 90:85-91, 2006 50. Rentas FJ, Harman R, Salata J, et al: Inactivation of Orientia tsutsugamushi in RBCs, plasma, and platelets using riboflavin and light, as demonstrated in an animal model. Transfusion 47:240-247, 2007 51. Li J, de Korte D, Woolum MD, et al: Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: Comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 87:82-90, 2004 349 152 REDDY ET AL to newborn infants: A review. Environ Mutagen 1:321-336, 1979 72. Maisels MA, Kring EA: Does intensive phototherapy produce hemolysis in newborns of 35 or more weeks of gestation? J Perinatol 26:498-500, 2006 73. Stein G, Sperschneider H, Koppe S: Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 3:52-62, 1985 74. Allman MA, Truswell AS, Tiller DJ, et al: Vitamin supplementation of patients receiving haemodialysis. Med J Aust 150:130-133, 1989 75. Gentile MG, Porrini M, Manna GM, et al: Water- and fat-soluble vitamin status in chronic renal insufficiency patients. Contrib Nephrol 98:89-97, 1992 76. Fouty B, Frerman F, Reves R: Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 352: 291-292, 1998 77. Schoenen J, Jacquy J, Lenaerts M: Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 50:466-470, 1998 78. Luzzati R, Del Bravo P, Di Perri G, et al: Riboflavine and severe lactic acidosis. Lancet 353:901-902, 1999 79. International Organisation for Standardisation: International Standard ISO 10993 biological evaluation of medical devicesâPart 1: Evaluation and testing. Geneva, Switzerland, International Organisation for Standardisation, 1993 80. International Organisation for Standardisation: International Standard ISO 10993 biological evaluation of medical devicesâPart 11: Tests for systemic toxicity. Geneva, Switzerland, International Organisation for Standardisation, 1993 81. International Organisation for Standardisation. International Standard ISO 10993 biological evaluation of medical devicesâPart 10: Tests for irritation and sensitization. Geneva, Switzerland, International Organisation for Standardisation, 1995 82. International Conference on Harmonisation of Technical Requirements for Pharmaceuticals (ICH): M3(R1) nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals. Geneva, Switzerland, ICH, 1997 83. Ames B, McCann J, Yamasaki E: Methods for detecting carcinogens and mutagens with the Salmonella/mammalianmicrosome mutagenicity test. Mutat Res 31:347-364, 1975 84. Green MHL, Muriel WJ: Mutagen testing using trp+ reversion in Escherichia coli. Mutat Res 38:3-32, 1976 85. Evans HJ: Cytological methods for detecting chemical mutagens, in Hollaender A (ed): Chemical mutagens, principles and methods for their detection, vol. 4. New York (NY), Plenum Press, 1976 86. Swierenga SHH, Heddle JA, Sigal EA, et al: Recommended protocols based on a survey of current practice in genotoxicity testing laboratories, IV. Chromosome aberration and sister-chromatid exchange in Chinese hamster ovary, V79 Chinese lung and human lymphocyte cultures. Mutat Res 246: 301-322, 1991 87. Galloway SM, Ardema AMJ, Ishidate MJ, et al: Report from working group on in vitro tests for chromosomal aberrations. Mutat Res 312:241-261, 1994 88. Heddle JA: A rapid in vivo test for chromosomal damage. Mutat Res 18:187-190, 1973 89. Mavournin KH, Blakey DH, Cimino, et al: The in vivo micronucleus assay in mammalian bone marrow and peripheral 52. Li J, Lockerbie O, de Korte D, et al: Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 45:920-926, 2005 53. Kumar V, Motheral T, Luzniak G, et al: Mirasol (TM) plasma pathogen reduction technology: Riboflavin-based process conserves, protein C, protein S and antithrombin activities. Transfusion 43(Suppl):80A, 2003 (abstr) 54. Kumar V, Motheral T, Luzniak G, et al: Mirasol (TM) pathogen reduction technology: Riboflavin-based process retains functional activities of immumoglobulins. Transfusion 43 (Suppl):80A, 2003 (abstr) 55. Perez-Pujol S, Tonda R, Lozano M, et al: Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 45:911-919, 2005 56. Goodrich RP, Li J, Pieters H, et al: Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 90:279-285, 2006 57. AuBuchon JP, Herschel L, Roger J, et al: Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 45:1335-1341, 2005 58. WHO: Twenty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. Evaluation of certain food additives. Tech Rep Ser 669:1-48 59. EVM. Expert Group on Vitamins and Minerals; revised review of riboflavin. 2002. 1-48 60. Federation of American Societies for Experimental Biology: Evaluation of the health aspects of riboflavin and riboflavin-5`-phosphate as food ingredients, SCOGS-114. Life Sciences Research Office, Federation of American Societies for Experimental Biology, Bethesda, Maryland. Prepared for US Food and Drug Administration, Washington, DC, 1979, pp 1-25 61. Martindale W, Sweetman SC (eds): The complete drug reference. 33rd ed. London, UK, Pharmaceutical Press, 2002, p 1386 62. BIBRA Working Group: Riboflavin and its derivatives: toxicity profile. Epscm, Surrey, UK, BIBRA, 1990, pp 1-7 63. Direct Food Substances Affirmed as Generally Recognized as Safe; Riboflavin. 21 CFR Sect. 184.1695; 2001 64. European Commission Health and Consumer Protection Directorate-General, Scientific Committee on Food: Opinion of the Scientific Committee on Food on the tolerable upper intake level of vitamin B2. Brussels, Belgium, European Commission, 2000, pp 1-10 65. Sisson TR, Kendall N, Shaw E, et al: Phototherapy of jaundice in the newborn infant. II. Effect of various light intensities. J Pediatr 81:35-38, 1972 66. Sisson TR: Photodegradation of riboflavin in neonates. Fed Proc 46:1883-1885, 1987 67. Bates CJ: Human requirements for riboflavin. Am J Clin Nutr 46:122-123, 1987 68. Kostenbauder HB, DeLuca PP, Kowarski CR: Photobinding and photoreactivity of riboflavin in the presence of macromolecules. J Pharm Sci 54:1243-1251, 1965 69. Yurdakok M, Erdem G, Tekinalp G: Riboflavin in the treatment of neonatal hyperbilirubinemia. Turk J Pediatr 30:159-161, 1988 70. Olsen JH, Hertz H, Kjaer SK, et al: Childhood leukemia following phototherapy for neonatal hyperbilirubinemia (Denmark). Cancer Causes Control 7:411-414, 1996 71. Speck WT, Rosenkranz HS: Phototherapy for neonatal hyperbilirubinemiaâA potential environmental health hazard 350 TOXICOLOGICAL REVIEW OF MIRASOL PRT 153 blood. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 239:29-80, 1990 90. Hayashi M, Tice RR, Macgregor JT, et al: In vivo rodent erythrocyte micronucleus assay. Mutat Res 312:293-304, 1994 91. Arndt PA, Garratty G, Hill J, et al: Two cases of immune haemolytic anaemia, associated with anti-piperacillin, detected by the âimmune complexâ method. Vox Sang 83:273-278, 2002 92. Creech HJ, O'Connell AP: Immunochemistry of conjugates prepared from serum albumins and acridine nitrogen mustards (ICR mutagens). Cancer Res 41:3844-3851, 1981 93. Dise CA, Burch JW, Goodman DB: Direct interaction of mepacrine with erythrocyte and platelet membrane phospholipid. J Biol Chem 257:4701-4704, 1982 94. Chen RF: Fluorescence of quinacrine mustard conjugated to proteins. Arch Biochem Biophys 172:39-50, 1976 95. Jusko WJ, Levy G: Plasma protein binding of riboflavin and riboflavin 5â²-phosphate in man. J Pharm Sci 58:58-62, 1969 96. Tapia G, Silva E: Photo-induced binding to the tryptophan residues of bovine and human serum albumin. Radiat Environ Biol 30:131-138, 1991 97. Diaz M, Ines Becker M, De Ioannes AE, et al: Development of monoclonal antibodies against a riboflavintryptophan photoinduced adduct: Reactivity to eye lens proteins. J Photochem Photobiol 63:762-767, 1996 98. Innis WSA, McCormick DB, Merrill AH: Variations in riboflavin binding by human plasma: Identification of immunoglobulins as the major proteins responsible. Biochem Med 34: 151-156, 1985 99. Merrill AH, Innis-Whitehouse WSA, McCormick DB: Characterization of human riboflavin-binding immunoglobulins, in Edmondson DE, McCormick DB (eds): Flavins and flavoproteins. Berlin, Walter de Gruyter & Co, 1987, pp 445-448 100. International Organisation for Standardisation: International Standard ISO 10993 biological evaluation of medical devicesâPart 5: Tests for in vitro cytotoxicity. Geneva, Switzerland, International Organisation for Standardisation, 1999 101. International Organisation for Standardisation: International Standard ISO 10993 biological evaluation of medical devicesâPart 4: Selection of tests for interactions with blood. Geneva, Switzerland, International Organisation for Standardisation, 2002 102. Material Sciences Toxicology Laboratories: Autian method, ATTP-I. Memphis (TN), University of Tennessee Center for the Health Sciences, 1977 103. HemolysisâRabbit blood, evaluation of hemodialyzers and dialysis membranes. 77-1294, 213. 1977. DHEW Publication (NIH). 104. Hellstern P, Sachse H, Schwinn H, et al: Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 63:178-185, 1992 105. International Conference on Harmonisation of Technical Requirements for Pharmaceuticals (ICH): S3B Pharmacokinetics: Guidance for Repeat Dose Tissue Distribution Studies. Geneva, Switzerland, ICH, 1995 106. Goodrich RP, Edrich RA, Li J, et al: The Mirasol PRT System for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apheresis Sci 35:5-17, 2006 107. Goodrich RP, Edrich RA, Goodrich L, et al: The antiviral and antibacterial properties of riboflavin and light: Applications to blood safety and transfusion medicine, in Silva E, Edwards AM (eds): Flavins: Photochemistry and photobiology. Cambridge (UK), The Royal Society of Chemistry, 2006, pp 83-113 351 æç®25 èªå·±å®£èšã®ããã® CE ããŒãã³ã°é©å察çå®å ã¬ã€ããã㯠2005 幎 3 æ æ¥æ¬è²¿ææ¯èæ©æ§ 352 â ç® æ¬¡ â ã¯ããã« ....................................................................................................................................................... 1 ãã¥ãŒã¢ãããŒãæä»€ãšã¯....................................................................................................................... 1 åžå Žæå ¥ããã³ãµãŒãã¹éå§(PLACING ON THE MARKET AND PUTTING INTO SERVICE) ................................. 1 å¿ é èŠæ±äºé (ESSENTIAL REQUIREMENTS) ............................................................................................... 1 èªç±ãªç§»å(FREE MOVEMENT).................................................................................................................... 2 ã»ãŒãã¬ãŒãæ¡é (SAFEGUARD CLAUSE).................................................................................................... 2 é©åæ§è©äŸ¡(CONFORMITY ASSESSMENT)..................................................................................................... 2 ããŒãã£ãã¡ã€ãããã£ïŒå ¬èªæ©é¢ïŒïŒNOTIFIED BODIESïŒ..................................................................... 2 æŽåèŠæ ŒïŒHARMONIZED STANDARDïŒ ....................................................................................................... 2 ç§»è¡æéïŒTRANSITION PERIODïŒ .............................................................................................................. 2 CE ããŒãã³ã°ãšã¯............................................................................................................................... 3 1 1.1. CE ããŒãã³ã°ã®åå (CE MARKING)............................................................................................ 3 1.2. CE ããŒãã³ã°ã貌ä»ãã補å ..................................................................................................... 3 ãã¥ãŒã¢ãããŒãæä»€ (NEW APPROACH DIRECTIVE) ............................................................... 3 2 2.1 æä»€ã®å¯Ÿè±¡è£œå ............................................................................................................................. 3 2.2. è€æ°ã®æä»€ãåæã«é©çšããå¿ èŠæ§............................................................................................. 4 2.3. åžå Žæå ¥ãšãµãŒãã¹éå§............................................................................................................... 4 補é è 責任 ........................................................................................................................................ 5 3 3.1. è£œé æ¥è ãšã¯................................................................................................................................. 5 3.2. æ£åŒä»£è¡šè ïŒAUTHORIZED REPRESENTATIVEïŒ ............................................................................... 5 3.3. èŒžå ¥æ¥è ïŒåžå Žæå ¥ã®è²¬ä»»è ....................................................................................................... 5 3.4. 補é ç©è²¬ä»» .................................................................................................................................... 5 é©åæ§è©äŸ¡ãšã¢ãžã¥ãŒã« .................................................................................................................. 6 4 èªå·±å®£èš.................................................................................................................................................... 6 èªå·±å®£èšã«ãŒãã§ã®ãªã¹ã¯....................................................................................................................... 6 é©åæ§è©äŸ¡ã«ã€ã㊠................................................................................................................................. 6 åºæ¬ã¢ãžã¥ãŒã«......................................................................................................................................... 7 5 äž»èŠãã¥ãŒã¢ãããŒãæä»€æŠèŠ ....................................................................................................... 9 5.1 æ©æ¢°æä»€ ïŒ98/37/ECïŒ.................................................................................................................... 9 5.1.1 æ©æ¢°æä»€ã®å¯Ÿè±¡å€è£œåäŸ ........................................................................................................... 9 ä»å±æžâ £.................................................................................................................................................... 9 5.2 äœé»å§æä»€ (73/23/EEC) ................................................................................................................ 10 -i- 353 5.2.1 äœé»å§æä»€ã®å¯Ÿè±¡å€è£œåäŸ ......................................................................................................11 EMC æä»€ïŒ89/336/EEC, 2004/108/ECïŒ .......................................................................................11 5.3 5.3.1 EMC æä»€ã®å¯Ÿè±¡å€è£œå............................................................................................................11 5.3.2 EMC æä»€ã®ç®ç..................................................................................................................... 12 5.3.3 EMC æä»€ã®ç¹åŸŽ...................................................................................................................... 12 5.3.4 89/336/EEC ãš 2004/108/EC.................................................................................................. 12 5.3.5 EMC æä»€ãžã®é©åæç¶ .......................................................................................................... 13 5.3.6 èŠæ Œã®éžæ............................................................................................................................... 14 5.3.7 詊éšã®å®æœ............................................................................................................................... 16 å»çæ©åšæä»€ (93/42/EEC)............................................................................................................. 16 5.4 5.4.1 ã¯ã©ã¹åé¡............................................................................................................................... 18 5.4.2 é©åæ§è©äŸ¡ã«ãŒãã®éžæ ......................................................................................................... 19 5.4.3 åºæ¬èŠä»¶ïŒå¿ é èŠæ±äºé ïŒ ..................................................................................................... 20 5.5 R&TTE æä»€ 5.6 ç©å ·æä»€ (93/68/EEC) .................................................................................................................... 22 6. ç¡ç·åã³é»æ°éä¿¡ç«¯æ«æ©åšæä»€ (1999/5/EC) ........................................................ 21 æè¡ææžã®äœææ¹æ³ ........................................................................................................................... 23 6.1 æ©æ¢°æä»€ ...................................................................................................................................... 24 6.2 äœé»å§æä»€ .................................................................................................................................. 25 6.3 EMC æä»€ .................................................................................................................................... 27 6.4 å»çæ©åšæä»€............................................................................................................................... 28 6.5 R&TTE æä»€................................................................................................................................. 29 6.6 ç©å ·æä»€ ...................................................................................................................................... 29 ããã¥ã¢ã«äœææã®çæç¹............................................................................................................. 31 7. 7.1 æ©æ¢°æä»€ ...................................................................................................................................... 31 7.2 äœé»å§æä»€ .................................................................................................................................. 33 7.3 EMC æä»€ .................................................................................................................................... 34 7.4 å»çæ©åšæä»€............................................................................................................................... 35 7.5 RïŒTTE æä»€ ............................................................................................................................... 35 7.6 ç©å ·æä»€ ...................................................................................................................................... 35 8. é©åå®£èšæžã®äœææ¹æ³ .................................................................................................................... 36 9 CE ããŒãã³ã°ã®è²Œä» ......................................................................................................................... 38 åèæ å ±ïŒæ¬§å·å§å¡äŒãµã€ã ................................................................................................................. 39 - ii - 354 ã¯ããã« ãã¥ãŒã¢ãããŒãæä»€ãšã¯ EU çµ±åã®äžç°ãšããŠãç£æ¥çã®æè¡äžã®çµ±äžãå³ãããã«ã1985 幎 5 æã«ãæè¡çãªæŽåãšèŠæ Œ ãžã®ãã¥ãŒã¢ãããŒãããæ±ºè°ãããããã¥ãŒã¢ãããŒãæä»€ã«èŠå®ããã補åã«ã€ããŠã¯ãåºæ¬ç èŠæ±äºé ã«é©åããŠããªããã°ãªããªãããŸãããã®èŠæ±äºé ã«é©åããŠãã補åã® EU åå ã§ã®åº è·ãæµéã®ããã«ã¯ãCE ããŒãã³ã°ã貌ä»ãããŠããå¿ èŠãããã çŸæç¹ã§ã¯ã以äžã®ãã¥ãŒã¢ãããŒãæä»€ãåºãããŠããã ïŒ1ïŒäœé»å§æ©åš ïŒ2ïŒåçŽå§åå®¹åš ïŒ3ïŒç©å · ïŒ4ïŒå»ºèšè³æ ïŒ5ïŒEMC ïŒ6ïŒæ©æ¢° ïŒ7ïŒå人ä¿è·å · ïŒ8ïŒéèªåééèš ïŒ9ïŒå蟌åŒèœååå»çæ©åš ïŒ10ïŒã¬ã¹ççŒæ©åš ïŒ11ïŒç±æ°Žãã€ã© ïŒ12ïŒæ°ççšçè¬ ïŒ13ïŒå»çæ©åš ïŒ14ïŒççºå±éºå Žæã«ãããæ©åšãšã·ã¹ãã ïŒ15ïŒã¬ãžã£ãŒçšè¹è ïŒ16ïŒãšã¬ããŒã¿ ïŒ17ïŒå·èµæ©åš ïŒ18ïŒå§åå®¹åš ïŒ19ïŒé ééä¿¡ç«¯æ«æ©åš ïŒ20ïŒäœå€èšºæçšå»çæ©åš ïŒ21ïŒèšæž¬åš ãã¥ãŒã¢ãããŒãæä»€ãçè§£ããããã«ã¯ãäžèšã®çšèªã®å®çŸ©ãçè§£ããå¿ èŠãããã åžå Žæå ¥ããã³ãµãŒãã¹éå§(Placing on the market and putting into service) EUåå ã«åããŠè£œåãåžå Žæå ¥ïŒãŸãã¯ãµãŒãã¹éå§ïŒããããšãæããå çåœã¯è£œåãæå³ãã ãç®çã«å¯ŸããŠé©åã«èšçœ®ãç¶æç®¡çãããã³äœ¿çšãããéãã補åã®åžå Žæå ¥ã»ãµãŒãã¹éå§ã«é¢ ããããå®å šãå¥åº·ããŸãã¯ãã®ä»ã®å ¬å ±å©çããªã¹ã¯ã«ãããããããšã®ãªãããã«ãå¿ èŠãªæªçœ® ãè¬ãã矩åãè² ããããã«ã¯ãå çåœåŽã®åžå Žç£èŠçŸ©åã䌎ãã å¿ é èŠæ±äºé (Essential Requirements) å¿ é èŠæ±äºé ã¯æä»€ã®éåã«èŠå®ãããæä»€ã®ç®çéæã«å¿ èŠãªããããäºé ãç¶²çŸ ãããåžå Žæ å ¥ã»ãµãŒãã¹éå§ã§ããã®ã¯ãå¿ é èŠæ±äºé ã«æºæ ãã補åã®ã¿ã§ããã â¢ å¿ é èŠæ±äºé ã¯å ¬å ±ã®å©çãä¿è·ããããã«å¿ èŠãªèŠçŽ ãèŠå®ããã â¢ å¿ é èŠæ±äºé ã¯åŒ·å¶ã§ãããå¿ é èŠæ±ã«æºæ ãã補åã®ã¿ãåžå Žæå ¥ããã³ãµãŒãã¹éå§ã§ããã â¢ å¿ é èŠæ±äºé ã¯ã補åã®ãã€ãªã¹ã¯èŠçŽ ãšããŠè©äŸ¡ãé©çšãããªããã°ãªããªãã - 1- 355 èªç±ãªç§»å(Free movement) ãã¥ãŒã¢ãããŒãæä»€ã®çºå¹ã«äŒŽã£ãŠãEUå ã§ã®åæä»€ã«é¢ããæè¡èŠæ Œã¯çµ±äžããããŸãæä»€ã® èŠæ±ãšæŽåããªãèŠå(äŸãã°ãæå®ãããæ©é¢ã«ããèªå¯ãèªèšŒã®èŠæ±)ã¯æ€å»ããããã€ãŸããåæ ä»€ã®é©çšå¯Ÿè±¡ãšãªãæ©åšã¯ã該åœããå šãŠã®æä»€ã®èŠæ±ã«åŸãããšã«ãã£ãŠãã©ã®EUå çåœã«ãã ãŠãæµéã§ããã ã»ãŒãã¬ãŒãæ¡é (Safeguard clause) CEããŒãã³ã°è²Œä»è£œåã䜿çšãããå®å šãå¥åº·ããŸãã¯å ¬å ±ã®å©çãæãªãå¯èœæ§ãããå Žåãå çåœã¯ãåœè©²è£œåã®åžå Žæå ¥ãçŠæ¢ãŸãã¯å¶éããããããããã¯åœè©²è£œåãåžå Žããæ€éãããã ãã«é©åãªæªçœ®ããã¹ãŠè¬ããã é©åæ§è©äŸ¡(Conformity Assessment) EUåžå Žã«æå ¥ããã補åã¯ãCEããŒãã³ã°ã貌ä»ããããã®é©åæ§è©äŸ¡æç¶ããšãå¿ èŠãããã ããŒãã£ãã¡ã€ãããã£ïŒå ¬èªæ©é¢ïŒ ïŒNotified BodiesïŒ ããŒãã£ãã¡ã€ãããã£ïŒå ¬èªæ©é¢ïŒã¯ãæä»€ãå®ããèŠä»¶ãæºãããŠãããã©ããã第äžè æ©é¢ãš ããŠé©åæ§è©äŸ¡ã宿œãããåå çåœã®é åå ã«èšç«ãããæ©é¢ã®äžããåå çåœã§æå®ãããã補 å矀ã«ãã£ãŠã¯ãããŒãã£ãã¡ã€ãããã£ã«ãã詊éšãèªèšŒãããªããã°ãªããªããã®ãããã æŽåèŠæ ŒïŒHarmonized StandardïŒ æŽåèŠæ Œã¯ã欧å·å§å¡äŒãšEUã®èŠæ Œæ©æ§ã®éã§åæãããäžè¬æéã«åŸã£ãŠäœæãããèŠæ Œã§ããã ããããã®æä»€ã«å¯Ÿããé©åæ§ã®æšå®ã«çšããããšã®ã§ããæŽåèŠæ Œã®ãªã¹ãã¯ã欧å·å®å ±ïŒOfficial JournalïŒã§å ¬è¡šãããŠããã®ã§ãé©å宣èšã®ããã«æŽåèŠæ Œãçšããå Žåã«ã¯ãã®ãªã¹ãã確èªã ãŠé©åãªèŠæ Œãéžæããå¿ èŠãããã ç§»è¡æéïŒTransition PeriodïŒ ãã¥ãŒã¢ãããŒãæä»€ã¯ãæä»€ãæ°ãã«çºä»€ãããå ŽåããŸãã¯æä»€ãæ¹èšãããå Žåãç§»è¡æéã èšå®ãããŠããã ç§»è¡æéã®æçµæ¥ãŸã§ã¯ãè£œé æ¥è ã¯åœå å¶åºŠããŸãã¯æ¹èšåã®æä»€ã«åŸã£ãŠèšèšã»è£œé ããã補åã® åžå Žæµéãã§ãããç§»è¡æéäžã¯ãè£œé æ¥è ãããããé©çšããããéžæã§ãããç§»è¡æéçµéåŸã¯ã é©çšãããæä»€ã«æºæ ãã補åã®ã¿ããEUåžå Žæå ¥ãšãµãŒãã¹éå§ãèš±å¯ãããã - 2- 356 CE ããŒãã³ã°ãšã¯ 1 1.1. ⢠CE ããŒãã³ã°ã®åå (CE Marking) CEããŒãã³ã°ã¯è£œé æ¥è ã«èª²ãããé©çšãããèŠæ±äºé ã«è£œåãé©åããŠããããšã瀺ãã㌠ã¯ã§ããã ⢠補é 責任è ã«ããé©å宣èšããªãããCEããŒãã³ã°ã貌ä»ãã補åã¯ã é©çšãããå šãŠã®EUæ¡é ã«æºæ ããŠããã é©åãªé©åæ§è©äŸ¡æç¶ããå®äºããŠããã CEããŒãã³ã°ã¯ãè£œé æ¥è ãCEããŒãã³ã°ã貌ä»ããããšã«ãããåœè©²è£œåãé©åããŠããããšã 瀺ãããŒãã³ã°ã§ãããèšããããã°ãCEããŒãã³ã°ã貌ä»ãããŠãã補åã¯ãé©çšãããå šæ¡é ã«æºæ ããé©åãªé©åæ§è©äŸ¡æç¶ããçµãããšãæå³ããŠãããCEããŒãã³ã°ã®è²Œä»ãå®ããæä»€ ã¯ãåºæ¬çã«ãã¥ãŒã¢ãããŒãæä»€ã«ãã£ãŠãCEããŒãã³ã°ã®è²Œä»ã決ããããŠããã 1.2. ⢠CE ããŒãã³ã°ã貌ä»ãã補å ç¹å®ã®æä»€ãå¥ã«å®ããå Žåãé€ãããã¥ãŒã¢ãããŒãæä»€ã®å¯Ÿè±¡ãšããã補åã«ã€ããŠã¯ãCE ããŒãã³ã°ã¯åŒ·å¶ã§ãããåžå Žæå ¥ããã³äžåžåã«ããã¹ãŠã®è£œåã«è²Œä»ãããªããã°ãªããªãã ⢠補åãè€æ°ã®æä»€ã®å¯Ÿè±¡ã§ããããããã®æä»€ããã¹ãŠCEããŒãã³ã°è²Œä»ãå®ããŠããå Žåã CEããŒãã³ã°ã¯ãåœè©²è£œåãããããã¹ãŠã®æä»€ã«æºæ ããŠãããšã¿ãªãããããšã瀺ãã ⢠2 2.1 ⢠CEããŒãã³ã°ãå®ããæä»€ã®å¯Ÿè±¡å€è£œåã¯ãCEããŒãã³ã°ã貌ä»ããŠã¯ãªããªãã ãã¥ãŒã¢ãããŒãæä»€ (New Approach Directive) æä»€ã®å¯Ÿè±¡è£œå ãã¥ãŒã¢ãããŒãæä»€ã¯ãEUåžå Žã§åããŠåžå Žæå ¥ïŒãŸãã¯ãµãŒãã¹éå§ïŒããäºå®ã®è£œåã« é©çšãããããããã£ãŠåæä»€ã¯ãå çåœã§è£œé ãããæ°è£œåããªãã³ã«ç¬¬äžåœããèŒžå ¥ããã äœ¿çšæžã¿è£œåã»äžå€åã»æ°è£œåã«é©çšãããã ⢠補åã®æŠå¿µã¯åã ã®ãã¥ãŒã¢ãããŒãæä»€ã§ç°ãªãã補åãæä»€ã®ç¯å²å ãã©ãããæ€èšŒããã® ã¯è£œé æ¥è ã®è²¬ä»»ã§ããã â¢ å€§å¹ ã«å€æŽãããäžå€è£œåããæ¹ããŠEUåžå Žã§åžå Žæå ¥ã»ãµãŒãã¹éå§ããéã«ãé©çšããã æä»€ã®æ¡é ã«æºæ ãã¹ãæ°è£œåãšã¿ãªãããå Žåããããããã¯ãç¹ã«èŠå®ãããªãéãã±ãŒã¹ ãã€ã±ãŒã¹ã§æ€èšãããå¿ èŠãããã ⢠æ§èœãç®çãçš®é¡ãå€ããã«ä¿®çããã補åã¯ããã¥ãŒã¢ãããŒãæä»€ã«åŸã£ãé©åæ§è©äŸ¡ã®å¯Ÿ 象ã§ã¯ãªãã ⢠ç¹å¥ãŸãã¯æä»çã«è»äºã»æ¿æ²»ç®çãæå³ããã補åã¯ãç¹å®ã®ãã¥ãŒã¢ãããŒãæä»€ã®ç¯å²ã - 3- 357 ãæç€ºçã«é€å€ãããããã®ä»ã®æä»€ã«é¢ããŠã¯ãECæ¡çŽç¬¬296æ¡ã«åŸããå çåœã¯è»äºç®çå° çšã®è£œåãç¹å®ã®æ¡ä»¶äžã§æä»€é©çšåéããé€å€ã§ããã 2.2. â¢ è€æ°ã®æä»€ãåæã«é©çšããå¿ èŠæ§ è€æ°ã®ãã¥ãŒã¢ãããŒãæä»€ãå®ããå¿ é èŠæ±äºé ã¯ãåœè©²è£œåã«é¢é£ããèŠæ±ã®å¯Ÿè±¡ãšãªãå± éºã®çš®é¡ã«å¿ããŠãçžäºã«éè€ãŸãã¯è£å®ããå Žåãããã ⢠補åãåžå Žæå ¥ããã³æµééå§ã§ããã®ã¯ã補åãé©çšããããã¹ãŠã®æä»€ã®æ¡é ã«æºæ ããã ã€é©çšããããã¹ãŠã®æä»€ã«åŸã£ãŠé©åæ§è©äŸ¡ã宿œãããå Žåã®ã¿ã§ããã 2.3. ⢠åžå Žæå ¥ãšãµãŒãã¹éå§ åžå Žæå ¥ãšã¯ãEUåå ã§ã®æµéãŸãã¯äœ¿çšãç®çãšããŠè£œåãåããŠEUåžå Žã§å ¥æå¯èœã«ãã åæã®æŽ»åã§ãããå ¥ææ¹æ³ãææã»ç¡æã®ãããã§ãã£ãŠãããã«ããŠã¯ãŸãã ⢠ãµãŒãã¹éå§ã¯ãEUåå ã§ãŠãŒã¶ãŒã補åãåããŠäœ¿çšããæç¹ãæãã ⢠ãã補åãEUåå ã§åããŠåžå Žæå ¥ããã³ãµãŒãã¹éå§ããéãåœè©²è£œåã¯ãã¥ãŒã¢ãããŒã æä»€ã«æºæ ããŠããªããã°ãªããªãã ãã¥ãŒã¢ãããŒãæä»€ã¯ãé©çšãããæä»€ã«å®ãããã髿°Žæºã®å®å šäºé²ã«æºæ ãã補åã®ãèªç±ãª ç§»åã確ä¿ããããã«çå®ãããããããã£ãŠãå çåœã¯ããã補åã®åžå Žæå ¥ãçŠæ¢ãå¶éããŸã ã¯é»å®³ããŠã¯ãªããªãã 以äžã®è£œåã¯åžå Žæå ¥ãšã¯ã¿ãªãããªãã 㻠第äžåœã®è£œé æ¥è ããEUåå ã®æ£åŒä»£è¡šè ã«ç§»ç®¡ããã補åã§ããã€ãåœè©²è£œé æ¥è ãåœè©²ä»£ 衚è ã«è£œåã®æä»€æºæ ã確ä¿ãããŠããå Žå 㻠補åã远å åŠçïŒçµç«ã梱å ãå å·¥ãã©ããªã³ã°ãªã©ïŒã®ããã«è£œé æ¥è ã«ç§»ç®¡ããã補å ã» èªç±ã«æµéããèš±å¯ãçšé¢ããïŒãŸã ïŒåããŠããªã補åãå¥ã®çšé¢ã®æç¶ãäžã«ãã補åïŒèŒž éãå庫ä¿ç®¡ãäžæèŒžå ¥ãªã©ïŒããããã¯èªç±å°åž¯ã«ãã補å 㻠第äžåœã«èŒžåºããç®çã§å çåœå ã§è£œé ããã補å ã» èŠæ¬åžããã¢ã«å±ç€ºããã補å ã» è£œé æ¥è ã®åšåº«ããŸãã¯EUåå ã§èšç«ãããæ£åŒä»£è¡šè ã®åšåº«äžã«ããããã€ããŸã åžå Žã§å ¥ æå¯èœã§ã¯ãªã補åïŒé©çšãããæä»€ã§ç¹ã«å®ããå Žåãé€ãïŒ ã«ã¿ãã°äžãŸãã¯é»ååååŒã®ææ®µã§æç€ºããã補åã¯ããããåããŠå®éã«åžå Žã§å ¥æå¯èœã«ãªã ãŸã§ã¯EUåžå Žã«æå ¥ããããšã¯ã¿ãªãããªãã誀解ãæãåºåã®çŠæ¢ãç®çãšããèŠåã»ååãå° éããããã«ãEUåžå Žã§ã®æµéãæå³ãããéæºæ 補åã«ã¯ããã®ããšãæç€ºããªããã°ãªããªãã 補åã¯ãEUåžå Žã«æå ¥ãããéãé©çšããããã¥ãŒã¢ãããŒãæä»€ãªãã³ã«ä»ã®EUæ³ã«æºæ ããŠã ãªããã°ãªããªãããããã£ãŠãEUåå ã§è£œé ãããæ°è£œåããã³ç¬¬äžåœããèŒžå ¥ãããå šè£œåïŒæ° åãäžå€ãã«ãããããïŒã¯ãEUåžå Žã§åããŠå ¥æå¯èœãšãªããšããé©çšãããæä»€ã®æ¡é ã«æºæ - 4- 358 ããŠããªããã°ãªããªããå çåœã¯ããããåžå Žç£èŠã®æ çµã¿ã«ãããŠç¢ºä¿ãã矩åãè² ããEUåž å Žã«ããäœ¿çšæžã¿è£œåã¯ãECæ¡çŽç¬¬28æ¡ããã³ç¬¬30æ¡ã«æ¢å®ãããååã«åŸã£ãŠèªç±ãªç§»åã®å¯Ÿè±¡ ãšãªãã 3 3.1. 補é è 責任 è£œé æ¥è ãšã¯ ãã¥ãŒã¢ãããŒãæä»€ã§ã®è£œé æ¥è ãšã¯ãèªèº«ã®å©çã®ããã« EU åžå Žãžã®è£œåæå ¥ãæå³ããŠãã 補åã®èšèšãšè£œé ã®è²¬ä»»è ã§ãããè£œé æ¥è ã¯ãEU åžå Žã«æå ¥äºå®ã®è£œåããé©çšããããã¥ãŒã¢ ãããŒãæä»€ã®æ¡é ã«åŸã£ãŠèšèšã»è£œé ããããã€å¿ é èŠæ±ã«ç §ãããŠé©åæ§è©äŸ¡ãè¡ãããããã« ãã矩åãè² ããè£œé æ¥è ã¯ãæçµè£œåãæ¢è£œéšåãæ¢è£œæ§æéšåã䜿çšã§ãããããã¯ããããã® æ¥åã倿³šã§ããããã ãè£œé æ¥è ã¯ãåžžã«å šäœç®¡çãç¶æãããŸã補åã«å¯Ÿãã責任èœåãæã㊠ããªããã°ãªããªãã 3.2. æ£åŒä»£è¡šè ïŒAuthorized representativeïŒ è£œé æ¥è ã¯ãä»»æã®å人ãŸãã¯æ³äººããèªèº«ã®ä»£çãšãªãæ£åŒä»£è¡šè ãšããŠä»»åœã§ããã ãã¥ãŒã¢ãããŒãæä»€ã®ç®çãããæ£åŒä»£è¡šè 㯠EU åå ã®è ãä»»åœããªããã°ãªããªãã è£œé æ¥è ã¯ãèªèº«ã®ä»£çã§ããæ£åŒä»£è¡šè ã®è¡åã«å¯ŸããŠäžè¬ç責任ãç¶æããã 3.3. èŒžå ¥æ¥è ïŒåžå Žæå ¥ã®è²¬ä»»è ãã¥ãŒã¢ãããŒãæä»€ã®å®çŸ©ã§ã¯ãèŒžå ¥æ¥è ïŒåžå Žæå ¥ã®è²¬ä»»è ïŒãšã¯ã第äžåœãã補åã EU åžå Ž ã«è£œåãæå ¥ãããEU åå ã§èšç«ãããä»»æã®å人ãŸãã¯æ³äººã§ãããèŒžå ¥æ¥è ã¯ãåœè©²è£œåã®è£œ é æ¥è ã EU åå ã§èšç«ãããŠããããã〠EU åå ã«è£œé æ¥è ã®æ£åŒä»£è¡šè ãååšããªãå Žåã補 åã«é¢ããå¿ èŠãªæ å ±ãåžå Žç£èŠæ©é¢ã«æäŸã§ããªããã°ãªããªãã 3.4. 補é ç©è²¬ä»» 補é ç©è²¬ä»»ã«é¢ããæä»€ã®å¯Ÿè±¡ã¯ãå人ãŸãã¯ç§æè²¡ç£ãžã®æå®³ã®åå ãšãªããEU åå ã§è£œé ãã ãã EU åå ã«èŒžå ¥ããããããã補åã§ããããããã£ãŠåæä»€ã¯ããã¥ãŒã¢ãããŒãæä»€ã®ç¯å² å ã®è£œåã«ãé©çšãããã補é ç©è²¬ä»»ã«é¢ããæä»€ã¯ãæçµè£œåã®åææãšæ§æéšåã«å ããããã ãåç£ããã³é»åã察象ãšããã 補é ç©è²¬ä»»ãã€ãŸãæå®³ãè£åãã責任ã¯çç£è ã«ãããçç£è ãšã¯ãæçµè£œåã®è£œé æ¥è ããŸã㯠æçµè£œåã®æ§æéšåã®è£œé æ¥è ãåææã®çç£è ããããã¯ïŒåæšè²Œä»ãªã©ã«ããïŒèªèº«ãè£œé æ¥è ãšããŠæç€ºããè ã§ããã第äžåœãã EU åžå Žã«è£œåãæå ¥ããèŒžå ¥æ¥è ã¯ããã¹ãŠè£œé è 責任ã«é¢ ããæä»€ã«åŸãè£œé æ¥è ãšã¿ãªããããè£œé æ¥è ãç¹å®ã§ããªãå Žåã補åã®åäŸçµŠè ã¯ãåçç㪠æéå ã«è£œé æ¥è ã®èº«å ãŸãã¯è£œåäŸçµŠè ãè² å·è ã«éç¥ããªãéã補é ç©è²¬ä»»ãè² ãã - 5- 359 è£œé æ¥è ã¯ãæ¬ é¥è£œåãåå ã§åäººïŒæ»äº¡ãè² å·ïŒããã³ç§æè²¡ç£ïŒç§çšã®ç©åïŒã«çºçããæå®³ã è£åããªããã°ãªããªããæä»€ã§ã¯ 1 ä»¶ã«ã€ã 500 ãŠãŒã以äžã®è²¡ç£ãžã®æå®³ã¯å¯Ÿè±¡å€ã§ããã粟 ç¥çæå®³ïŒèŠçãªã©ïŒã«ã€ããŠã¯åœå æ³ã§å¯Ÿå¿ãããæä»€ã¯æ¬ é¥è£œåèªäœã®ç Žå£ã察象ãšããªãã®ã§ã 補é ç©è²¬ä»»ã«é¢ããæä»€ã®äžã§ãã®è£å矩åã¯ãªããããã¯ãåœå æ³ã®æš©å©ã䟵害ããªãã 補é ç©è²¬ä»»ã«é¢ããæä»€ã«ãããå çåœã¯ãé£ç¶äºæ ã«ã€ããŠéé¡ã®äžéãèšããããšãã§ããèšå® é¡ã®æäœã¯ 7 åäžãŠãŒãã«åºå®ãããŠããããã ããçŸåšã»ãšãã©ã®å çåœã¯äžéãèšããŠããªãã åžå Žæå ¥ãã 10 幎åŸãçç£è ã®è£œé ç©è²¬ä»»ã¯èšŽèšäžã§ãªãéãæ¶æ» ããã 4 é©åæ§è©äŸ¡ãšã¢ãžã¥ãŒã« èªå·±å®£èš æä»€ã®èŠæ±ãžã®é©åæ§ã¯ãèªå·±å®£èšã«ãã£ãŠç€ºãããšãã§ããå Žåããããããã«ãããæ©åšã®åºè· ã«å ç«ã£ãŠèªèšŒãèªå¯ãåŸãªããã°ãªããªãå Žåãšæ¯èŒããŠãè£œé æ¥è ã®è² æ ã¯è»œæžããããŸãåºè· ãŸã§ã®æéã®ççž®ãå¯èœã§ããã ãã®èªå·±å®£èšãšã¯ããã®æ©åšãæä»€ã®èŠæ±ã«é©åããŠããããšãèªãã®è²¬ä»»ã§ä¿èšŒããæšã宣èšãã ããšãæããåŸã£ãŠãèªå·±å®£èšãè¡ãªã£ãè£œé æ¥è ãåã³ãã®å®£èšæžã«çœ²åããå人ã¯ããã®å®£èšã« é¢ããŠå€§ããªè²¬ä»»ãæã€ããšã«ãªãã èªå·±å®£èšã«ãŒãã§ã®ãªã¹ã¯ ⢠é©åãã¹ãèŠæ Œã®è©äŸ¡ã®èª€ã ⢠æè¡æ§é ãã¡ã€ã«ã®äžå ⢠çŸå°ã§ã®å®å šäžé©åã«ããè£å€ãªã©ã®äžæž¬ã®äºæ ãªã© é©åè©äŸ¡ãé£è§£ãªãããããŒãã£ãã¡ã€ãããã£ã«ããé©åè©äŸ¡ããäžéšãååŒè©Šéšãåããé©å蚌 ææžãæè¡æ§é ãã¡ã€ã«ã«çµã¿èŸŒãã±ãŒã¹ãå¢ããŠããã é©åæ§è©äŸ¡ã«ã€ã㊠⢠é©åæ§è©äŸ¡ã¯ã¢ãžã¥ãŒã«ã«çްååããããã¢ãžã¥ãŒã«ã¯ã補åã®æå€§ç¯å²ã«é©çšãããããã€ã ã®æç¶ããããªãã ⢠ã¢ãžã¥ãŒã«ã¯ã補åã®èšèšãã§ãŒãºãŸãã¯çç£ãã§ãŒãºããããã¯ãã®äž¡æ¹ã«é¢ããã8ã€ã®åº æ¬ã¢ãžã¥ãŒã«ãããã³ããã8ã€ã®èããããããªãšãŒã·ã§ã³ã倿§ãªæ¹æ³ã§çžäºã«çµã¿åãã ãããšã«ãã£ãŠãå®å šãªé©åæ§è©äŸ¡æç¶ãã確ç«ããããšãã§ããã ⢠ååãšããŠãèšèšãã§ãŒãºããã³çç£ãã§ãŒãºäžã補åã¯ã¢ãžã¥ãŒã«ã«åŸã£ãé©åæ§è©äŸ¡ã®å¯Ÿè±¡ ã§ããã - 6- 360 ⢠åãã¥ãŒã¢ãããŒãæä»€ã¯ãèããããé©åæ§è©äŸ¡æç¶ãã®ç¯å²ãšå 容ãèŠå®ããããã¯å®å šäº é²ã®å¿ èŠãªæ°ŽæºãæäŸãããšã¿ãªããããæä»€ã¯ãŸããè€æ°ã®éžæè¢ãçšæãããå Žåã«ãã©ã® ãããªæ¡ä»¶äžã§è£œé æ¥è ãéžæã§ãããã®æ±ºå®åºæºãèšããŠããã 補åãæä»€ã«é©åããŠãããã©ããã蚌æããæ¹æ³ãšããŠãã¢ãžã¥ãŒã«æ¹åŒãšããææ³ã䜿ããè£œé æ¥è ã¯ãå¿ èŠãªã¢ãžã¥ãŒã«ãéžæãããããã¯çµã¿åãããããšã«ãã£ãŠãããã€ãã®æ¹æ³ã®äžãã é©åãªèšŒææ¹æ³ãéžæããããšãã§ããããã¥ãŒã¢ãããŒãæä»€ã¯ãã©ã®æä»€ãå¿ ãèšèšå 容ã®è©äŸ¡ ãšçç£ã·ã¹ãã ã®è©äŸ¡ã®äž¡é¢ããæ§æãããŠããããã®ãããã©ã®ã¢ãžã¥ãŒã«ãéžæããã«ã€ããŠãã èšèšé¢ãšçç£é¢ã®ããããã®é©åæ§ã蚌æããªããã°ãªããªãã åºæ¬ã¢ãžã¥ãŒã« AïŒçç£ã®å éšç®¡çïŒ ç€Ÿå ã®èšèšã»çç£ç®¡çã察象ãšããããã®ã¢ãžã¥ãŒã«ã§ã¯ããŒãã£ãã¡ã€ãã ãã£ã«ããé¢äžã¯äžèŠã§ãèªå·±å®£èšã«ãããå¿ é èŠæ±äºé ãžã®é©åã宣èšãã CEããŒãã³ã°è²Œä»ãå¿ èŠãšãªãã BïŒååŒè©ŠéšïŒ èšèšãã§ãŒãºã察象ãšããçç£ãã§ãŒãºã§ã®è©äŸ¡ãèŠå®ããã¢ãžã¥ãŒã«ãåŸã« ç¶ããªããã°ãªããªããããŒãã£ãã¡ã€ãããã£ã«ããECååŒèªèšŒæžãååŸ ããªããã°ãªããªãã CïŒååŒãžã®é©åæ§ïŒ çç£ãã§ãŒãºã察象ãšããã¢ãžã¥ãŒã«Bã®åŸã«ç¶ããã¢ãžã¥ãŒã«Bã«åŸã£ãŠçº è¡ãããECååŒèªèšŒæžã«èšèŒãããŠããååŒãšã®é©åããŠããããšãå®£èš ããCEããŒãã³ã°ã®è²Œä»ãå¿ èŠãšãªãã DïŒçç£ã®å質ä¿èšŒïŒ çç£ãã§ãŒãºã察象ãšããã¢ãžã¥ãŒã«Bã®åŸã«ç¶ããè£œé æ¥è ãèšå®ããçç£ã æçµè£œåã®ååŒè©Šéšãçç£ã詊éšã®ããã®å質ã·ã¹ãã ã®ç®¡çã»èªèšŒãå¿ èŠã ããŒãã£ãã¡ã€ãããã£ã¯ãISO 9001èŠæ Œã«æºããŠè©äŸ¡ã EïŒè£œåã®å質ä¿èšŒïŒ çç£ãã§ãŒãºã察象ãšããã¢ãžã¥ãŒã«Bã®åŸã«ç¶ããè£œé æ¥è ãèšå®ããçç£ã æçµè£œåã®ååŒè©Šéšãçç£ã詊éšã®ããã®å質ã·ã¹ãã ã®ç®¡çãèªèšŒãå¿ èŠã ããŒãã£ãã¡ã€ãããã£ã¯ãISO 9001èŠæ Œã«æºããŠè©äŸ¡ã FïŒè£œåã®è©ŠéšïŒ çç£ãã§ãŒãºã察象ãšããã¢ãžã¥ãŒã«Bã®åŸã«ç¶ããããŒãã£ãã¡ã€ããã㣠ã¯ãã¢ãžã¥ãŒã«Bã«åŸã£ãŠçºè¡ãããECååŒèªèšŒæžã«èšèŒãããååŒãžã®é©å æ§ã管çããé©åèšŒææžãçºè¡ããã GïŒãŠããã詊éšïŒ èšèšãã§ãŒãºãšçç£ãã§ãŒãºã察象ãšãããããŒãã£ãã¡ã€ãããã£ã¯å補å ãåå¥ã«èª¿æ»ããé©åèšŒææžãçºè¡ããã HïŒå šäœã®å質ä¿èšŒïŒ èšèšãã§ãŒãºãšçç£ãã§ãŒãºã察象ãšãããè£œé æ¥è ãèšå®ããèšèšã補é ã æçµè£œåã®æ€æ»ã詊éšã«é¢ããå質ã·ã¹ãã ã®æ¿èªã»ç®¡çãè¡ãããŒãã£ãã¡ ã€ãããã£ã®ä»å ¥ã«ãããISO 9001ããæŽŸçããã ã¢ãžã¥ãŒã«Aã¯ããå éšçç£ç®¡çããšåŒã°ããã補åãæä»€ã«é©åããŠããããšãèªå·±è©äŸ¡ã§ããã« ãŒãã§ãããæä»€ããšã«ãæºåãã¹ãæè¡æ§é ãã¡ã€ã«ã®å å®¹ãæ±ºãŸã£ãŠããããã該åœãã¹ãæä»€ ãçèªããæè¡æ§é ãã¡ã€ã«ãšé©åå®£èšæžãäœæããCEããŒãã³ã°ã貌ä»ããããšã§ã察çã¯å®äº ã§ããã - 7- 361 ããããCEããŒãã³ã°è²Œä»åŸã補åã«åé¡ãçããæã¯ãé©åå®£èšæžã®çœ²åãããè£œé æ¥è ã«è£œå ã«é¢ãã責任ããããããšã«ãªããäžãäžãäžé©åãåœå±ã«ç¢ºèªãããå Žåã«ã¯ã補åãéããã«åž å ŽããåŒãäžããããŸãã¯è£œé æ¥è ããçŠåºåã眰åã®å¯Ÿè±¡ã«ãªãããšãããã äžéšã®è£œåã«ã€ããŠã¯ãããŒãã£ãã¡ã€ãããã£ã«ããååŒè©Šéšãå¿ èŠãšãããå Žåãããã®ã§ãé© åè©äŸ¡ã«äžå®ãæ®ãå Žåã«ã¯ãæä»€ãçç¥ããŠããããŒãã£ãã¡ã€ãããã£ã«ç¢ºèªãã¹ãã§ããã - 8- 362 5 äž»èŠãã¥ãŒã¢ãããŒãæä»€æŠèŠ 5.1 æ©æ¢°æä»€ ïŒ98/37/ECïŒ é£çµããéšåãŸãã¯æ§æéšæã®éåã§ãå°ãªããšããã®ãã¡ã®ã²ãšã€ãé©åãªäœæ¥è£ 眮ãå¶åŸ¡ãåå åè·¯ãªã©ã«ãã£ãŠåããã®ãã€ãŸããéšåã®éåäœã§å¯åéšããããã®ã 5.1.1 æ©æ¢°æä»€ã®å¯Ÿè±¡å€è£œåäŸ äººåã®ã¿ãååãšãããã®(æéæ©ãé€ã)ãæ£è ã«çŽæ¥äœ¿çšãããå»çæ©åšãéåå°ã»å𝿥œæœèšçšã«ç¹ å®ãããæ©åšãèžæ°ãã€ã©ãŒãã¿ã³ã¯ãå§å容åšãåååçšæ©åšãæ©æ¢°ãæ§æããæŸå°èœæºãç«åšã å±éºç©ã®å®¹åšãç§»åã®ããã®ææ®µãšãªããã®ãè¹è¶ã人ãéã¶ããŒããŠã§ã€ã»ã±ãŒãã«ã«ãŒã蟲æ¥ã» ææ¥çšãã©ã¯ã¿ãŒãè»ã»èŠå¯çšæ©åšã人ãéã¶æéæ©ãé±å±±ã®å·»äžãæ©æ¢°ãåå Žã®ãšã¬ããŒã¿ãŒãå·¥ å ŽçŸå Žã§ã®ãã€ã¹ã ãŸããæ©æ¢°æä»€ ä»å±æžâ £ã«æå®ããã補å以å€ã¯ãååŒè©Šéšãåããå¿ èŠããªãã®ã§ãé©åå®£èšæž ãšæè¡ææžãäœæããCE ããŒãã³ã°ã貌ä»ããããšã§ãèªå·±å®£èšãã§ãããèšãæããã°ãä»å±æž â £ã«èšèŒãããŠãã補å矀ã¯ãããŒãã£ãã¡ã€ãããã£ã«ããé¢äžãå¿ èŠãšãªãã ä»å±æžâ £ A. æ©æ¢° 1. æšæåã³é¡äŒŒææãèããã³é¡äŒŒææã®å å·¥çšäžžã®ãïŒåãã²ãšã€ããŸãã¯å€æ°ã®ãã®ïŒ 1.1 åºå®ããããæã¡ãå·¥äœç©ã®éã蟌ã¿ãæååã¯ååã§è¡ããäœæ¥äžã«åå éšãåºå®ãã ãåææ©æ¢° 1.2 æåã®åŸåŸ©éåãããã®ããããã³ãããŸãã¯ãã£ãªããžãåããäœæ¥äžã«åå éšãåºå® ãããåææ©æ¢° 1.3 å èµããæ©æ¢°çéãè£ çœ®ã§å å·¥ç©ãéããæåã§å å·¥ç©ã®åãä»ããåãå€ããã§ããã äœæ¥äžã«åå éšãåºå®ãããåææ©æ¢° 1.4 æ©æ¢°çãªå·¥äœç©èŽãè£ çœ®ãæã¡ãæåã§å·¥äœç©ã®åãä»ããåãå€ããã§ãããäœæ¥äžã« åå éšãç§»åããåææ©æ¢° 2. æšå·¥çšã®æå衚é¢åãç€ 3. æåã§å å·¥ç©ã®åãä»ããåãå€ããã§ããæšå·¥çšã®èªåçé¢ä»äžç€ 4. æšæåã³é¡äŒŒææãèåã³é¡äŒŒææã®å å·¥çšã§ã察象ç©ãæåã§åãä»ããåãå€ããã§ ãããåºå®åŒãŸãã¯å¯ååŒããããæã€åž¯ã®ãããã³å¯åãã£ãªããžãæã€åž¯ã®ã 5. 1.ãã 4.ãŸã§ãšã7.ã«èšèŒããçš®é¡ãçµã¿åããããæšæåã³é¡äŒŒææçšã®å å·¥æ©æ¢° 6. æååŒã§ãã€ããã«ãä»ãæšå·¥çšã»ããšãç€ 7. æšæåã³é¡äŒŒææçšã®æååŒåçŽã¹ãã³ãã«æåæ© - 9- 363 8. æšå·¥çšæºåž¯åŒãã§ãŒã³ãœãŒ 9. æåã§å·¥äœç©ã®åãä»ããåãå€ããã§ããããã¬ã¹ãã¬ãŒããæã€éå±å·éå å·¥çšã㬠ã¹ãå¯åäœæ¥éšåã®å·¥çšã¯ 6mm 以äžãé床㯠30mm/s 以äžã®ãã® 10. æåã§åãä»ããåãå€ããã§ããå°åºåŒãŸãã¯å§çž®åŒãã©ã¹ããã¯æåœ¢æ© 11. æåã§åãä»ããåãå€ããã§ããå°åºåŒãŸãã¯å§çž®åŒããæåœ¢æ© 12. 次ã®ãããªå°äžäœæ¥çšã®æ©æ¢°ïŒ -ã¬ãŒã«äžã®æ©æ¢°ïŒæ©é¢è»ããã³ç·©æ¥è» -æ°Žå§å€©ã°ãæ¯æè£ çœ® âå°äžäœæ¥çšã®æ©æ¢°èšåã«è£ åããå çæ©é¢ 13. å§çž®æ©èœä»ãå®¶åºçšå»æ£ç©å容çšã®äž»å°ç©ã¿èŸŒã¿ãã©ã㯠14. èªåšç¶ãæãæã¡ãã»ã¯ã·ã§ã³ 3,4,7 ã«èšèŒãããã¬ãŒããªã©ãšåãå€ãå¯èœãªäŒå軞 15. æéçšè»äž¡ 16. 3m ãè¶ããåçŽé«ãããèœäžããå±éºã®ããæéçšæ©æ¢° 17. è±ç«è£œé çšã®æ©æ¢° B å®å šéšå 1. ç¹ã«äººãæ¢ç¥ããå®å šã確ä¿ãã黿°æå¿è£ 眮ïŒéç©è³ªçããªã¢ãã»ã³ãµããããé»ç£æ¢ ç¥æ©ïŒ 2. äž¡ææäœã«ããå®å šæ©èœã確å®ã«ããè«çãŠããã 3. 9,10,11 ã«èšèŒããå§æŸæ©ãä¿è·ããèªåå¯ååŒã®é®èœç© 4. 転åæä¿è·æ§é ïŒROPSïŒ 5. èœäžç©ã«å¯Ÿããä¿è·æ§é ïŒFORPSïŒ æ©æ¢°æä»€ã§é©åãã¹ãæŽåèŠæ Œã«ã¯äžèšã® 3 ã¿ã€ããããã ã¿ã€ã A åºæ¬èŠæ ŒïŒãã¹ãŠã®æ©æ¢°ã«å ±éã«é©çšã§ããåºç€æŠå¿µãèšèšäžè¬åå ïŒäŸ ïŒEN292 æ©æ¢°ã®å®å šæ§ïŒèšèã®å®çŸ©ïŒ ã¿ã€ã B äžè¬èŠæ ŒïŒåºç¯å²ãªæ©æ¢°ã«é©çšã§ããå®å šæ§ã»å®å šè£ 眮ã«ã€ã㊠ïŒäŸ ïŒEN418 éåžžåæ¢ïŒ B1: å®å šã«é¢ããç¹å®äºé ïŒå®å šè·é¢ã枩床ãªã©ïŒ B2: å®å šé¢é£ããã€ã¹ïŒã€ã³ã¿ãŒããã¯ãã¬ãŒããã»ã³ãµãŒãªã©ïŒ ã¿ã€ã C 補åèŠæ ŒïŒç¹å®ã®æ©æ¢°ã«é¢ãã詳现ãªå®å šèŠæ±äºé ïŒäŸ ïŒEN201 ãã©ã¹ããã¯å°åºæåœ¢æ©ïŒ 5.2 äœé»å§æä»€ (73/23/EEC) 50âŒ1000VïŒACïŒã75âŒ1500VïŒDCïŒã®é»æºã§é§åãã補åã 黿°çèŠå ã«ãã£ãŠãå±éºãçºçããå¯èœæ§ã®ããæ©æ¢°ã«ã€ããŠäœé»å§æä»€ã®é©åãå¿ èŠã§ããã 察象ïŒäº€æµ 50âŒ1000V çŽæµ 75âŒ1500V ã§äœåããæ©åš - 10 - 364 次ã®å®å šæ§ã確ä¿ã§ããèšèšã®é©åãããªããã°ãªããªãã -黿°æ©åšãã®ãã®ããçãã黿°çå±éº -黿°æ©åšã«å¯Ÿããå€éšã®äœããã®åœ±é¿ã§çãã黿°çå±éº 黿°æ©åšãŠãŒã¶ãŒãæ©åšã®æäœæ¹æ³ãæ£ããçè§£ã§ããããã«ãæ©åšæ¬äœããŸãã¯æ·»ä»ããèŠåãæ³š ææžãã«å¿ èŠæ å ±ãæç€ºããªããŠã¯ãªããªãã 5.2.1 äœé»å§æä»€ã®å¯Ÿè±¡å€è£œåäŸ ä»ã®æä»€ãèŠåã®å¯Ÿè±¡ãšãªãããã«å¯Ÿè±¡å€ãšããã補åãäŸãã°ãççºããããç°å¢ã§äœ¿çšããã黿° æ©åšãæŸå°ç·åã³å»ççšã®æ©åšã人ãè·ç©çšãšã¬ããŒã¿ãŒã黿°ã¡ãŒã¿ãŒãå®¶åºçšã³ã³ã»ã³ãããã© ã°ã黿°æµå¶åŸ¡æ©åšãè¹ãé£è¡æ©ã»ééã§äœ¿ãããç¹å¥ãªæ©åš EMC æä»€ïŒ89/336/EEC, 2004/108/ECïŒ 5.3 é»ç£æ³¢ãçºçãããŸãå€éšããã®é»ç£æ³¢ã«ãã£ãŠåœ±é¿ãããã補åã«é¢ããèŠå¶ãç¹ã«é€å€ãããã ã®ãé€ããã»ãšãã©ã®é»æ°/é»åæ©åšã察象ãšãªãã ãã®æä»€ã¯ãé»ç£äž¡ç«æ§ã«é¢ããå çåœã®æ³åŸã®è¿äŒŒåã®ããã®æ¬§å·è°äŒã䞊ã³ã«æ¬§å·é£åçäºäŒæ 什ãã®ãããªæå³ã®é·ãã¿ã€ãã«ãæã€ããéåžžã¯åã«EMC æä»€ãšåŒã°ããã ãªããEMCããšããçšèªã¯ãé»ç£äž¡ç«æ§(electromagnetic 5.3.1 compatibility) ãæå³ããŠããã EMC æä»€ã®å¯Ÿè±¡å€è£œå é©çšå¯Ÿè±¡ããé€å€ãããã®ã¯ã以äžè£œåãšãªã ⢠åäžã®æ©èœãŠããã(single functional unit) ãšããŠäŸçµŠãããªãã㮠⢠ãšã³ãã»ãŠãŒã¶ãŒã«ãã䜿çšãæ³å®ãããŠããªãã㮠⢠æ¬è³ªçã«ãä»ãžã®é»ç£å¹²æžãçããããŸãä»ããã®é»ç£å¹²æžãåããããšããªãã㮠⢠Regulation (EC) No. 1592/2002 ã®å¯Ÿè±¡ãšãªãèªç©ºçšè£œå ⢠ç¡ç·èŠåã®å ã§ã¢ããã¥ã¢ç¡ç·å®¶ã䜿çšãããåžè²©ãããªãç¡ç·æ©åš ⢠åäžã®ä¿è·èŠæ±ãã«ããŒãããããéå®çãªæä»€(R&TTE æä»€ãèªåè»EMC æä»€ãå»ç æ©åšæä»€ãªã©) ã®å¯Ÿè±¡ãšãªãã㮠⢠å±ç€ºäŒãªã©ã§ã®å±ç€ºã®ã¿ãç®çãšãããã® è£ çœ®ã«çµã¿èŸŒãããã®éšåãšããŠè£œé æ¥è ã«äŸçµŠãããã³ã³ããŒãã³ãã¯ããšã³ãã»ãŠãŒã¶ãŒã«ãã 䜿çšãæ³å®ãããŠããªãããšãããé©çšå¯Ÿè±¡å€ãšèŠåãããšãã§ãããããããè£ çœ®ã«çµã¿èŸŒããã ã®ã³ã³ããŒãã³ãã§ãã£ãŠããããããšã³ãã»ãŠãŒã¶ãŒåãã«äŸçµŠãããå Žå(äŸãã°ãå°å£²åºã§äž è¬æ¶è²»è åãã«è²©å£²ããããããŒãœãã«ã»ã³ã³ãã¥ãŒã¿çšã®ãã¶ãŒã»ããŒãããã£ã¹ã¯ã»ãã©ã€ãã® ããã«) ã«ã¯ãEMC æä»€ã®å¯Ÿè±¡ãšãªãåŸãã - 11 - 365 5.3.2 EMC æä»€ã®ç®ç EMC æä»€ã®æå€§ã®ç®çã¯ã以äžã®ïŒç¹ã§ããã é»ç£å¹²æžã®é²æ¢ ãã®ç®çã®ãããEMC æä»€ã¯ã(1) æ©åšãçºçããé»ç£åŠšå®³ãç¡ç·/éä¿¡æ©åšããã®ä»ã®æ©åšã®åäœ ã劚害ããªãããšãåã³(2) æå³ããç°å¢ã«ãããŠèš±å®¹ã§ããªãæ§èœäœäžãçããããšãªãåäœã§ã ãããã«ãäºæãããé»ç£åŠšå®³ãžã®èæ§ãæã€ããšãã®ïŒã€ãä¿è·èŠæ±(protection requirements) ãš ããŠå®ããŠãããEMC æä»€ã®å¯Ÿè±¡ãšãªãæ©åšãæµéãããããã«ã¯ããã®ä¿è·èŠæ±ãæºè¶³ãããã ãšãå¿ é ãšãªãã èªç±ãªæµéã®ä¿èšŒ EMC æä»€ã®çºå¹ã«äŒŽã£ãŠãEU å ã§ã® EMC ã«é¢ããæè¡åºæºã¯çµ±äžããããŸãååœããšã®ç¬èªã® EMC èŠå¶ (äŸãã°ãæå®ãããæ©é¢ã«ããèªå¯ãèªèšŒã®èŠæ±) ã¯æ€å»ããããã€ãŸããEMC æä»€ ã®é©çšå¯Ÿè±¡ãšãªãæ©åšã¯ãEMC æä»€ãå«ãã該åœããå šãŠã®æä»€ã®èŠæ±ã«åŸãããšã«ãã£ãŠãEU å ã®ã©ã®åœã«ãããŠãæµéã§ããã 5.3.3 EMC æä»€ã®ç¹åŸŽ EMC æä»€ã¯æ¬¡ã®ãããªç¹åŸŽãæã€ã åºãé©çšç¯å² åºæ¬çã«åžè²©ããã黿°/é»åæ©åšã®ã»ãšãã©ã¯ãEMC æä»€ã®å¯Ÿè±¡ãšãªãããã®ç¹ã§ãæ¥æ¬ã®é»æ°çš åå®å šæ³ã®ãããªãæå®ãããåç®ã®ã¿ã察象ãšãªãèŠåãšã¯å€§ããç°ãªãã ãšããã·ã§ã³ãšã€ãã¥ããã£ã®åæ¹ã®ã«ã㌠EMCæä»€ã®ä¿è·èŠæ±ã¯æ©åšãä»ã«å¹²æžãäžããªãããš(ãšããã·ã§ã³) ã®ã¿ã§ã¯ãªããæ©åšãä»ãã ã®å¹²æžãåããªãããš(ã€ãã¥ããã£) ãèŠæ±ããŠãããæ¥æ¬ã®é»æ°çšåå®å šæ³ãVCCI èŠå¶ãã¢ã¡ ãªã«ã®FCC èŠå¶ã®ããã«ãã»ãšãã©ã®æ©åšã«ã€ããŠã¯ãšããã·ã§ã³ã®ã¿ãèŠå¶ããããšãå€ãäžã§ã ããã¯EMCæä»€ã®å€§ããªç¹åŸŽã§ããã 5.3.4 89/336/EEC ãš 2004/108/EC çŸåšã89/336/EEC ãš2004/108/EC ãšãããïŒã€ã®EMC æä»€ãååšããŠããã 89/336/EEC ããã¯1989 幎ã«çºè¡ãããæä»€92/31/ECãåã³93/68/EEC ã«ããä¿®æ£ãåããäžã§ã10 幎以äžã« ããã£ãŠäœ¿çšãããŠããããã®æä»€ã¯ä»¥åŸ2004/108/EC ã«ãã£ãŠçœ®ãæãããããã2009幎7 æ19 æ¥ãŸã§ã¯ãæå¹ã§ããã 2004/108/EC - 12 - 366 ããã¯2004 幎12 æã«çºè¡ãããæ¹èšçã®EMC æä»€ã§ããã89/336/EEC ã¯2007 幎7 æ20 æ¥ã ãã£ãŠãã®æ°ããæä»€ã§çœ®ãæããããããã®åŸã2009幎7 æ19 æ¥ãŸã§ã¯89/336/EEC ã«åŸã£ãæ© åšã®åºè·ãèªããããç§»è¡æéãšãªãã2009 幎7 æ20æ¥ä»¥éã¯89/336/EEC ã¯å®å šã«äœ¿çšã§ããªã ãªãããã以éã«åºè·ããæ©åšã«ã€ããŠã¯2004/108/EC ã«åŸãããšãå¿ é ãšãªãã89/336/EEC ã ãã®å€æŽã¯äž»ãšããŠé©åæç¶ã«é¢ãããã®ã§ãããæè¡çèŠæ±ã«é¢ãã倿Žã¯ãªãã 5.3.5 EMC æä»€ãžã®é©åæç¶ é©åæç¶ã®éžæ EMC æä»€ã®é©çšå¯Ÿè±¡ãšãªãããšãããã£ããªãã°ããŸããã©ã¡ãã®æä»€ãé©çšããã(äžèšã®ãã ã«ã2007幎7 æ19 æ¥ãŸã§ã¯89/336/EEC ã®ã¿ãã2009 幎7æ20 æ¥ä»¥éã¯2004/108/EC ã®ã¿ãé©çš å¯èœ) ãšãæŽåèŠæ Œãå šé¢çã«é©çšãããã©ãããéžæããã 89/336/EEC â èŠæ Œã«ãŒã ããã¯ãæä»€ã®ä¿è·èŠæ±ãžã®é©åæ§ã䞻匵ããæ ¹æ ãšããããã«ãæŽåèŠæ Œãå šé¢çã«é©çšããå Žå ã«çšããæç¶ãã§ãããå€ãã®å Žåãæ©åšãæå®ã®æŽåèŠæ Œã«é©åãããã©ããã®è©ŠéšãEMC è©Šéš æã§è¡ãªãããã®çµæã«åºã¥ããŠãã®æ©åšãä¿è·èŠæ±ã«é©åããŠãããã©ããã®å€æãè¡ãªãããšã« ãªãããã®æ©åšãä¿è·èŠæ±ã«é©åããŠãããšå€æãããªãã°ãé©åå®£èšæžãäœæããäžã§ãæ©åšã« CE ããŒãã³ã°ã貌ä»ããããªããèŠæ Œã«ãŒããTCFã«ãŒããšããåŒã³æ¹ã¯éç§°ã§ãããæä»€ã§ã¯ã ã®ãããªè¡šçŸã¯çšããããŠã¯ããªãã 89/336/EEC â TCFã«ãŒã ããã¯ãæŽåèŠæ Œãé©çšããªãã£ãããããã¯éšåçã«é©çšããå Žåã«çšããæç¶ãã§ããããã®æ ç¶ãã§ã¯ãè£œé æ¥è ã¯æä»€ã®ä¿è·èŠæ±ãžã®é©åã®æ ¹æ ã瀺ãæè¡ææž (technical construction file; æ è¡æ§æãã¡ã€ã«) ãäœæããã³ã³ããã³ãã»ããã£(competent body)ã«æè¡å ±åæžããããã¯èšŒææž ãçºè¡ããŠããããæè¡ææžãäœæããã³ã³ããã³ãã»ããã£ããã®æè¡å ±åæžããããã¯èšŒææžã å ¥æãããªãã°ãé©åå®£èšæžãäœæããäžã§ãæ©åšã« CE ããŒãã³ã°ã貌ä»ããã 2004/108/EC 2004/108/EC ã«ãããŠã¯ãè£œé æ¥è ã¯ãEMC ã«é¢ããè©äŸ¡ã宿œããæä»€ã®ä¿è·èŠæ±ãžã®é©åæ§ ã確èªããããšãæ±ããããããããã該åœããå šãŠã®æŽåèŠæ Œãæ£ããé©çšããå Žåã«ã¯ãããã ãã£ãŠè©äŸ¡ã宿œããããã®ãšèŠåãããšãå¯èœã§ãããåŸã£ãŠã該åœããæŽåèŠæ Œã«åŸã£ãŠè©Šéšã è¡ãªãããã®çµæã«åºã¥ããŠãã®æ©åšãä¿è·èŠæ±ã«é©åããŠãããšå€æãããªãã°ããã以äžã®è©äŸ¡ ã¯äžèŠãšèããããšãã§ããããã㯠89/336/EEC ã®èŠæ Œã«ãŒãã«çžåœãããã®ã§ãããã 89/336/EECã®å Žåãšã¯ç°ãªãããã®å Žåã§ãæè¡ææžã®äœæã¯å¿ é ãšãªãã æŽåèŠæ Œãå šé¢çã«é©çšããªãã£ãå Žåã«ã¯ãEMC ã«é¢ããè©äŸ¡ã®å®æœã«ãã£ãŠããããä¿è·èŠæ± ã«é©åããããšã確èªããããšãå¿ èŠãšãªãããã㯠9/336/EECã®TCFã«ãŒãã«çžåœãããã®ã§ã - 13 - 367 ããã89/336/EEC ã®å Žåãšã¯ç°ãªããå€éšã®æ©é¢ã®é¢äžã¯æ±ããããŠããªããäžèšã®ããããã®æ¹ æ³ã«ãã£ãŠãã®æ©åšãä¿è·èŠæ±ã«é©åããŠãããšå€æãããªãã°ãæè¡ææžãšé©åå®£èšæžãäœæãã äžã§ãæ©åšã« CE ããŒãã³ã°ã貌ä»ããã è£œé æ¥è ã¯ãæŽåèŠæ Œãé©çšãããã©ããã«é¢ããããããŒãã£ãã¡ã€ãããã£ã«æèŠãæ±ããããš ãå¯èœã§ãããããŒãã£ãã¡ã€ãããã£ã«æèŠãæ±ãããã©ããã¯å šãä»»æã§ããããããŒãã£ãã¡ ã€ãããã£ã¯ãEMC æä»€ã«é¢ããç¥èãçµéšãæã£ãŠãããå¿ èŠã«å¿ããŠããŒãã£ãã¡ã€ããã㣠ã«çžè«ããããšã§ãäžé©åã®å¯èœæ§ãããéšåã®ææãªã©ã®æçãªã¢ããã€ã¹ãåããããã 5.3.6 èŠæ Œã®éžæ æŽåèŠæ Œãé©çšãã (éšåçã«ã§ãã£ãŠã) ããšãéžãã ãªãã°ãé©çšããèŠæ Œãéžæããããšãå¿ èŠãšãªããé©çšããèŠæ Œã¯ãEMC æä»€ã®å ã§ã®æŽååãæ¬§å·å®å ± (Official Journal)ã§å ¬è¡šãããèŠ æ Œã®äžãããæ¬¡ã®ãããªååã«åŸã£ãŠéžæããã ãã®èŠæ Œãé©çšå¯èœã§ãããã©ããã®å€æã¯ãããããã®èŠæ Œã«æèšãããŠããé©çšç¯å²(scope) ã« åºã¥ããŠè¡ãªããåºæ¬çã«ã¯ãé©çšããèŠæ Œã¯æ©åšã®æå³ãããçšéã«ãã£ãŠæ±ºå®ãããäŸãã°ãã³ ã³ãã¥ãŒã¿ãå èµããæž¬å®åšã¯ãããŸã§ã枬å®åšã§ãããæ å ±æè¡æ©åšãšã¯ãªããªãã é©çšå¯èœãªèŠæ Œãè€æ°ããå Žåã¯ããã®æ©åšã«ããçžå¿ãã(éåžžã¯ãé©çšç¯å²ãããéå®çãª)èŠæ Œ ãåªå ããããã®æ©åšã«é©çšå¯èœãªè£œåèŠæ Œã補åçŸ€èŠæ Œãããå Žåã¯ãäžè¬èŠæ Œãé©çšããããšã¯ ã§ããªãã補åèŠæ Œ (product standard) ã補åçŸ€èŠæ Œ (product family standard) ã¯ç¹å®ã®çš®é¡ã®è£œ åã«é©çšããããã®ã§ãããæ å ±æè¡æ©åšãAV æ©åšãšãã£ã補å矀ã«é©çšããããã®ãããç¡åé» é»æºè£ 眮ãã¢ãŒã¯æº¶æ¥æ©ãšãã£ãéåžžã«éå®ãããçš®é¡ã®è£œåã«é©çšããããã®ãŸã§ã倿°ã®èŠæ Œã ãããäžè¬èŠæ Œ (generic standard) ã¯ããç°å¢ã§äœ¿çšããã補åã«æšªæçã«é©çšããããã®ã§ããã äœåæ¥ç°å¢åãã®ãã®ãåã³å·¥æ¥ç°å¢åãã®ãã®ãçšæãããŠããã èŠæ Œã«ãã£ãŠã¯ EMC ã®äžéšã®åŽé¢ (äŸãã°ãšããã·ã§ã³ãšã€ãã¥ããã£ã®äžæ¹ã®ã¿) ããã«ã㌠ããŠããªãå Žåãããããã®ãããªèŠæ Œãé©çšããå Žåã«ã¯ãå¿ èŠãªå šãŠã®åŽé¢ãã«ããŒããããã« è€æ°ã®èŠæ Œãçµã¿åãããŠé©çšããå¿ èŠããããåçšé»æºã«æ¥ç¶ãããæ©åšã«å¯Ÿããé«èª¿æ³¢é»æµãšã ãã·ã§ã³èŠæ Œã®é©çšãããã®å¥ã®äŸãšãªãã è€åæ©èœæ©åšã«ã€ããŠã¯ãããããã®æ©èœã«å¯ŸããŠç°ãªã£ãèŠæ Œãé©çšããå¿ èŠãããå Žåãããã æŽåèŠæ Œã®ãªã¹ãã¯æ¬§å·å§å¡äŒã®ãã¥ãŒã¢ãããŒãã«é¢ãããµã€ãã§ç¢ºèªã§ãããã®ä»ã®æ å ±ãæã« å ¥ããããšãã§ããããã®æŽåèŠæ Œã®ãªã¹ãã¯æ¬¡ããŒãžã®ããã«èšèŒãããŠããã - 14 - 368 89/336/EEC ã®TCF ã«ãŒããçšããå Žåãåã³2004/108/EC ã«åŸã£ãŠè©äŸ¡ã宿œããå Žåã«ã¯ãæŽ åèŠæ Œä»¥å€ã®èŠæ Œã䜿çšããããšãå¯èœã§ããããã®ãããªèŠæ Œã®äŸãšããŠã¯ãæŽååãããŠããªã åœéèŠæ Œãåœå èŠæ Œããããã¯æ¥çèŠæ Œãèããããã æŽåèŠæ Œãªã¹ãäŸ (Offical Journal 2004/C 98/05) - 15 - 369 5.3.7 詊éšã®å®æœ èŠæ Œãé©çšããå ŽåãéžæããæŽåèŠæ Œã«åŸã£ãŠè©Šéšã宿œãããã®èŠæ Œã®èŠæ±ãæºè¶³ãããã©ãã ã®å€æãè¡ãªããå®éã®è©Šéšã¯å€éšã®è©Šéšæ (EMC ãã¹ãã»ã©ã) ã«äŸé Œããå Žåãå€ããšèãã ãããããã®å Žåã§ãè©Šéšæ¡ä»¶ (è©Šéšæã«æ¥ç¶ããåšèŸºæ©åšãåäœæ¡ä»¶ãã€ãã¥ããã£è©Šéšã«ããã ååŠå€å®ã®åºæºãªã©) ã®æ±ºå®ã¯è£œé æ¥è ãè¡ãªãå¿ èŠãããããšã«æ³šæãããè€éãªè£ 眮ã®å Žåã«ã¯ã 詊éšã«å ç«ã£ãŠã®æ€èšãæã¡åããç¹ã«æ éã«è¡ãªãããšãå¿ èŠãšãªãã詊éšã宿œããåæ Œã瀺ã 詊éšå ±åæžãå ¥æãããªãã°ããããé©åã®æ ¹æ ãšããŠäœ¿çšããããšãã§ãããäœããè©Šéšæãçºè¡ ãã詊éšå ±åæžã«ã¯ããã®è£ 眮ã®ç¹å®ã®ãµã³ãã«ãããæ¡ä»¶ã§è©Šéšããçµæã瀺ãããã ãã§ããã å€éšã®è©Šéšæãã詊éšå ±åæžãå ¥æããå Žåã§ãã£ãŠããé©åæ§ã®å€æãé©åæ§ã®ç¶æã®è²¬ä»»ã¯è£œé æ¥è ã«ããã å»çæ©åšæä»€ (93/42/EEC) 5.4 EU ã«ã¯ãå»çæ©åšã«é¢ããäžèšäžçš®é¡ã®æä»€ãããã ⢠å»çæ©åšæä»€ïŒ93/42/EECïŒ â¢ äœå€èšºæå»çæ©åšæä»€ïŒ98/79/ECïŒ â¢ å蟌åèœåå»çæ©åšæä»€ïŒ90/385/EECïŒ äœå€èšºæå»çæ©åšæä»€ïŒ98/79/ECïŒã§ã¯ã蚺æçšå»è¬ååã³é¢é£æ©åšã察象ã«ããŸããå蟌åèœåå»ç æ©åšæä»€ïŒ90/385/EECïŒã§ã¯ãããŒã¹ã¡ãŒã«ãŒçã®åèŸŒåæ©åšããããã察象ã«ãªãã ããã§ã¯ãäžè¬ã®å»çæ©åšã察象ãšããå»çæ©åšæä»€ïŒ93/42/EECïŒã«ã€ããŠãèšè¿°ããããã®æä»€ã¯ãäž è¬å»çæ©åšåã³ãã®ä»å±åã«é©çšãããå»çæ©åšã¯åšå ·ãæ©æ¢°ãçšå ·ãææãŸãã¯ãã®ä»ã®åç®ã§ã ã£ãŠãåç¬ã§ã®äœ¿çšãããã¯çµã¿åãããŠã®äœ¿çšããåããããŸãé©çšã®ããã«å¿ èŠãªãœãããŠã§ã¢ ãå«ããè£œé æ¥è ã人äœãžã®äœ¿çšãæå³ãã補åã§ã ⢠ï çŸç ã®èšºæãäºé²ãç£èŠãæ²»çåã¯èŠçç·©å ⢠å·å®³ãŸãã¯èº«äœé害ã®èšºæãäºé²ãç£èŠãæ²»çåã¯èŠçç·©å ⢠解ååŠåã¯ççåŠäžã®æ€æ»ã代æ¿åã¯ä¿®æ£ ⢠ï åèèª¿ç¯ ãç®çãšãããã®ã§ããã ãªããæ¥æ¬ã§ã¯å»çæ©åšãšããŠæ±ãããŠããªãçŠç¥çšå ·ãå¥åº·åšå ·ãªã©ã ãã®æä»€ã®å¯Ÿè±¡ãšãªãå Žåã ããã - 16 - 370 æä»€ã®æ§æã¯ãæ¡æïŒArticleïŒãšä»å±æžïŒAnnexïŒãšã«å€§å¥ããããæ¡æã¯CEããŒãã³ã°è²Œä»ã®æ¹æ³ ã«ã€ããŠããŸãä»å±æžã«ã¯æ¡æãæºããããã®èŠé ã詳ããèšèŒãããŠããã æ¡æïŒArticleïŒ ïŒæ¡ïŒè£œåã®åºæ¬èŠä»¶ãžã®é©å ïŒæ¡ïŒåºæ¬èŠä»¶ãžã®é©åãç€ºãæŽåèŠæ Œ ä»å±æžïŒAnnexïŒ ä»å±æžïŒïŒåºæ¬èŠä»¶ïŒè£œåãšããŠå¿ ãæºãããªã ãã°ãªããªãèŠæ±äºé ïŒ ïŒæ¡ïŒä¿è·æªçœ® â ïŒæ¡ïŒè£œåã®ãªã¹ã¯ã«ããã¯ã©ã¹åé¡ ä»å±æžïŒïŒã¯ã©ã¹åé¡åºæº ïŒïŒæ¡ïŒåžå Žæå ¥åŸã«èµ·ããäºæ ã«é¢ããæ å ± ïŒïŒæ¡ïŒè£œåã®ãªã¹ã¯ã®åºŠåãã«å¿ããé©åæ§è©äŸ¡ æé åã³é©åå®£èš ä»å±æžïŒâïŒïŒé©åæ§è©äŸ¡æé ä»å±æžïŒïŒã«ã¹ã¿ã ã¡ãŒãæ©åšãèšåºè©äŸ¡çšæ©åš ïŒïŒæ¡ïŒåžå Žåºè·è²¬ä»»è ã®ç»é²ãè£œé æ¥è ã®ç»é² äºåæåã³ïŒ¥ïŒ£åå 責任è â ïŒïŒæ¡ïŒèšåºè©Šéš ä»å±æžïŒïŒïŒèšåºè©äŸ¡ ïŒïŒæ¡ïŒéç¥æ©é¢ ä»å±æžïŒïŒïŒéç¥æ©é¢èªå®åºæº ïŒïŒæ¡ïŒïŒ£ïŒ¥ããŒãã³ã° ä»å±æžïŒïŒïŒïŒ£ïŒ¥ããŒãã³ã° å»çæ©åšã«ãããããŒãã³ã°ã¯ãåœè©²å»çæ©åšæä»€ãžã®é©åæ§ãæ£è ãå»çåŸäºè ãå®å šç®¡çæ© é¢ãè¡æ¿åœå±ã«å¯ŸããŠç€ºãããã®è¡šç€ºã§ãããEUã«ãããããŒãã³ã°ã¯ã補åã®å®å šæ§ãæå¹ æ§ãè£œé æ¥è ã®è²¬ä»»ã«ãããŠèªããé©åæ§ã®å®£èšãè¡ããã®ã§ãããè¡æ¿åœå±çã«ãã£ãŠæ¿èªã»èªèšŒã è¡ãæ¥æ¬ã®å¶åºŠãšã¯å€§ããç°ãªãã å»çæ©åšã¯ãä»å±æžïŒïŒAnnex IïŒã«ç€ºãããåºæ¬èŠä»¶ãæºè¶³ããŠããããšãå¿ é ãšãªãããã®åºæ¬ èŠä»¶ãžã®é©åæ§ã¯è£œé æ¥è ã®è²¬ä»»ã«ãããŠç«èšŒãããªããã°ãªããªãããã®ããæè¡ææžïŒtechnical documentation fileïŒãäœæããåºæ¬èŠä»¶ãžã®é©åæ§ãåžžã«å®¢èгç蚌æ ãšããŠæç€ºã§ããããã«ã㊠ããå¿ èŠãããããã®åºæ¬èŠä»¶ãžã®é©åã¯ãåžžã«ææ°ã®æè¡ã¬ãã«ãåæ ããªããŠã¯ãªãããå€ãã® å Žåãæ¬§å·æŽåèŠæ ŒãçšããŠç«èšŒãããã ãŸããCEããŒãã³ã°ã®ããã®é©åæ§è©äŸ¡ã«ã¯å¹Ÿã€ãã®ã«ãŒãããããå»çæ©åšã®ãªã¹ã¯ã«å¿ãã㯠ã©ã¹åé¡ã«ãã£ãŠéžæã§ããã«ãŒããå€ãããå»çæ©åšæä»€ã§ã¯äººäœã«å¯Ÿããå»çæ©åšã®é©çšïŒäœ¿çšïŒ æéãäœå ãžã®äŸµè¥²æ§ã黿°çãšãã«ã®ãŒã®äœ¿çšãäžæ¢åŸªç°åšç³»åã³ç¥çµç³»ãžã®é©çšãªã©ãšãã£ãèŠ çŽ ãèæ ®ããæãäœãªã¹ã¯ã®Class I ããClass IIaïŒClass IIbïŒãããŠæããªã¹ã¯ã®é«ãClass IIIã®ïŒ ã€ã¯ã©ã¹ã«åé¡ããããè£œé æ¥è ã¯ããã®è²¬ä»»ã«ãããŠãåãæ±ãå»çæ©åšã®ãªã¹ã¯ã«å¿ãã管çã æ±ããããã ãã ããå»çæ©åšã¯æ£è ã®çåœãžçŽæ¥åœ±é¿ãäžããæ©åšã§ããããªã¹ã¯ãé«ããªãã°å šãŠãè£œé æ¥è ã®è²¬ä»»ã ãã«å§ããèªå·±å®£èšã®ã¿ã§ã¯åžå Žæå ¥ã«éããŠæžå¿µãããããããããã£ãŠããªã¹ã¯ã®é«ã 補åã¯ç¬¬äžè ãé¢äžãããã§ãã¯æ©èœãæãããããšã«ãã£ãŠå®å šæ§ãæå¹æ§ã確å®ã«ããŠè¡ãããš ããä»çµã¿ã«ãªã£ãŠããã ãã®ç¬¬äžè ãšã¯ãåœå±ããéç¥ãããããŒãã£ãã¡ã€ãããã£ã§ããããã®æ©é¢ã®é¢äžã«ãã£ãŠãåº æ¬èŠä»¶ãžã®ç¶ç¶çãªé©åæ§ãç£èŠãããããšã«ãªããäŸãã°Class I ã«è©²åœããæè¡çšã¡ã¹ã¯åºæ¬ç ã«è£œé æ¥è ã®è²¬ä»»ã«ãããŠèªå·±å®£èšãè¡ãããšã«ãã£ãŠïŒ£ïŒ¥ããŒãã³ã°ã衚瀺ããŠè²©å£²ããããšã ã§ããäžæ¹ããããããªã¹ã¯ã®é«ãClass IIa ã®è£èŽåšçã¯ããã®é©åæ§è©äŸ¡ã®äžéšãããã¯å šéçš ã«ãããŠããŒãã£ãã¡ã€ãããã£ã®é¢äžã矩åä»ããããŠããã - 17 - 371 5.4.1 ã¯ã©ã¹åé¡ ããã§ã¯é©åæ§è©äŸ¡ã«ãŒãã®éžæåºæºãšãªãã¯ã©ã¹åé¡ã®ã«ãŒã«ã«ã€ããŠèª¬æãããå»çæ©åšã¯ã㮠補åã®ç¹è³ªã«ããããŠãäžèšã®ããã«å€§å¥ãããã 補åç¹åŸŽ é©çšã«ãŒã« ã»é䟵襲æ§å»çæ©åš 䟵襲æ§ïŒäœè¡šãããã¯éå£éšãéãäžéš ãŸãã¯å šéšãäœå ã«è²«éãããããªæ©åš ã«ãŒã« ã«ãŒã« ã«ãŒã« ã«ãŒã« ïŒïŒæ£è ãšã®æ¥è§Šããªããããã¯ç®èãä»ããŠã®æ¥è§Šãããã®ã¿ ïŒïŒè¡æ¶²ãäœæ¶²ãäœçµç¹ããã³ã¬ã¹ã®åŠçåã³ä¿ç®¡ ïŒïŒè¡æ¶²ãäœæ¶²ããã®ä»æ¶²äœã®çµæã®æ¹å ïŒïŒåµå·éšã«å¯ŸããŠã®æ¥è§ŠïŒæ©æ¢°çä¿è·ã滲åºç©åžåïŒ ã»äŸµè¥²æ§å»çæ©åš ã«ãŒã« ã«ãŒã« ã«ãŒã« ã«ãŒã« ïŒïŒäœã®éå£éšã«å¯Ÿãé©çšïŒå€ç§çæ¹æ³ã§ãªãïŒ ïŒïŒäŸµè¥²æ§æ©åšã§äžéçïŒïŒïŒå以äžïŒãªäœ¿çš ïŒïŒäŸµè¥²æ§æ©åšã§çæçïŒïŒïŒæ¥ä»¥äžïŒãªäœ¿çš ïŒïŒäŸµè¥²æ§æ©åšã§é·æçïŒïŒïŒæ¥ä»¥äžïŒãªäœ¿çšãŸãã¯åèŸŒåæ©åš ã»èœåå»çæ©åš æ¡åã»éå以å€ã®ååæºåã³ é»æ°çãšãã« ã®ãŒæºã®å€æã«ãã£ãŠäœçšããæ©åš ã«ãŒã« ïŒïŒãšãã«ã®ãŒã®å€æãããã¯ãšãã«ã®ãŒã䜿çšããæ²»ççšæ©åš ã«ãŒã«ïŒïŒïŒèšºæçšæ©åš ã«ãŒã«ïŒïŒïŒè¬æ¶²ã®æäžïŒæ³šå ¥ æã㯠äœå ããç©è³ªãåãåºãæ©åš ã«ãŒã«ïŒïŒïŒãã®ä»ã®èœåå»çæ©åš ã»ãã®ä»ç¹å¥ã«ãŒã« ã«ãŒã«ïŒïŒïŒè¬å€ã䌎ãè£å©çã«äœçšããæ©åš ã«ãŒã«ïŒïŒïŒæ§ç ã®äºé²ãç®çãšããæ©åš ã«ãŒã«ïŒïŒïŒå»çæ©åšã®æŽæµãç®çãšããæ©åš ã«ãŒã«ïŒïŒïŒèšºæçšïŒžç·ãã£ã«ã ã«ãŒã«ïŒïŒïŒåç©ç±æ¥ã®æ©åš ã«ãŒã«ïŒïŒïŒè¡æ¶²ãã㯠å®éã«å€ç§æè¡ã«çšããæç³žãå¿ èŠãšããªãçž«å糞ã®ã¯ã©ã¹åé¡ã®äŸããããããŸãæåã«æå³ãã 䜿çšç®çããäžè¡šã®å€§ãŸããªåé¡ãã該åœããã«ãŒã«åé¡ãèŠã€ããããã®å Žåãçž«å糞ã¯å€ç§æè¡ ã«ããäœã«å¯Ÿã䟵襲çãªã®ã§ã«ãŒã«ïŒâŒã«ãŒã«ïŒäžã®ããããã«è©²åœããããã®äžãããæç³žãè¡ã ãäœå ã§åžåãããããã«ãŒã«ïŒã®å€ç§ç䟵襲æ§ããããé·æã®äœ¿çšãŸãã¯åèŸŒåæ©åšã«è©²åœããã 以äžã®å€æçµè·¯ã«ãŠãäœå ã§ã®åžåãããã«è©²åœããããClass III ãšãªãã - 18 - 372 5.4.2 é©åæ§è©äŸ¡ã«ãŒãã®éžæ å»çæ©åšã®ãªã¹ã¯ã«å¿ããã¯ã©ã¹åé¡ã«ãã£ãŠé©åæ§è©äŸ¡æé ãç°ãªãã é©åæ§è©äŸ¡ã«ãŒãã¯ä»å±æžIIâŒä»å±æžVIIïŒAnnex IIâVIIïŒã«èŠå®ããåã¢ãžã¥ãŒã«ã§æ§æãããŠããã åç¬ãŸãã¯ïŒã€ã®çµã¿åããã«ãã£ãŠé©çšããããŸããã®ã«ãŒãã«ã¯æè»æ§ããããã²ãšã€ã®ã¯ã©ã¹ ã«å¯Ÿãè€æ°ã®éžæè¢ããããè£œé æ¥è ã®æ¥åå 容ïŒèšèšãè¡ããªããçç£æ°éãå°ãªãçïŒã«å¿ããŠ éžæããããšãå¯èœãšãªãã Annex IIïŒVïŒVI â å質ã·ã¹ãã ã«ããé©åå®£èš å»çæ©åšã®ããã®å質ãããžã¡ã³ãã·ã¹ãã ISO13485 ã«æºæ ããå質管çäœå¶ã®ç¢ºç«ã»ç¶æãè©²åœ ããAnnex IIã¯å¯Ÿè±¡ç¯å²ãšããŠèšèšããæçµæ€æ»ãŸã§ã®å šäœããAnnex V ã¯è£œé ãšæçµæ€æ»ããAnnex VI ã¯æçµæ€æ»ã«ç¹å®ãããã®ã§ãäœãã®å ŽåãããŒãã£ãã¡ã€ãããã£ãé©åæ§ã®å¯©æ»ãè¡ãã Annex III â ååŒè©Šéšã«ããé©åå®£èš è£œé æ¥è ã«ãã£ãŠèŠå®ããã補é å·¥çšã§è£œé ããã代衚ãµã³ãã«ã«ã€ããŠãæ¬§å·æŽåèŠæ Œçãçšã㊠ããŒãã£ãã¡ã€ãããã£ãå®éã«è©äŸ¡ãè¡ãã補åãåºæ¬èŠä»¶ãæºãããŠãããåŠããè©äŸ¡ããã Annex IV â è£œåæ€èšŒã«ããé©åå®£èš è£œåæ¯ãããã¯è£œåããããããµã³ãã«ããæçµè£œåãããŒãã£ãã¡ã€ãããã£ã詊éšããè£œåæ¯ã ããã¯ãããæ¯ã«èªèšŒæžãçºè¡ããã Annex VII â é©åå®£èš æ¯èŒçãªã¹ã¯ã®äœãClass I ãªãã³ã«Class IIaã«é©çšãããã¢ãžã¥ãŒã«ã§ãåºæ¬èŠä»¶ãžã®é©åæ§ã¯è£œ é æ¥è ã®è²¬ä»»ã§è¡ããããClass I ã®å Žåã¯ããŒãã£ãã¡ã€ãããã£ã®é¢äžãªãã«èªå·±å®£èšããããš ãã§ããã - 19 - 373 äŸãã°Class IIa ã®å»çæ©åšã®å Žåãé©åæ§è©äŸ¡ã®ã«ãŒãã¯Annex IIïŒç·åå質ãããžã¡ã³ãã·ã¹ã ã ïŒã®é©çšãããã¯Annex VIIïŒé©å宣èšïŒïŒ Annex VïŒè£œé æ¥åå質ãããžã¡ã³ãã·ã¹ãã ïŒãªã© èšïŒã€ãããè£œé æ¥è ã¯ããã®äžããæãèªãã®æ¥åã«é©ããïŒã€ãéžæããã 5.4.3 åºæ¬èŠä»¶ïŒå¿ é èŠæ±äºé ïŒ CEããŒãã³ã°ã®è²Œä»ãè¡ãå»çæ©åšã¯ãä»å±æžïŒïŒAnnex IïŒã«ç€ºãããåºæ¬èŠä»¶ãæºè¶³ããŠããã ãšãå¿ é ãšãªãã ïŒïŒæ£è ã®å¥åº·ã»å®å šãèæ ®ããèšèšã»è£œé ïŒïŒèšèšã®æ¹æ³ã¯äžè¬ã«èªããããæè¡æ°Žæºãèæ ®ããå®å šååã«é©å â ïŒå šè¬çèŠä»¶ ïŒïŒæå³ããæ§èœãéæããããã®èšèšã補é åã³å è£ ïŒïŒæ£è åã¯äœ¿çšè ã®å¥åº·ãå®å šãè ããçšã«æªåœ±é¿ãäžããªãèšèšã»è£œé ïŒïŒèŒžéåã³ä¿ç®¡æ¡ä»¶äžã«ãããæ§èœå£åã鲿¢ããèšèšã»è£œé ïŒïŒæå¹æ§ãèµ·ããããäžå ·åãäžåãèšèšã»è£œé ïŒïŒååŠçã»ç©ççåã³çç©åŠçç¹æ§ïŒäŸïŒçäœé©åæ§ïŒ ïŒïŒææåã³çŽ°èæ±æïŒäŸïŒå è£ ãæ» èïŒ ïŒïŒæ§é åã³ç°å¢ç¹æ§ïŒäŸïŒä»ã®æ©åšãšã®çµã¿åããäœ¿çšæã®å®å šæ§ïŒ â ¡ïŒèšèšåã³çµç«ãŠ ã«é¢ããèŠä»¶ ïŒïŒïŒæž¬å®æ©èœãæããæ©åšïŒäŸïŒèŠå®æ³å®åäœã®äœ¿çšïŒ ïŒïŒïŒæŸå°ç·ã«é¢ããé²è· ïŒïŒïŒãšãã«ã®ãŒæºã«æ¥ç¶ãããæ©åšãŸãã¯ãšãã«ã®ãŒæºãæããæ©åšã«é¢ããèŠä»¶ ïŒïŒïŒè£œé æ¥è ãäŸçµŠããæ å ±ïŒè¡šç€ºã»ã©ãã«ã»åæ±èª¬ææž çïŒ ïŒïŒïŒèšåºããŒã¿ã«ããå®èšŒ äžèšé ç®ã¯èœåã»éèœåæ©åšã«é¢ããããå šãŠã®å»çæ©åšã«é©çšã§ããããå¶å®ãããŠãããããå» çæ©åšã®ç¹æ§ã«ãã£ãŠã¯é©çšã§ããªãå Žåãããããã®ãããªå Žåã«ã¯ãé©çšã§ããªãçç±ãæç¢ºã« èšè¿°ããã - 20 - 374 R&TTE æä»€ 5.5 ç¡ç·åã³é»æ°éä¿¡ç«¯æ«æ©åšæä»€ (1999/5/EC) Radio Equipment and Telecommunications Terminal Equipmentã®ç¥èªãç¡ç·æ©åšãšé»æ°éä¿¡ç«¯æ«æ© åšã®åžå Žãžã®åºè·ãèªç±ãªæµéããµãŒãã¹äŸäžã«é¢ããæä»€ãå ¬è¡éä¿¡åç·ã«æ¥ç¶ãããéä¿¡ç«¯æ«æ© åšã ãã§ãªãç¡ç·æ©ã察象ãšãªãã è©²åœæ©åš ã»åšæ³¢æ°åž¯9kHz-3,000GHzã®ç¡ç·æ©åš ⢠éä¿¡ç«¯æ«æ©åš ⢠éšåçã«æ¬¡ã®æ©åšã«ãé©çšããã ⢠å»çæ©åšã®éä¿¡æ©èœã®éšåããŠãããç ⢠è»èŒçšéä¿¡ãŠããã æä»€ã®å¯Ÿè±¡å€æ©åš ⢠åçšç®çã§ãªãã¢ããã¥ã¢ç¡ç·æ©åš ⢠海äžç¡ç·æ©åš ⢠é³å£°ïŒTVåä¿¡æ© â¢ æ°éèªç©ºé¢é£æ©åš ⢠èªç©ºç®¡å¶é¢é£æ©åšïŒã·ã¹ãã ⢠ã±ãŒãã«ãšé ç· R&TTEæä»€ãé©çšããããã¹ãŠã®æ©åšã¯ã次ã®äºã€ã®äœããã®ã¯ã©ã¹èå¥ïŒECI: Equipment Class IdentifierïŒãè¡ãããããã®ã¯ã©ã¹èå¥ã¯ãæ©åšã®äœ¿çšè ãå€å¥ã§ããããšãä¿èšŒããªããã°ãªã㪠ãã ClassïŒïŒEUå šåã§ã®äœ¿çšãå¯èœãªæ©åš äŸïŒISDNæ©åšãPSTNæ©åšãGSMãåä¿¡æ©ãªã© ClassïŒïŒEUå šåã§ã®äœ¿çšãäžå¯ã§ãç¹å®ã®åœã§ã®äœ¿çšã«éãããæ©åš äŸïŒTETRAæ©åšãTERAPOLæ©åšãPMRæ©åšããã¬ã¡ãŒã¿ãªã© åç·ã«æ¥ç¶ããã補åã«ã€ããŠã¯ãã¢ãžã¥ãŒã«AãšããŠãæè¡ææžãã¡ã€ã«åã³é©åå®£èšæžã«ãã£ãŠã 補é è ã®èªå·±å®£èšãå¯èœããã®å Žåãåç·ã«æ¥ç¶ããã補åã§ãèªå·±å®£èšãããã®ã«é¢ããŠã¯ãCE ããŒãã³ã°è²Œä»ã®ã¿ãå¿ èŠãšãªããããŒãã£ãã¡ã€ãã»ããã£ã®IDçªå·ã¯äžèŠãšãªãã ç¡ç·æ©ã«ã¯ãCEããŒãã³ã°ãšããŒãã£ãã¡ã€ãã»ããã£ã®IDçªå·ã¯å¿ èŠã§ãããç¡ç·æ©ã§æŽåèŠæ Œ ãååšããã°ã远å ã®åœå¥èªèšŒã¯äžèŠãšãªãããããŒãã£ãã¡ã€ãããã£ã®é¢äžã¯å¿ èŠãšãªããèŠå ïŒã¢ã©ãŒãïŒããŒã¯ã¯CEããŒãã³ã°ãšåãµã€ãºã§è¡šç€ºããªããã°ãªããªãã - 21 - 375 5.6 ç©å ·æä»€ (93/68/EEC) 14æ³æªæºã®åäŸã察象ãšããç©å ·ãEN71ïŒç©ççããã³æ©æ¢°çç¹åŸŽãå¯çæ§ãééå±ç§»è¡ ãªã©ïŒ ã«é©åããŠããå Žåã¯ãã¢ãžã¥ãŒã«Aã«ããèªå·±å®£èšãã§ãããEN71ã«é©åããªã補åã«ã€ããŠã¯ã ã¢ãžã¥ãŒã«B+Cãé©çšããããšãå¿ èŠã§ãããå ·äœçã«ã¯ãååŒè©ŠéšèªèšŒãååŒãžã®é©å宣èšãå¿ èŠ ãšãªãã ã³ã¬ã¯ã¿ãŒåéåãååããŸãã¹ããŒã補åãªã©ã®æ°ãã«ãªã¹ã¯è©äŸ¡ãå¿ èŠã«ãªã補åã¯ããã®æä»€ ã®å¯Ÿè±¡ã«ãªããªãã察象補åã«ãã£ãŠã¢ãžã¥ãŒã«åããããªãã - 22 - 376 6. æè¡ææžã®äœææ¹æ³ åæä»€ã«ãã£ãŠã°ãã€ããããããæè¡ææžãæè¡æ§é ãã¡ã€ã«ãTCFïŒTechnical Construction FilesïŒ ãªã©ãšå®çŸ©ãããŠããããã®ç« ã§ã¯ç·ç§°ããŠãæè¡ææžãšããã ããã€ãã®ãã¥ãŒã¢ãããŒãæä»€ã¯ãé©çšãããèŠæ±ã«è£œåãé©åããŠããããšã蚌æããæ å ±ãèš ãããæè¡ææžã®äœæãè£œé æ¥è ã«çŸ©åä»ããŠããããã®æè¡ææžã¯ãå質ã·ã¹ãã ïŒã¢ãžã¥ãŒã«Dã EãHãããã³ãã®ããªãšãŒã·ã§ã³ïŒã«åºã¥ããŠæä»€ãé©åæ§è©äŸ¡æç¶ããèŠå®ããŠããå Žåãå質 ã·ã¹ãã ææžã®äžéšãšãªãããšãããã æè¡ææžã¯ãæä»€ãå¥ã®æéãæç€ºããå Žåãé€ããåœè©²è£œåã®æçµè£œé æ¥ããæäœ10幎éä¿ç®¡ã ããªããã°ãªããªããããã¯ãè£œé æ¥è ãŸãã¯EUåå ã«èšç«ãããæ£åŒä»£è¡šè ã®è²¬ä»»ã§ãããå Žå ã«ãã£ãŠã¯ãèŒžå ¥æ¥è ãŸãã¯EUåžå Žã«è£œåãæå ¥ããè ããã®è²¬ä»»ãè² ããªããã°ãªããªãã æè¡ææžã®å 容ã¯ãé¢é£ãã補åã«åºã¥ããŠæä»€ããšã«å®ãããããäžè¬ã«ãæè¡ææžã«ã¯èšèšã補 é ãããã³è£œåã®éçšã«ã€ããŠèšèŒããªããã°ãªããªããæè¡ææžã®å 容ã®è©³çްã¯è£œåã®æ§è³ªã«ã㣠ãŠç°ãªãããŸããé¢é£æä»€ã®å¿ é èŠæ±ãžã®è£œåé©åæ§ã蚌æããããã§ãæè¡çèŠç¹ããäœãå¿ èŠãš ããããã«ãã£ãŠç°ãªãããããã¯ãïŒæŽåèŠæ Œãé©çšãããå Žåã«ã¯ïŒèŠæ Œå¯Ÿè±¡ã®å¿ é èŠæ±ã瀺ã ããšã«ããé¢é£æä»€ã®ä»£ããã«ãããã®æŽåèŠæ Œã«é©åããŠããããšã蚌æããããã§ãæè¡çèŠç¹ ããäœãå¿ èŠãšããããã«ãã£ãŠãç°ãªãã ããã€ãã®æä»€ã§ã¯ãåœè©²æç¶ãã宿œãããå çåœã®å ¬çšèªãããŒãã£ãã¡ã€ãããã£ãèšç«ãã ãå çåœã®å ¬çšèªããããã¯ããŒãã£ãã¡ã€ãããã£ãèš±å¯ããèšèªã§æè¡ææžãèšè¿°ããããšãèŠ æ±ãããã第äžè ã«ããé©åãªæ¹æ³ã§ã®æ€èšŒãèŠæ±ããŠããé©åæ§è©äŸ¡æç¶ãã宿œããããã«ãæ è¡ææžã¯åžžã«ããŒãã£ãã¡ã€ãããã£ãçè§£ã§ããèšèªã§èšè¿°ãããªããã°ãªããªããäžéšã®ãã¥ãŒ ã¢ãããŒãæä»€ã§ããã®ç¹ãæç€ºãããŠããªãå Žåãåæ§ã§ããã æè¡ã¯æ¥é²ææ©ã§ãããæåã«æè¡ææžãäœæããæç¹ã§ã®æè¡çèŠæ±æ°Žæºãšæ°å¹ŽåŸãšã§ã¯å€§ããªå·® ç°ãã§ãå¯èœæ§ããããè£œé æ¥è ã¯åžžã«ææ°ã®æè¡æ°Žæºãåæ ããé©åç¶æ ãç¶æããããšãæ±ãã ããã äŸãã°æŽåèŠæ Œãæ¹èšãããå Žåããããåæ ãåºæ¬èŠä»¶ã«é©åããªããã°ãªããªãã ãŸãã補åã®ãªã¹ã¯ãåãå·»ãç°å¢ã«ãã£ãŠãå€åããŠããããããªã¹ã¯åæãå«ãã宿çã«æè¡ ææžãçŸåšã®ç¶æ³ã«å¯Ÿå¿ãããã®ã«ãªã£ãŠãããåŠãã®èŠçŽããå¿ èŠã«ãªãã - 23 - 377 6.1 æ©æ¢°æä»€ æè¡ææžã¯ãåœè©²æ©æ¢°ãæ©æ¢°æä»€ã®èŠæ±äºé ã«åèŽããŠããããšãè£ä»ããè³æã§ãããåœç¶ãªããã é©å宣èšã®äœæã«å ç«ã¡äœæããããäœæã«åœãã£ãŠã¯ãEU åå ã®ããããã®åœã®å ¬çšèªãšããã ç¹ã« 1 åã®ãã¡ã€ã«ã«ãŸãšããå¿ èŠã¯ãªããäžãäžåœå±ã«ããèŠæ±ãããå Žåã«ãéããã«æåºã ãããšãã§ããã°ãããããªãã¡ãåé¢é£éšéã§æžé¡ã管çããŠãããå¿ èŠã«å¿ããŸãšããŠæåºã§ã ãã°è¯ããåœå±ããã®èŠæ±ãšã¯ãææªã®å Žåãäºæ ã§ããããã®ãšãã«æè¡ææžã¯ïœ¢ç©èšãã¬åŒè·äººïœ£ ã®åœ¹å²ãæ ãããã§ãããããæä»€ãªã©ã®èšè¿°ã ãã«ãã ããããé¢ä¿è 以å€ã§ãåãããããªèšè¿° æ¹æ³ãèŠæ±ããããæ©æ¢°æä»€ã§ã¯ã以äžã®äºé ãæè¡ææžãšããæšã®èšèŒãããã ⢠å¶åŸ¡åè·¯å³ãšãšãã«ãæ©æ¢°å šäœã®å³é¢ ⢠èšç®ã詊éšçµæãªã©ãšãšãã«ãæ©æ¢°ã®å¥åº·ãšå®å šã®å¿ é èŠæ±äºé ãžã®é©åã確èªããããã«å¿ èŠ ãªæ©æ¢°ã®è©³çŽ°å³ â¢ ä»¥äžã®ãªã¹ã: æ©æ¢°æä»€ã®å¿ é èŠæ±äºé èŠæ Œãããã³æ©æ¢°ã®èšèšæã«çšããããä»ã®æè¡ä»æ§æžé¡ â¢ æ©æ¢°ã®å±éºæºåé€ã«çšããææ³ã®èª¬æãå¿ èŠã«å¿ããè©Šéšæã®æè¡ã¬ããŒããæè¡ææž ⢠ãããæŽåèŠæ ŒãçšããŠé©åã宣èšããã®ã§ããã°ã補é è ãããã¯ä»ã®è©Šéšæãè¡ã£ã詊éšã® çµæã瀺ãæè¡ã¬ããŒã ⢠ããã¥ã¢ã«ã®ã³ããŒ æ©æ¢°å šäœã®å³é¢ãšã¯ãåœè©²æ©æ¢°ãç¥ãããã®è³æã§ãå¶åŸ¡åè·¯ã®èª¬æãšãšãã«ãæ©æ¢°ã®åããç¥ãã ãšãç®çãšããŠããã以äžã«è¿°ã¹ãåçš®è³æãæ£ããçè§£ããããã®éèŠãªæ å ±ãšãªãããšãèããŠ äœæãããç¹ã«å®å šå¶åŸ¡åè·¯å³ã«é¢ããŠã¯ãäžè¬åè·¯å³ãšã¯å¥ã«äœæããã®å¶åŸ¡å 容ãåããããã ãããæ©æ¢°ã®ä»æ§æžãªã©ã«èšèŒãããã°ãããæµçšã§ããå Žåãããã æ©æ¢°ã®è©³çްå³ãšã¯ãåéšã®å³é¢ã§ãå¿ èŠã«å¿ãè·éèšç®ãéå£éšãšå±éºéšã®è·é¢èšç®ãªã©ãèšããŠèŠ æ±äºé ã«é©åããŠããããšã瀺ããåœç¶ãªããããããã¯å³ãæ©èœèª¬æå³ãåè·¯å³ãããã°ã©ãã³ã° é¢é£è³æãªã©ãå¿ èŠã«å¿ãå«ãŸãããæ²¹å§ã空å§ã®åè·¯å³ãªã©ãããã«å«ãŸããããŸããè³Œå ¥åã®é¢ é£è©Šæãããã«å«ãŸããããããã¯ã«ã¿ãã°ã®åãã§ãã£ãããåè³Œå ¥åã«å¯Ÿããæä»€ãžã®é©åå®£èš æžã第äžè èªèšŒã瀺ãèªèšŒæžã®åãã§ãã£ããããããã®ä»ãéšåãªã¹ããªã©ãå¿ èŠãšãªãã å³é¢é¡ã®äœæã«åœãã£ãŠã¯ãç¬èªã®èšå·ãç¥å·ã䜿çšããããšã¯æ¥µåé¿ããªããã°ãªããªããããã ãããåŸã䜿çšããå Žåã¯ããã®èª¬æãå¥éè¡ãã誀解ãé¿ããå¿ èŠãããã æ¬¡ã«ãé©åã蚌æããããã«çšããèŠæ Œé¡ã®ãªã¹ãã§ãããçšããèŠæ Œã¯ãã¹ãŠãªã¹ãã¢ããããã ãŸããèŠæ Œã«ã¯å«ãŸããªããèšç®ãªã©ã®æ ¹æ ãšãªãè³æ(åŠè¡ææžãªã©)ããªã¹ãã¢ããããã æè¡ææžã®ç¬¬ 1 ã¯ããªã¹ã¯è©äŸ¡ã¬ããŒãã§ãããæ¹æ³ãæ§åŒã¯èŠå®ãããŠããªãã®ã§ãã©ã®æ¹æ³ã çšããŠãè¯ãããæ¬ã¬ããŒãã«ã¯ãæ¡çšããå®å šæ¹çã®èª¬æãå®å šãšç¢ºèªããã«è³ã£ãçç±ãªã©ãèš è¿°ãããŠããå¿ èŠãããããã®ä»ã説æã®ããå¿ èŠã«å¿ããåãªã¹ã¯ã«å¯ŸããŠç¢ºèªããè©Šéšæã®ã¬ã - 24 - 378 ãŒããªã©ãçšæããã æè¡ã¬ããŒããšã¯ãèŠæ Œã«åŸã£ãŠé©åã確èªããããšã瀺ãã¬ããŒãã§ããã該åœããèŠæ Œ(ã²ãšã€ ãšã¯éããªã)ã®èŠæ±é ç®ã«å¯Ÿãããã®é©åäžé©åã確èªããŠäœæãããã説æã®ããããã€ãã®è³ æãæ·»ä»ããããšãå€ããããã¥ã¢ã«ã«é¢ããŠã¯ããµãŒãã¹ããã¥ã¢ã«ã®ããã«ãèªç€ŸãµãŒãã¹ã¹ã ãŒã·ã§ã³åãã§äœæããæãšããŠãŠãŒã¶ãŒã«æž¡ããªããããªããã¥ã¢ã«ãå«ãã å šäœãšããŠæè¡ææžã«èŠæ±ãããå 容ã¯ãèªç€Ÿè£œåãããã«ããŠèŠæ±äºé ã«é©åããŠããããã説æ ããããšã§ãããæ©æ¢°æä»€ã®æè¡ææžã«é¢ããèšè¿°ã¯äžè¬çãªäºé ãªã®ã§ããã®åå¥ã«ãã ãã£ãç 矩ã®å€æãé¿ããåºçŸ©ãªçè§£ã®ããšã§ããããããšãéèŠã§ããããŸããæãšããŠããæè¡ææžã¯ãŠ ãŒã¶ãŒã«æäŸãããã®ã ããšã®èª€è§£ãããããåé ã«ãè¿°ã¹ããšãããæè¡ææžã¯ææªã®å Žåãäºæ ã®å Žåã«èªç€Ÿè£œåã®æ£åœæ§ã瀺ãè³æãšãªããã®ã§ããããŠãŒã¶ãŒã«æäŸããæ§æ Œã®ãã®ã§ã¯ãªãã åŸã£ãŠãæè¡ææžã®äœæã«åœãã£ãŠã¯ãããã®åºæ¬çèãæ¹ãå¿ããªãããã«ããããšãéèŠã§ããã æ©æ¢°æä»€ã®é ç®ã«ã¯èšèŒãããŠããªãäºé ã§ããããèšèšç®¡çãçç£ç®¡çãå質管çãªã©ã¯ã補åã å®å šã«ããããã«éèŠãªç®¡çé ç®ã§ããããããã®ç®¡çäœå¶ã®äžã«ãäžèšæžé¡ãäœæããå¿ èŠã«å¿ã 倿Žïœ¥ç®¡çãããªããç¶æãããå¿ èŠããããèšèšç®¡çãšããŠãåæã®éçºæ®µéã ãã§ã¯ãªããèšèš 倿Žãè¡ãããéã«ãããã®å€æŽã«ããæ°ããªå±éºãçããªãããšã確èªãããªããã°ãªããªããã ããã®ç¢ºèªã®è³æã¯æ°ããªæè¡ææžã®1ããŒãžãšããŠè¿œå ãããã倿Žãããå¿ èŠãããããã®å€æŽ å±¥æŽã¯ç®¡çãããã©ã®è£œçªã®è£œåãã©ã®ãããªæ§é ãããŠããã®ãåããããã«ãªã£ãŠããªããã°ãª ããªããçç£ç®¡çã»å質管çã«ãããŠã¯ãèšèšã®æç€ºéãçç£ãè¡ãã補åã®å®å šã確ä¿ããããã ã®ç®¡çãèŠæ±ããããéšåæé ã»è³Œå ¥ãçç£çŸå Žã§ã®æ€æ»çµæãªã©åçš®ããŒã¿ã¯ä¿ç®¡ãããæç€ºéã ã®çç£ãè¡ãããããšã®è£ã¥ãè³æãšãªãã 6.2 äœé»å§æä»€ æè¡ææžã«é¢ããŠã¯ãæä»€ã®ä»å±æžïŒã® 3 é ã«èšèŒãããããããæžé¡ã¯ãåé ã«ããããã«çç£ äžæ¢åŸ 10 幎ã®ä¿ç®¡ãèŠæ±ãããã å 容ã¯ïŒ ⢠補åã®äžè¬çãªèª¬æã â¢ åºæ¬èšèšãçç£é¢é£å³é¢ãåè·¯å³/æ§æå/éšåãªã©ã®æ§æã ⢠ãããå³é¢ã補åã®æäœãçè§£ããããã®èª¬æã ⢠é©å蚌æã«çšããèŠæ Œã®ãªã¹ãããèŠæ Œãçšããªãã£ãå Žåã¯ãã®æ¹æ³ã ⢠èšç®çµæã詊éšçµæããªã© ⢠詊éšã¬ããŒã ã§ããã - 25 - 379 æè¡ææžãšã¯ãåœè©²è£œåãå®é»å§æä»€ã®èŠæ±äºé ã«åèŽããŠããããšãè£ä»ããè³æã§ãããããã ã£ãŠãåœç¶ãªããé©å宣èšã®äœæã«å ç«ã¡æºåãããŠããã¯ãã§ãããäœæã«åœãã£ãŠã¯ãEU åå ã®ããããã®åœã®å ¬çšèªãšãããç¹ã« 1 åã®ãã¡ã€ã«ã«ãŸãšããå¿ èŠã¯ãªããäžãäžåœå±ã«ããèŠ æ±ãããå Žåã«ãéããã«æåºããããšãã§ããã°ãããããªãã¡ãåé¢é£éšéã§æžé¡ã管çããŠã ããå¿ èŠã«å¿ããŸãšããŠæåºã§ããã°è¯ããåœå±ããã®èŠæ±ãšã¯ãææªã®å Žåãäºæ ã§ããããã®ãš ãã«ãããæè¡ææžã¯ãç©èšãã¬åŒè·äººïœ£ã®åœ¹å²ãæ ãããã§ãããããæä»€ãªã©ã®èšè¿°ã ãã«ãã ããããé¢ä¿è 以å€ã§ãåãããããªèšè¿°æ¹æ³ãèŠæ±ãããã è£œåæŠèŠã¯ãäžè¬çã«åæ±èª¬ææžã«èšèŒãããŠãããšèãããããããããä¿ç®¡ããããšã§ç®çã¯é æããããç¹æ®è£œåã§ãåæ±èª¬ææžã§èª¬æããããªãå Žåã«ã¯ãå¥é説æè³æã®äœæããæ¹ãããã èšèšã®åºæ¬ç念ãå³é¢ãªã©ã®æ§æã«ã€ããŠã¯ãäŒç»æžã仿§æžããŸããµãŒãã¹ããã¥ã¢ã«ã該åœããã ãã該åœããæžé¡ããªãå Žåã¯ãæ°ãã«äœæãèŠãããããã®ä»æžé¡ã®é¢é£ã瀺ãããšã§ã第äžè ã æè¡ææžãçè§£ãããããã©ãããæ±ºãŸã£ãŠããŸããšãã£ãéèŠãªæžé¡ã§ããã®ã§æ éã«çšæãã ãã 説æè³æã«ã€ããŠã¯ãåæ±èª¬ææžã該åœããããããå³é¢é¡ã«ç¹æã®èšå·ã衚çŸãçšããå Žåã¯ãã ã®èšè¿°ãèŠãããIEC èŠæ Œã ISO èŠæ Œã«èŠå®ãããŠããªãèšå·ã衚çŸã䜿ãå Žåã¯ç¹ã«æ³šæãå¿ èŠ ã§ããã èŠæ Œã®ãªã¹ãã¯ãé©åå®£èšæžãžã®èšèŒãå¿ èŠã§ãããéšåçã«åç §ããèŠæ Œããªã¹ãããå¿ èŠãããã ç¹å®ã®èŠæ Œã«æããã補åè©äŸ¡ã«çšãããã¹ãŠã®èŠæ ŒãèšèŒãããèŠæ Œã«ã¯ããã®çºè¡å¹Žã«ããå€±å¹ ããŠããèŠæ Œãããã倱å¹ããŠããèŠæ Œã§è©äŸ¡ãããå Žåãå床æå¹ãªèŠæ ŒãçšããŠè©äŸ¡ãããçŽã å¿ èŠããããååçã«ã¯æŽåèŠæ ŒãçšããŠè©äŸ¡ããªããã°ãªããªãããããæŽåèŠæ Œãç¡ããç¬èªã« è©äŸ¡ããå Žåã¯ããã®æ¹æ³ã®è©³çްãèšèŒããªããã°ãªããªããç¬èªã®è©äŸ¡ãšãã£ãŠããã§ãããéã ã®åœéèŠæ ŒãååœèŠæ Œãæ¡çšããå¿ èŠããããç§åŠçã»æè¡çã»çè«çè£ã¥ãã®ç¡ãè©äŸ¡æ¹æ³ã¯èªã ãããªãã äžèšãèŠæ Œã§ã®è©äŸ¡è©Šéšã®çµæã瀺ããæžé¡ããèšç®çµæã§ãã詊éšçµæã§ããã詊éšã®åçŸæ§ã®å¿ èŠæ§ããããã€ã»ã©ãã§ã»ã ããâŠãšãã£ãèšèŒãå¿ èŠã§ãããè©Šéšæ¥ãå Žæã詊éšå¡ãäœ¿çšæž¬å®åšã 枬å®åšã®æå¹æ§ãæž©åºŠã»æ¹¿åºŠã»æ°å§ãªã©ã®è©Šéšç°å¢ãªã©ã¯ãæäœé詊éšçµæã«èšèŒããå¿ èŠãããã åœç¶ãªããã詊éšããè ã®çœ²åãã詊éšçµæãæ€èšŒããè ã®çœ²åãªã©ãå¿ èŠã§ãããæä»€ã«ã¯å ·äœç èšè¿°ã¯ç¡ããããªã¹ã¯ã¢ã»ã¹ã¡ã³ããªã©ãããã«è©²åœãããä»åŸããªã¹ã¯ããŒã¹ã®å®å šå¯ŸçãèŠæ±ã ããã®ã§ããªã¹ã¯ã¢ã»ã¹ã¡ã³ãã¬ããŒãã¯éèŠãªæžé¡ã®ã²ãšã€ã«ãªãã ããã詊éšããŒã¿ãªã©ãããšã«ã該åœããèŠæ Œã«ããè©äŸ¡ããçµæãè¿°ã¹ãæžé¡ã詊éšã¬ããŒãã§ã ãã該åœããå šé ç®ã®é©åäžé©åã®å€å®ãèšèŒãããšãšãã«ã該åœããªãé ç®ã®èšèŒãéèŠã§ããã ã¬ããŒãäœæè ã®çœ²åãšãšãã«ãæ€èšŒè ã®çœ²åãèšããã - 26 - 380 以äžããæä»€ã§ã®èšèŒäºé ã§ãããååçã«ã¯ããã§ã«ååšããæžé¡ãçšããããšãå¯èœã§ããã㟠ããèšèšå€æŽãªã©ã«ããåžžã«å€æŽãããæ§æ Œã®æžé¡ãå€ãã®ã§ãç¹å¥ã«äœæããããšã¯å§ããªãã ïŒã ã ãèšèªã®åé¡ãããã®ã§ãéçšã®çŸå®ã«ã¯é£ããç¹ããããïŒ äžèšä»¥å€ã«ããåçãªã©ã¯é©åã蚌æããæå¹ã¯ææ®µã§ããã®ã§ãé©åè©äŸ¡ã«çšãã補åã®åçãªã© ã®ä¿ç®¡ãå§ããããŸããèšèšç®¡çã»çç£ç®¡çã»å質管çãªã©ãåžžçšäºé ã§ããããã¹ãŠã®é¢é£æé æž ã翻蚳ããå¿ èŠã¯ç¡ãã§ãããããéèŠãªææžã®ç¿»èš³ã¯å¿ èŠã§ããã åºæ¬ã¯ãå®å šãªè£œåãäŸçµŠããããšã«ãããæè¡ææžã¯å®å šãªè£œåãèšèšçç£ããæ®µéã§å¿ èŠã«å¿ ããŠäœæããããã®ã§ãããããèŠæ Œã«èšèŒã®é ç®ããæä»€ã®èŠæ±é ç®ã¯æäœéã®èŠæ±ãšèããå¿ èŠ ãªæžé¡ãæŽããããšãèèŠã§ããã 6.3 EMC æä»€ æè¡ææžã¯æä»€ã®èŠæ±ãžã®é©åã®æ ¹æ ãç€ºãææžã§ãããéåžžã以äžã®æ å ±ãå«ãã ⢠æ©åšã«é¢ãã説æ ⢠ãã®æ©åšã®ä»æ§æžãåæ±èª¬ææžãªã© ⢠æŽåèŠæ Œãé©çšããå Žåããã®èŠæ Œã®äžèЧãåã³ãããã®æŽåèŠæ Œãžã®é©åã®èšŒæ (詊éšå ±åæž) ⢠æŽåèŠæ Œãé©çšããªãã£ãããããã¯éšåçã«ã®ã¿é©çšããå Žåã«ã¯ãEMC ã«é¢ããè©äŸ¡ã®èšè¿°ã èšèšäžã®èšç®ã®çµæã宿œãã詊éšã詊éšå ±åæžãå«ãä¿è·èŠæ±ãžã®é©åã®ããã«çšããæé ã®èª¬æ â¢ é»æ°åè·¯å³ãéšåé 眮å³ããã®ä»ã®å³é¢é¡ (ããã¯EMCæä»€ã§ã¯æç€ºçã«ã¯èŠæ±ãããŠã¯ããªããã è©äŸ¡ã®è³æãšããŠå¿ èŠãšãªããšèãããã) ⢠äžèšã®å³é¢é¡ãçè§£ããããã«å¿ èŠãªæ å ± (åäž) ⢠89/336/EECã®TCF ã«ãŒããé©çšããå Žåã«ã¯ãã³ã³ããã³ãã»ããã£ããã®æè¡å ±åæžåã¯èšŒææž ⢠2004/108/EC ã§ãããŒãã£ãã¡ã€ãããã£ã®é¢äžãéžæããå Žåã«ã¯ãããŒãã£ãã¡ã€ãããã£ãã ã®ã¹ããŒãã¡ã³ã(æèŠæž) ⢠é©åå®£èšæž (ãããæè¡ææžã«å«ããããšã¯ EMC æä»€ã§ã¯èŠæ±ãããŠã¯ããªã) 89/336/EEC ã® TCF ã«ãŒããé©çšããå Žåããã®ææžã¯ TCF ãšåŒã°ããããŸãã89/336/EEC ã¯ã èŠæ Œã«ãŒããé©çšããå Žåã«é¢ããŠã¯æè¡ææžã®äœæãèŠæ±ããŠããªããããã®å Žåã§ããã®ãããª ææžåã¯è¡ãªã£ãŠããããšãæãŸãããæè¡ææžã¯ãEU ã®å ¬çšèªã®ãããã (äŸãã°è±èª) ã§æžã å¿ èŠããããæè¡ææžã«å«ããããšããè³æ (ç¹ã«ãå³é¢ãªã©ã®)ã«æ¥æ¬èªãå«ãŸããŠããå Žåãå° ãªããªããšèããããããæ¥æ¬èªãèªããªãå°éå®¶ã§ããã®è³æãçè§£ã§ããããã«ãæäœéãéèŠ ãªéšåã«ã€ããŠã ãã§ãè±èªã§èšè¿°ãã(ãããã¯è±èªã䜵èšãã)ããã«ãã¹ãã§ãããè€æ°ã®æä»€ (äŸãã° EMC æä»€ãšäœé»å§æä»€) ãžã®é©å宣èšãè¡ãªãéã«ã¯ãåäžã®æè¡ææžã§ãããå šãŠã®æ 什ã®ããã®ææžãå Œããããããšãå¯èœã ãããã®å Žåã«ã¯ãããã®æä»€ãæè¡ææžã«å¯ŸããŠäœãèŠ æ±ããŠããã®ãã確èªãããããã®èŠæ±ãåæã«æºè¶³ãããããšãå¿ èŠãšãªãã - 27 - 381 6.4 å»çæ©åšæä»€ è£œé æ¥è ã¯ãèªå·±è²¬ä»»ã«ãããŠåœè©²å»çæ©åšãæ¬æä»€ã®åºæ¬èŠä»¶ã«å¯ŸããŠã©ã®ããã«é©åããŠããã ãé©åãã€ååã«èšŒæãããããæè¡ææžãäœæããããšãæ±ããããŠãããæè¡ææžã¯ãããã°è£œ åã«é¢ããŠã®èº«åèšŒææžã®åœ¹å²ãæãããèŠå¶åœå±ãå«ã第äžè ã«å¯ŸããŠé©æ§ãªèº«å ïŒåºæ¬èŠä»¶ãæº ããã補åã§ããããšïŒã§ããããšã蚌æããå¯äžã®ãã®ã§ãããèŠè«ã«å¿ããŠåžžã«æåºå¯èœã§ãªã ãã°ãªããªããã€ãŸãæè¡ææžã¯ãè£œé æ¥è å éšã«å¯ŸããŠã§ã¯ãªãå€éšã®ç¬¬äžè ã«å¯ŸããŠååã«èª¬åŸ åãããããã«èšè¿°ãããããšãæ±ããããããŸãããã®ç®çã«ããEUåå ã®å ¬çšèªã§ç·šãããã ãå¿ èŠãããã æè¡ææžäœæã®å®è·µçæé ã¯ã以äžã®éãã§ããã æè¡ææžã®åºæ¬çãªæ§æãšããŠâïŒ åé¡ é ç® è£œåã®äžè¬æ å ± ã»å¯Ÿè±¡è£œåïŒæ¬§å·åå ã«åºè·ããããšããå šãŠã®æ©çš®ãæç¢ºã«ãã ã»å è£ ä»æ§ ã»è£œåã®ä»æ§ãçè§£ã§ãããããªæŠèŠèª¬æ 補åã®æå³ããç®ç ã»è£œåã®æå³ããç®çïŒäœ¿ç𿹿³ã察象æ£è 矀ã䜿çšç°å¢ åã³ ãŠãŒã¶ãŒã®ç¹å® ç ãã®éšåã®å 容ã¯éåžžã«éèŠã«ãªãã®ã§æç¢ºã«èšè¿°ããŸãã æå³ããç®çã¯ãã¯ã©ã¹åé¡ã«ã圱é¿ãäžããŸãã è£œé æ¹æ³ã®æŠèŠ ã»è£œé æ¹æ³ã®èŠçŽïŒäžè¬ç衚çŸãçšããŠè£œé æè¡ã®æŠèŠãåãã ããã«èšè¿°ããŸããïŒå è£ ãæ» èæ¹æ³ãå«ãïŒ ã»è£œåã®ç¹æ§ã®ç¢ºèªæ¹æ³ åœè©²æ©åšãšçµã¿åã ããæ©åš ã»æ©åšãšçµã¿åãããŠäœ¿çšããæ©åšã®èšè¿°ïŒä»å±åïŒãªãã·ã§ã³ïŒã·ã¹ãã æ§æ ç ã¯ã©ã¹åé¡ ã»é©çšããä»å±æžïŒã§ã®ã¯ã©ã¹åé¡ã«ãŒã«åã³é©çšããçç± æè¡çèŠæ±äºé ã® æç¢ºå ã»é©çšæä»€ ã»æããã§ãªãå Žåé©çšæä»€éžæã®çç± åºæ¬èŠä»¶ãã§ã㯠ãªã¹ã ã»åºæ¬èŠä»¶ãžã®é©åç¶æ³ïŒé©çšæŽåèŠæ Œ çïŒ ã»é©åæ§ã瀺ã蚌æ ïŒè©Šéšã»è©äŸ¡ã¬ããŒã çïŒ ã»åºæ¬èŠä»¶ã«è©²åœããªãå Žåã®çç±ä»ã è£œåæ å ± æè¡æ å ± å 容 åºæ¬çãªæ§æãšããŠâïŒ åé¡ èšèš é ç® å 容 ãªã¹ã¯åæ ã»è£œåã«æœåšããå šãŠã®ãªã¹ã¯ïŒé節床ïŒçºççïŒã®ç¹å®åã³ãªã¹ã¯ã®è»œæžå¯Ÿç ã»ãªã¹ã¯åæã®çµè«ïŒè£œåã®å¹èœã«å¯ŸããŠãªã¹ã¯ã蚱容ã§ãããåŠã 補é ã»ç¹æ®å·¥çš ã»åææã®ä»æ§ïŒçäœé©åæ§çïŒ ã»ç¹æ®å·¥çšïŒã¯ãªãŒã³ã«ãŒã ãæŽæµãæ» èïŒåã³ããããã®é©çšèŠæ Œ ã»é©çšå質ã·ã¹ãã èŠæ Œ 補åè©Šéš ã»è£œåã®èŠæ±æ§èœã»å®å šæ§ã確èªããåºæºã»ææ®µïŒæšæºã»æé çïŒ è¡šç€ºé¡ ã»åæ±èª¬ææžïŒæ·»ä»ææž ç 補åã®æå¹æé ã»è£œåã®æå¹æéïŒææã®å£åãå è£ ãæ» èã®æå¹æ§ãèœåæ©åšã®å Žåã¯ã ã¹ãã¢ããŒãã®å ¥æå¯èœæ§çãèæ ®ããŠã®èšå® èšåºè©äŸ¡ ã»è£œåã®èšåºçæå¹æ§ã®è©äŸ¡ïŒèšåºè©Šéš æã㯠æç®æ å ±èª¿æ» å€æŽæ å ± ã»è£œå仿§ã®å€æŽå±¥æŽïŒè£œåã®å€æŽåŸã®ä»æ§ã倿Žã®æ€èšŒ æãã¯ åŠ¥åœæ§ç¢ºèªã® ããŒã¿ç - 28 - 382 6.5 R&TTE æä»€ Annex II 4 é ã®èšèŒéããèšèšãçç£ã補åãªãã¬ãŒã·ã§ã³ã®èšèŒãç¹ã«ã以äžãåãããŠããã ⢠補åã®äžè¬çãªèª¬æ â¢ åºæ¬èšèšãçç£é¢é£å³é¢ãåè·¯å³/æ§æå/éšåãªã©ã®æ§æ ⢠é©å蚌æã«çšããèŠæ Œã®ãªã¹ãããèŠæ Œãçšããªãã£ãå Žåã¯ãã®æ¹æ³ ⢠å³é¢ã補åã®æäœãçè§£ããããã®èª¬æ ⢠èšç®çµæã詊éšçµæ ⢠詊éšã¬ããŒã 補é è ããŸãã¯ä»£è¡šè ã¯ãé©åå®£èšæžãæè¡ææžã®äžã«çµã¿èŸŒãå¿ èŠãããã 6.6 ç©å ·æä»€ ç©å ·æä»€ã«ã¯ãæè¡ææžãšãã£ãåŒç§°ã¯åºãŠããªãããArticle 8 ã«è£œé è ãããã¯ãEU åå ã®ä»£ç 人ãä¿æãã¹ãæ å ±ã«é¢ããèšèŒãããããããã¯ãé©åã®ç¢ºèªã«çšããèŠæ Œã®çªå·ããããã®è©Šéš ã¬ããŒããé¢é£æè¡ææžãå¿ èŠã«å¿ããããŒãã£ãã¡ã€ãããã£çºè¡ã® EC ååŒèªå®æžãããŒãã£ã ã¡ã€ãããã£ãžæåºããæžé¡ã®åããªã©ãå¿ èŠã«ãªãããã¡ãããè£œé æ¥è åã補åã®ä¿ç®¡å Žæãªã© ãæç¢ºã«ããå¿ èŠãããããã®ä»ãèšèšãçç£é¢é£æžé¡ã®ä¿ç®¡ã矩åä»ããããŠããã ãããæžé¡ã¯ãåœè©²ç©å ·ãç©å ·æä»€ã®èŠæ±äºé ã«åèŽããŠããããšãè£ä»ããè³æã§ãããç¹ã« 1 åã®ãã¡ã€ã«ã«ãŸãšããå¿ èŠã¯ãªããäžãäžåœå±ã«ããèŠæ±ãããå Žåã«ãéããã«æåºããããšã ã§ããã°ãããããªãã¡ãåé¢é£éšéã§æžé¡ã管çããŠãããå¿ èŠã«å¿ããŸãšããŠæåºã§ããã°è¯ãã åœå±ããã®èŠæ±ãšã¯ãææªã®å Žåãäºæ ã§ããããã®ãšãã«ãããã®æžé¡ã¯ãç©èšãã¬åŒè·äººïœ£ã®åœ¹ å²ãæ ãããã§ãããããæä»€ãªã©ã®èšè¿°ã ãã«ãã ããããé¢ä¿è 以å€ã§ãåãããããªèšè¿°æ¹æ³ ãèŠæ±ããããäœæã«åœãã£ãŠã¯ãPL äºæ ãªã©ã®å Žåã«ãEU åå ã§äœ¿çšãããããã§ããããã EU å çåœã®ããããã®åœã®å ¬çšèªãšããã é©åã®ç¢ºèªã«çšããèŠæ Œã®çªå·ããããã®è©Šéšã¬ããŒããé¢é£æè¡ææžã«é¢ããèšè¿°ã¯ãä»ã®æä»€ã§ èšããšããã®é©åå®£èšæžã«è©²åœãããç¹ã«æ§åŒã®æå®ã¯ãªãã®ã§ãè±æãªã©ã§æžé¡ãäœæããéã«ã ã¬ããŒããæžé¡ã®åç§°ãç¹å®çªå·ãçºè¡è ãç·ããŒãžæ°ãæ¹ççªå·ãªã©å¿ èŠäºé ãèšèŒããæžé¡ãäœ æããæžé¡ãšäžç·ã«ä¿ç®¡ããŠããã°ããã詊éšã¬ããŒãããé¢é£æè¡ææžã«é¢ããŠã¯ãå Žåã«ãã£ãŠ ã¯ãé¢é£æžé¡ã®ç®æ¬¡ã«çžåœãããããšãã§ããã çç£è ãä¿ç®¡å Žæã®åç§°ãäœæãé£çµ¡å ãªã©ã¯ã衚çŽãšããŠäœæããŠãè¯ãããäžèšæžé¡ã®äžéšãšã ãŠèšèŒããŠããããšãã§ããããã¡ããå¥éäœæãå¯èœã§ããã EC ååŒèªå®æžãæåºæžé¡ãªã©ã¯ãããããã®ãŸãŸãã¡ã€ã«ããã°ããã - 29 - 383 åè¿°ã®æåºæè¡æžé¡ã«ã¯ãèšèšé¢é£ã®æžé¡ãªã©ãå«ãŸãããæ©æ§å³ã黿°åè·¯å³ãåçãªã©ãèãã ããããç©å ·ã®å Žåã¯ã匷床èšç®ãæ¯æ§ã®ç¢ºèªãéèŠã§ããã®ã§ããããã®èšŒææžãªã©ãå¿ããŠã¯ãª ããªãã æ©æ§å³ã«ã¯ãå¿ èŠã«å¿ããçµã¿å³ãå«ããå¿ èŠããããããã¯ãåã ã®éšåã®çµã¿åããç¶æ ã§ã®å åãééã確èªããããã®ãã®ã§ãããåšç¥ã®ããã«ãèŠæ Œã§ã¯ãããééã§ã®ææã®æã¿ãã¿ãå æãèæ ®ããŠãããéšåèš±å®¹èª€å·®ã®æå€§å€ãæå°å€ã§ã®æã¿èŸŒã¿ã®ç¢ºèªãå¿ èŠã§ããã æ©æ§å³ã«ã¯ãèŠåæãã©ãã«ã®å³é¢ãå«ãŸãªããŠã¯ãªããªãããã®èšè¿°å 容ãã¯ã£ãããšãããå¿ èŠ ããããå³é¢ã®ä¿ç®¡ã ãã§ãªããã©ãã«ãå°å·ç©ãã®ãã®ã®ä¿ç®¡ããå§ããããã©ãã«ã®æè³ªãäœ¿çš ããŠããã€ã³ã¯ã®ã¡ãŒã«ãåçªã®èšè¿°ãå¿ èŠã§ãããããã¡ããæ©æ§éšåã®ææã®ç¹å®ã«å¿ èŠãªæ å ±ã 塿ã®ç¹å®ã®ããã®æ å ±ãªã©ãå¿ èŠãšãªãããããŠããããããããã®ææãã€ã³ã¯ã塿ã«å¯ŸããŠ æ¯æ§ã®æç¡ã嫿éã確èªããŠé¢é£æžé¡ãå ¥æãä¿ç®¡ããŠããå¿ èŠãããã嫿éã®æž¬å®çµæãå ¥æ ããå Žåã¯ããã®çµæãæä»€ã¯é¢é£èŠæ Œã®èŠå®å€ãæºè¶³ããŠããããšã確èªããŠããããšãå¿ããŠã¯ ãªããªãã æ©æ§ãè¡šç€ºãæ¯æ§ãªã©ã¯åœè©²æŽåèŠæ Œã«åŸã£ãŠé©åã確èªãããå¿ èŠãããããããã¯ã詊éšã¬ã㌠ããšããŠãŸãšããããä¿ç®¡ãããªããã°ãªããªãããã®é©å確èªã¯ãé¢é£ããèŠæ Œã®ãã¹ãŠã®é ç®ã« é¢ããŠè¡ãããå¿ èŠãããã補åã«ãã£ãŠã¯ãå€ãã®é ç®ãé該åœã«ãªãå Žåãããããé該åœã§ã ãããšã®ç¢ºèªãéèŠãªããšã§ããã 黿°åè·¯å³ã«ã¯ãåè·¯ã®è©³çްãèšèŒããåéšåã®ç¹å®ãã§ããå¿ èŠãããã䜿çšé»å§ã¯ãïŒïŒV ä»¥äž ã§ãããããåéšã®é»å§ãªã©ã®èšå ¥ãæå¹ã§ãããã¡ãªã¿ã«ã黿°ã䜿ãç©å ·ã®å Žåã¯ãããšãïŒïŒ V 以äžã§ãã£ãŠããä»åŸã¯å®é»å§æä»€ãèæ ®ããå¿ èŠæ§ãåºãŠããã®ã§æ³šæãèŠãããèšèšãçç£é¢ 飿žé¡ã«ã¯ãäžèšæžé¡ã ãã§ã¯ãªããèšèšç®¡çãçç£ç®¡çã®æžé¡ãå«ããè¿å¹ŽãISO9001 èªèšŒååŸ ãé²ãã§ããã®ã§ãããããæã£ãŠããããšãšèãããããé©åã確èªããŠèšèšïœ¥çç£ãè¡ãããŠã ãããšãæäœéãæä»€ãèŠæ Œã®é©åã確èªããªãèšèšå€æŽããªãããªããããªä»çµã¿ãã€ããããŠã ãããšã®ç¢ºèªãå¿ èŠã§ããã - 30 - 384 7. 7.1 ããã¥ã¢ã«äœææã®çæç¹ æ©æ¢°æä»€ æ©æ¢°ã®åãæ±ãã説æããåæ±ããã¥ã¢ã«ãç¹æ€æŽåãªã©ãèšè¿°ããæŽåããã¥ã¢ã«ãä¿®çã«é¢ãã èšè¿°ã®ãµãŒãã¹ããã¥ã¢ã«ã念é ã«ãããŠèšè¿°ããã æ©æ¢°ã¯æå ¥ãããããªããé·ãé䜿çšããããã®ã§ãããåŸã£ãŠæ¥ã 䜿çšãããããã¥ã¢ã«ãæ©æ¢°ã® 寿åœã«å¿ããäžå€«ããèŠæ±ããããåœç¶ãªãããèªã¿æããã®ã§ãªããŠã¯ãªããªãããã©ããªäººã䜿 ãã®ãïŒããèæ ®ããããã«èŠåã£ã衚çŸãæ±ããããããŸããèªã人ã«ãšã£ãŠïœ¢å€åœèªïœ£ã§æžããã ããã¥ã¢ã«ã¯äžé©åã§ããã䜿çšããèšèªã¯ãæ©æ¢°ã䜿çšãããåœã®å ¬çšèªã§ããããšãèŠæ±ãããã äœæ¥ã®æµãã«æ²¿ã£ãŠãïœ¢äœæ ïŒïœ£ãã©ãããŠïŒããšãã£ã質åãåæã«ããèšè¿°ãè¡ãããããããã äœæããããšãèŠæ±ããããæäœèª¬æã¯ã§ããã ãåçŽæå¿«ã«èšè¿°ãã䜿çšããåäœããããã¯åéš ã®åŒã³åãªã©ã¯ãã¹ãŠã®ææžã§çµ±äžããããå®å šã«é¢ãã説æãèŠåãªã©ã¯æåã®è²ã倧ãã圢ãå€ ããããšã«ãã匷調ããã説ææã ãã§ãªããçµµãå³è¡šã«ããçè§£ã®ä¿é²ãèéãããã¹ãã§ããã æ©æ¢°ãè€éã§å€ãã®æžé¡ãããªãå Žåã¯ããããã®çžäºé¢é£ãåããããã«ããå¿ èŠããããåãã ã¥ã¢ã«ãæžé¡ã«ã¯èå¥çªå·ãã€ãããªã©ããŠèª€è§£ãçããªãããã«ããå¿ èŠãããããŸããç¹å®ã®æ è¡ãæãã人ãèšç·Žãåãã人ãè¡ãç¹æ€ãæŽåãä¿®çã«é¢ããèšè¿°ã¯ãäžè¬äœæ¥å¡ãè¡ãäœæ¥ã«é¢ ããèšè¿°ãšæç¢ºã«åããå¿ èŠãããã ããã¥ã¢ã«ã®ç¬¬äžç®çã¯ãèšèšã«ããæé€ã§ããªãã£ãå±éºã«é¢ããèšè¿°ãè¡ãããšã«ããæ©æ¢°ãå® å šã«äœ¿çšãããšããã«ãããããªãã¡ãæ®çå±éºã®äŒéã§ããããŸããäžãäžæ éãããã¯äºæ 㪠ã©ãçããå Žåã®è²¬ä»»æåšã瀺ããã®ã§ãããã責任æåšã®è¡šç€ºãšããŠãèŒžå ¥æ¥è ãä¿®çæ ç¹ã®äœæ ãªã©é£çµ¡ãåãããšãã§ããã ãã®æ å ±ã®èšè¿°ãèŠæ±ããããããã«ã補åãç¹å®ããããã®è£œåçª å·ãªã©ãå¿ èŠãšãªãã æ©æ¢°ãå®å šã«äœ¿ãããã«ã¯ãæå³ãã䜿çšïœ£ãäœã§ããããèšè¿°ããããšã¯åœç¶ã®ããšã§ãããæå³ ãã䜿çšã«é¢ããŠã¯ã倧ããåããŠãçµã¿ç«ãŠåè§£ã«é¢ããããšã䜿çšéå§åã«é¢ããããšã䜿çšã« é¢ããããšãæå ¥ããå®æç¹æ€ã«é¢ããããšããããŠå»æ£ã«é¢ããããšãªã© 補åã®ã©ã€ããµã€ã¯ã« ãèæ ®ãæŒããªãèšèŒããå¿ èŠãããããŸããïœ¢äºæž¬å¯èœãªèª€äœ¿çšïœ£ã«ããå±éºåé¿ã®å¿ èŠæ§ãããæ£ ããäœ¿çšæ¹æ³ãèšè¿°ããªã¹ã¯ãå ãããšåæã«ïœ¢èª€äœ¿çšïœ£ãïœ¢çŠæ¢è¡çºïœ£ãªã©ãå¿ èŠã«å¿ãèšè¿°ããã 以äžãæ©æ¢°æä»€ã«ç¹æãšæãããèšè¿°é ç®ã瀺ãã 1) å®å šã«äœ¿çšããããã®èšçœ®æ¹æ³ãä¿ç®¡æ¹æ³ãéæ¬æ¹æ³ã®èšè¿°ãæ©æ¢°ãããã®éšåã®å¯žæ³,éé, éå¿ãŸããã¯ã¬ãŒã³ã®ããã¯ã®å Žæããã©ãŒã¯ãå ¥ããå Žæãªã©ã®èšè¿°ãå¿ èŠã 2) æ©æ¢°ã«åãä»ããå·¥å ·ã«é¢ããèšè¿°ããå·¥å ·éžæã®ããã«å¿ èŠãªæ å ±ã®èšè¿°ã 3) éšé³ã«é¢ããèšè¿°ããã³éšé³ã®æžå°ã«å¿ èŠãªèšåã®èšè¿°ã70dBA æªæºã§ããã°ããã®æšã®èšè¿°ã - 31 - 385 ããŒã¯ã 63Pa ãè¶ãããªãã°ãã®æšã®èšè¿°ã85dBA ãè¶ ãããªãã°ãã®èšè¿°ãããã³æž¬å®æ ã®é転æ¡ä»¶ã®èšè¿°ã 4) ççºç°å¢ã§ã®äœ¿çšãäºæž¬ãããå Žåã¯ããã®ããã®å¿ èŠãªæ å ±ã®èšè¿°ã 5) æ©æ¢°ã®äœ¿çšã«é¢ããèšè¿°ãšããŠïŒ 5.1) 䜿çšãä¿å®ç¹æ€ã«èŠããäœæ¥ã¹ããŒã¹ã瀺ãã 5.2) 枩床,湿床,æ¯å,é»ç£æŸå°,䜿çšé«åºŠå¶éãªã©äœ¿çšç°å¢ã«é¢ããèšè¿°ããã®ä»ã黿°ããšã¢ãŒãªã© ã®ãšãã«ã®ãŒæºã«èŠæ±ãããæ¡ä»¶(宿 Œ)ã®è¡šç€ºã 5.3) ååãžã®æ¥ç¶æ¹æ³ã®èšè¿°ãç¹ã«é»æ°ã®éè² è·ã«é¢ããŠãççµ¡é»æµå®æ Œã®è¡šç€ºããéè² è·ä¿è·è£ 眮ã®å®æ Œãåãä»ãæ¹ãªã©ã«é¢ããæ å ±ã 5.4) ãã¿ã®é€å»å»æ£ã«é¢ããèšè¿°ãå¿ èŠãããã°ããã®åŠçæ¹æ³ãªã©ãèšè¿°ããã 5.5) äœæ¥è ãåãã¹ãä¿è·è£ 眮ãå®å šè·é¢ãå®å šè¡šç€ºãªã©ã®ä¿è·ææ®µã«é¢ããèšè¿°ã 6) æ©æ¢°ãã®ãã®ã«é¢ããèšè¿°ãšããŠïŒ 6.1) èšçœ®æ¹æ³,ä¿è·æµãªã©ã®æ¡ä»¶ãã¢ã³ã«ãŒããããããã¯ãã®èšçœ®æ¹æ³ãä¿è·æµã®å¯žæ³ã圢ç¶ã»æ æãªã©ã 6.2) å¿ èŠãªå®å šè£ 眮ã®èšè¿°ãå®å šããããã©ã€ãã«ãŒãã³ãã€ã³ã¿ãŒããã¯ã¹ã€ãããªã©ã®ã€ãªã 蟌ã¿ãäžæµïœ¥äžæµã®æ©æ¢°ãšã®é£æºã®ããæ¹ãªã©ã 6.3) å®å šåè·¯ã®èšè¿°ãä»ã®åè·¯å³ãšã¯å¥ã«ãå®å šåè·¯ãããããåœè©²æ©æ¢°ã®å®å šåè·¯ã®ã¿ãªããã 飿ºããæ©æ¢°ãšã®ã€ã³ã¿ãŒãã§ãŒã¹ãæèšããã 6.4) éšé³æ¯åã®ããŒã¿ãæ¯åã«é¢ããŠããã®å€ãšãæž¬å®æ¡ä»¶ãæèšããã 6.5) 䜿çšããã¬ã¹ïœ¥èžæ°ãªã©ã®æ å ±ãè£ çœ®å ã«çºçããã¬ã¹ãèžæ°ãåãªã©ãèšèŒããã 7) æ©æ¢°ã®äœ¿çšã«é¢ããèšè¿°ãšããŠïŒ 7.1) ããã¥ã¢ã«å¶åŸ¡ã«é¢ããèšè¿°ãäœæ¥è ãè¡ãå¶åŸ¡ã«é¢ããŠèšè¿°ãããéåžžäœæ¥ã®ã¿ãªããã調 æŽããç¹æ€ãªã©ãå«ãã 7.2) èª¿æŽæ¹æ³ãå¿ èŠãªèª¿æŽã®èª¬æãèª¿æŽæ¹æ³ã調æŽå€ã調æŽç®æã調æŽé »åºŠãªã©ãèšè¿°ã®ããšã 7.3) éåžžåæ¢ã«é¢ããèšè¿°ãéåžžäºæ ãžã®å¯ŸåŠæ¹æ³ãéåžžæã«ããã人å(ãããã¯åå)ã«ããæ© 械ã®åããæ¹ã被害è ã®æåºæ¹æ³ãªã©ã 7.4) ä¿®çã«é¢ããèšè¿°ãåè§£ãä¿®çãçµã¿ç«ãŠã調æŽã®æ¹æ³ãè£ä¿®éšåã®åçªãéžæã®åºæºãå ¥æ æ¹æ³ãªã©ã 7.5) ä¿®çåŸã®åèµ·åãåéšåäœç¢ºèªãæ©èœç¢ºèªãåæåã®æ¹æ³ãé åºãªã©ã®èšè¿°ã 7.6) å®å šçšå ·ã®æç€ºãšäœ¿ç𿹿³ãå¿ èŠãªäººäœä¿è·å ·(ãã«ã¡ããããŽãŒã°ã«ãæè¢ãªã©)ã®éžæã«å¿ èŠãªæ å ±ïŒèŠæ±ãããç¹æ§ãªã©ïŒããã³ãããã䜿çšããæšã®æç€ºãšãã®äœ¿ç𿹿³ã®èšè¿°ã 7.7) ç¹æ€æŽåã«é¢ããèšè¿°ãé »åºŠãè£ä¿®éšåã»ææãäœæ¥å 容ãªã©ãèšè¿°ã 7.8) ç¹æ€æŽåã«å¿ èŠãªå³é¢ãªã©ãçšæããããšã 7.9) åè§£å»æ£ã«é¢ããèšè¿°ãåè§£æ¹æ³ãåè§£æã®å±éºæ§ãç¹ã«ãæ®çã¬ã¹ãååŠç©è³ªãªã©ã®å±éºæ§ ãšãã®åŠçæ¹æ³ã®èšè¿°ã 7.10) éåžžäºæ ã«åœãã£ãŠäœ¿çšããæ¶ç«åšã®çš®å¥ãçºçãäºæž¬ãããæå®³ç©è³ªã«é¢ããèŠåãšå¯ŸåŠæ¹ æ³ãäœæ¥ã«ããçºçãäºæž¬ãããã¬ã¹ãååŠç©è³ªãåãªã©ã®å±éºæ§ã®èšè¿°ã被害ã®é²æ¢çã被 害ãžã®å¯ŸåŠæ¹æ³ãªã©ãèšè¿°ã - 32 - 386 7.2 äœé»å§æä»€ æè¡ææžã«é¢ããé ã§è¿°ã¹ãããã«ãããã¥ã¢ã«(åæ±èª¬ææž)ã®ç¬¬äžç®çã¯ãèšèšã«ããæé€ã§ã㪠ãã£ãå±éºã«é¢ããèšè¿°ãè¡ãããšã«ãã補åãå®å šã«äœ¿çšãããšããã«ãããããªãã¡ãæ®çå± éºã®äŒéã§ãããåœç¶ãªãããèªã¿æããã®ã§ãªããŠã¯ãªããªãã ãã©ããªäººã䜿ãã®ãïŒããèæ ® ããããã«èŠåã£ã衚çŸãæ±ããããããŸããèªã人ã«ãšã£ãŠïœ¢å€åœèªïœ£ã§æžãããããã¥ã¢ã«ã¯äžé© åã§ããã䜿çšããèšèªã¯ã補åã䜿çšãããåœã®å ¬çšèªãèŠæ±ãããã 補åãå®å šã«äœ¿ãããã«ã¯ãæå³ãã䜿çšïœ£ãäœã§ããããèšè¿°ããããšã¯åœç¶ã®ããšã§ãããæå³ ãã䜿çšã«é¢ããŠã¯ã倧ããåããŠãçµã¿ç«ãŠåè§£ã«é¢ããããšã䜿çšéå§åã«é¢ããããšã䜿çšã« é¢ããããšãæå ¥ããå®æç¹æ€ã«é¢ããããšããããŠå»æ£ã«é¢ããããšãªã© 補åã®ã©ã€ããµã€ã¯ã« ãèæ ®ãæŒããªãèšèŒããå¿ èŠãããããŸããïœ¢äºæž¬å¯èœãªèª€äœ¿çšïœ£ã«ããå±éºåé¿ã®å¿ èŠæ§ãããæ£ ããäœ¿çšæ¹æ³ãèšè¿°ããªã¹ã¯ãå ãããšåæã«ïœ¢èª€äœ¿çšïœ£ãïœ¢çŠæ¢è¡çºïœ£ãªã©ãå¿ èŠã«å¿ãèšè¿°ããã æå³ãã䜿çšã®èª¬æãšããŠã¯ãå®å šã«äœ¿çšããããã®æ³šæäºé ã補åã®æäœæ¹æ³ãç¹æ€ïœ¥æå ¥ãã®æ¹ æ³ãæ éçºèŠæ¹æ³ãªã©ãããããããã®èšè¿°ã¯ãæäœã®æµãã«æ²¿ã£ãŠãïœ¢äœæ ïŒïœ£ãã©ãããŠïŒããšã ã£ã質åãåæã«ããèšè¿°ãè¡ããããããããäœæãããæäœèª¬æã¯ã§ããã ãåçŽæå¿«ã«èšè¿°ãã 䜿çšããåäœããããã¯åéšã®åŒã³åãªã©ã¯çµ±äžããããå®å šã«é¢ãã説æãèŠåãªã©ã¯æåã®è²ã 倧ãã圢ãå€ããããšã«ãã匷調ããã説ææã ãã§ãªããçµµãå³è¡šã«ããçè§£ã®ä¿é²ãèéããã ã¹ãã§ããããã補åãè€éã§ãå€ãã®æžé¡ãããªãå Žåã¯ããããã®çžäºé¢é£ãåããããã«ãã å¿ èŠããããåããã¥ã¢ã«ãæžé¡ã«ã¯èå¥çªå·ãã€ãããªã©ããŠèª€è§£ãçããªãããã«ããå¿ èŠãã ãã è£œåæ¬äœãžã®è¡šç€ºãèŠæ±ããã補é è é¢é£æ å ±ã補åã®åçªã補åã®é»æ°å®æ Œãªã©è£œåã«ããããæ å ±ã¯ãããã¥ã¢ã«ã§ãéè€ãããããšããå§ãããã ããã«ãå£ã»å€©äºïœ¥åºãªã©ãžã®åãä»ããå¿ èŠãšãã補åã«é¢ããŠã¯ããã®èšçœ®æ¹æ³ã®è©³ãã説æã å¿ èŠãšãªããèšçœ®æã«é»æºã³ãŒããã€ãªããã補åã®å Žåã¯ãå¿ èŠã«å¿ãé黿µä¿è·ã®èšçœ®æ¹æ³ãé» æºã³ãŒãã®éžæã«é¢ããŠã説æãèŠããããã®ä»ã補åã®æå ¥ãïœ¥ç¹æ€ãªã©ã«å¿ èŠãªã¹ããŒã¹ã®èšè¿° ããæŸç±ãªã©ã«å¿ èŠãªææ°ã®ããã®ç©ºéãéå£ã®å€§ãããªã©ã®èšè¿°ãå¿ èŠãšãªãã åœéèŠæ Œã§ã¯é»æºã³ãŒãã®äº€æã«é¢ããèšè¿°ãèŠæ±ããŠãããããã¯ã黿ºã³ãŒãã®äº€æãåæãšã ãŠèããŠããããã§ã黿ºã³ãŒãã®æ¥ç¶æ¹æ³ã®çš®é¡ã«ãããããã«èŠåã£ãäº€ææ¹æ³ã®èª¬æããã㥠ã¢ã«ãžèšè¿°ããªããã°ãªããªãããã¡ããããŠãŒã¶ãŒã«ãã亀æãå§ããã®ã§ã¯ãªãããµãŒãã¹ã¹ã ãŒã·ã§ã³ãžé£çµ¡ãããšãã亀æäžèœãªã®ã§è£œåã廿£ãããšããã£ãå 容ã«ãªãã ç¹æ®ãªç°å¢ã§äœ¿çšããã黿°è£œåã®å Žåã¯ããã®äœ¿çšç°å¢ãéèŠãªèšè¿°äºé ã«ãªãã®ã§ã䜿çšãšä¿ç®¡ ã®ããã®æž©åºŠã»æ¹¿åºŠã»é«åºŠãªã©å¿ èŠãªæ¡ä»¶ãèšè¿°ããããŸããæ¶²äœãæ°äœã䜿çšããè£ çœ®ã§ã¯ããã ã®åãæ±ãæ¹ãªã©ã®èª¬æãå¿ èŠã«ãªããæè¿ã§ã¯ãã¬ãŒã¶ãŒã玫å€ç·ã䜿ã£ã補åã®å€ãããã®ã§ã - 33 - 387 ãããããã®ä¿è·ã«é¢ããèšè¿°ãå¿ èŠã«ãªãã äžèšã®ããšãèãããšããªã¹ã¯ã¢ã»ã¹ã¡ã³ããããã«éèŠã§ããããèªèã§ããã䜿çšïœ¥ä¿ç®¡æ¡ä»¶ã æªãããã«èµ·ãããããããªãå±éºã®é²æ¢ã詊çšããæ°äœãæ¶²äœã«ããèµ·ãããããããªãå±éºã®é² æ¢ãã¬ãŒã¶ãŒã玫å€ç·ã«ããå±éºã®é²æ¢ãªã©ãåé ã§è¿°ã¹ãããã«ãæ®çå±éºã®äŒéãè¡ãããšã èŠæ±ãããããã§ããããã®ããããªã¹ã¯ã¢ã»ã¹ã¡ã³ãããã£ãããšè¡ãã補åã«(é¡åšã»æœåšäž¡æ¹ ãå«ã¿)ååšããå±éº(æº)ãçºèŠãããã®å±éºæ§ããŠãŒã¶ãŒãžé£çµ¡ããããšã«ãããäºæ ãé²ãå¿ èŠã ããããšãèªèããã ãããã 7.3 EMC æä»€ 2004/108/EC ã¯ãæ©åšãšãšãã«ä»¥äžã®æ å ±ãæäŸããããšãæ±ããŠããããããã®å€ã㯠89/336/EEC ã§ ã¯æç€ºçã«ã¯èŠæ±ãããŠããªãã£ããã89/336/EEC ãé©çšããå Žåããåæ§ã®æ å ±ãæäŸããããšãæš å¥šããã ⢠ãã®æ©åšãç¹å®ããããã®æ å ± (ååŒããããçªå·ã補é çªå·ãªã©) â¢ è£œé æ¥è ã®ååãåã³äœæ â¢ è£œé æ¥è ã EU å ã«ãªãå Žåã«ã¯ãEU å ã®ä»»åœããã代ç人ã®ååãåã³äœæ ⢠ä¿è·èŠæ±ãžã®é©åã確ããšããããã«å¿ èŠãªããã®æ©åšã®çµã¿ç«ãŠãèšçœ®ãä¿å®ããããã¯äœ¿çšã«é ããŠã®æ³šæäºé ãäŸãã°ãå°éå®¶ã«ããèšçœ®ãæ©åšãžã®çµã¿èŸŒã¿ãæå³ããæ©åšã«ãããã䜿çšãæ å³ããŠããé»ç£ç°å¢ (ç¹ã«ãã·ãŒã«ãã»ã«ãŒã ãªã©ã®ç¹æ®ãªé»ç£ç°å¢ã§ã®äœ¿çšãæå³ããŠããå Žå)ã äŸçµŠé»æºã®å質 (æªã¿ãé»å§å€åããµãŒãžãªã©)ãæ©åšã®æ¥å°ã®æ¹æ³ã䜿çšãã¹ãã±ãŒãã«ã®çš®é¡ãã· ãŒã«ãã®åŠçæ¹æ³ãã±ãŒãã«ã®åŒãåãã®æ¹æ³ãå€éšã«åãä»ããã¹ããã£ã«ã¿ã®æå®ãªã©ã ⢠ãã®æ©åšãäœå® å°ã§ã®äœ¿çšã«é©ããªãå Žåã«ã¯ãæç¢ºãªäœ¿çšäžã®å¶é ⢠ãã®æ©åšãæå³ãããããã«äœ¿ãããã«å¿ èŠãªæ å ± ãããã®æ å ±ãèšèŒããå Žæãäžèšã«ç€ºãã èŠæ Œã«ãã£ãŠã¯ãã®ä»ã®æ å ±ã®æç€ºãèŠæ±ãããŠããããšãããããã®ãããªèŠæ Œãé©çšããå Žåã«ã¯ã ã®èŠæ±ã«ãåŸãå¿ èŠããããäŸãã°ã補åçŸ€èŠæ Œã®ïŒã€ã§ãã EN 55011ã¯ãæ©åšã«ãã®ã°ã«ãŒããšã¯ã© ã¹ã衚瀺ããããšãèŠæ±ããŠããã - 34 - 388 ãŸããäºæãããå¹²æžãåããéã®æ§èœã®äœäžã蚱容ããã®ã§ããã°ããã®æ§èœã®äœäžã«é¢ããŠãæèšã ã¹ãã§ãããå¹²æžãåããéã®æ§èœããŠãŒã¶ãŒãæåŸ ããã§ãããæ§èœãäžåãããã€ãã®ãããªæ§èœã® äœäžã«é¢ããæ å ±ã瀺ãããŠããªããªãã°ããã®æ©åšã¯æä»€ã®ä¿è·èŠæ±ã«é©åããŠããªããšèããããã 7.4 å»çæ©åšæä»€ ä»å±æžïŒïŒAnnex IïŒã«ç€ºãããåºæ¬èŠä»¶ã® 13 é ã«ãè£œé æ¥è ãäŸçµŠããæ å ±ã«é¢ãã詳现ã®èŠæ±äºé ã ãããè£œé æ¥è ã¯ãåé ç®ã®èŠæ±ã«åŸã£ãŠæ©åšã®è¡šç€ºãåæ±èª¬ææžãªã©ãäœæããå¿ èŠãããã 7.5 RïŒTTE æä»€ R&TTEæä»€ã®äžã«ã¯ãããã¥ã¢ã«ãåæ±èª¬ææžäœæã«ã€ããŠãç¹å¥ã®èšèŒã¯ãªãã 7.6 ç©å ·æä»€ æä»€ã«ã¯æ Œå¥åæ±èª¬ææžã«é¢ããèšèŒã¯ãªããããã¯ãåäŸã䜿ããšãã£ãç©å ·ã®æ§æ Œã«ãããã®ã§ ãããããããããã±ãŒãžãžã®è¡šç€ºããæ¬äœãžã®èŠåæè¡šç€ºãªã©èŠªã«ããããæ®çå±éºã®äŒé衚瀺 ãå€ãèŠå®ãããŠããããšã¯ãããèŠæ±ãçç¡ãªããã§ã¯ãªããããšãã°ãçµã¿ç«ãŠã«ããå±éºãç ããå¯èœæ§ãèããããå Žåãªã©ã¯ãçµã¿ç«ãŠæ¹æ³ã®èª¬æãèŠæ±ãããããã©ã³ã³ãªã©ã®ããã«çŽãª ã©ã䜿ãå Žåã¯ããã®åºå®æ¹æ³ãç¹æ€æ¹æ³ã¯éèŠäºé ã§ãããèª¬ææžãžã®èšèŒãå¿ èŠã§ããã ããã¥ã¢ã«ã¯ãåœç¶ãªããèªã¿æãåããæããã®ã§ãªããŠã¯ãªããªãããããã芪ãèªãããšãäº æž¬ãããã®ã§ãããã«èŠåã£ã衚çŸãæ±ãããããã€ã©ã¹ãã®äœ¿çšãã倧ããªæŽ»åãè²ã®äœ¿çšã«ãã éèŠäºé ãç®ç«ããããããªå·¥å€«ãå¿ èŠã§ãããããŸããèªã人ã«ãšã£ãŠïœ¢å€åœèªïœ£ã§æžããããã㥠ã¢ã«ã¯äžé©åã§ããã䜿çšããèšèªã¯ãç©å ·ã䜿çšãããåœã®å ¬çšèªãèŠæ±ãããã ïœ¢äºæž¬å¯èœãªèª€äœ¿çšïœ£ã«ããå±éºåé¿ã®å¿ èŠæ§ãããæ£ããäœ¿çšæ¹æ³ãèšè¿°ããªã¹ã¯ãå ãããšåæã« 誀䜿çšïœ£ãïœ¢çŠæ¢è¡çºïœ£ãªã©ãå¿ èŠã«å¿ãèšè¿°ãããããšãã°ãæµ®ã茪ãªã©ãžã®ãæåœå ·ãšããŠã®äœ¿çš ã®çŠæ¢ããããã«çžåœããããããã¯ãå€ãã®å Žåãæ¬äœè¡šç€ºãšããŠèŠæ±ãããããããã¥ã¢ã«ãå åšããå Žåã«ã¯ããã®è¡šç€ºãå¿ èŠãšãªãã æ¬äœããããã±ãŒãž(åè£ ç®±ãå±ç€ºç®±ãªã©)ã«å¯ŸããŠã衚瀺ãèŠæ±ããããCE ããŒãã³ã°ã®è¡šç€ºã¯ã ã¡ããã補é è ãèŒžå ¥æ¥è ã®ç¹å®ã®ããã«ãã®åç§°ãããŽããã©ã³ãããŒã¯ãäœæãé£çµ¡å ãªã©ãå¿ èŠãšãªãããã¡ãããåè¿°ã®èŠåæãªã©ãå¿ é ã§ããã ç©å ·ç¹æã®è¡šç€ºãšããŠã¯ã察象幎霢ããããããã±ãŒãžãæ¬äœãžã®è¡šç€ºãéèŠã§ããããè©Šéšæ©é¢ã« ãšã£ãŠãã察象幎霢ã«ããèŠå®ãããå€æåºæºãç°ãªãã®ã§ãéåžžã«éèŠãªé ç®ã§ãããèšèšæã«å¯Ÿ è±¡å¹Žéœ¢ãæ±ºå®ããããã®åŸã®å€æŽã«å¯ŸããŠã¯èŠæ³šæã§ããã - 35 - 389 é©åå®£èšæžã®äœææ¹æ³ 8. â¢ è£œé æ¥è ãŸãã¯EUå ã«èšç«ãããæ£åŒä»£è¡šè ã¯ããã¥ãŒã¢ãããŒãæä»€ãå®ããé©åæ§è©äŸ¡æ ç¶ãã®äžéšãšããŠãé©åå®£èšæžãäœæããªããã°ãªããªãã ⢠é©åå®£èšæžã«ã¯ãè£œé æ¥è ãæ£åŒä»£è¡šè ãããŒãã£ãã¡ã€ãããã£ïŒè©²åœããå ŽåïŒã補åãæŽ åèŠæ Œãã®ä»ã®èŠç¯ææžãžã®åç §ïŒå¿ èŠã«å¿ããŠïŒã«å ãã宣èšçºè¡ã®åºãšãªãæä»€ãèå¥ãã ããã®é¢é£æ å ±ããã¹ãŠèšèŒãããªããã°ãªããªãã é©åå®£èšæž(Declaration of Conformity: DoC)ã¯ããã®æ©åšãæä»€ã®èŠæ±ã«é©åããæšããè£œé æ¥è (ã ããã¯ãã®ä»»åœããã代ç人) ã宣èšããææžã§ããã以äžã®æ å ±ãå«ããªããã°ãªããªãã ⢠é©åã宣èšããæä»€ã®ãªã¹ã ⢠宣èšã®å¯Ÿè±¡ãšãªãæ©åšãåå®ãããåç§°ãååŒã補é çªå·ãªã©ã®æ å ± ⢠æŽåèŠæ Œãé©çšããå Žåã«ã¯ããã®ãªã¹ã(èŠæ Œã®åç §ã«ã¯ã幎åã³Amendmentãå«ãã) â¢ è£œé æ¥è ã®ååãšäœæ ⢠該åœããå ŽåãEUå ã®ä»£ç人ã®ååãšäœæ ⢠ããŒãã£ãã¡ã€ãããã£ã®ååãšäœæ ⢠宣èšã®æ¥ä» ⢠é©åå®£èšæžã«çœ²åãã人ã«é¢ããæ å ±(æå±ãè©æžãªã©) ⢠é©åãªæš©éãæã€å人ã«ãã眲å é©åå®£èšæžã¯EUã®å ¬çšèªã®ããããã§äœæãããªããã°ãªããªããé©åå®£èšæžæ·»ä»ãå¿ é ã®è£œåã« ã€ããŠã¯ãå®£èšæžã¯äœ¿çšãããå çåœã®å ¬çšèªã§èšèŒãããªããã°ãªããªãããããã¯è£œé æ¥è ãæ£ åŒä»£è¡šè ããŸãã¯æµéæ¥è ã翻蚳ãæäŸããªããã°ãªããªããé©åå®£èšæžã®å ·äœçãªæžåŒã¯èŠå®ã¯ãª ãããåèãŸã§ã«ãµã³ãã«ã玹ä»ããã é©åå®£èšæžãæè¡ææžãšåæ§ãæ©åšã®åºè·ããäžå®æéä¿ç®¡ããªããã°ãªããªããåæä»€ã«ãã£ãŠã ä¿ç®¡æéãä¿ç®¡å Žæã«ã€ããŠã¯ãããããã®æä»€ã«ãã£ãŠæ±ããç°ãªããã (1) æä»€ããšã®æ±ããèšèŒããäžèŠ§è¡šãçšæãã (2) EUåå ã§10幎éä¿ç®¡ããããšãæšå¥šããããããã®æä»€ãåç §ããã æ©æ¢°æä»€ã®å Žåã補åã䜿çšãããå çåœã®èšèªã«èš³ãããã®ã補åã«æ·»ä»ããå¿ èŠãããããã®ä»ã®EU æä»€ã®å Žåãé©åå®£èšæžãé¡§å®¢ã«æäŸããããšã¯çŸ©åä»ããããŠããªãããå€ãã®è£œé æ¥è ã¯ãé©å å®£èšæžã®ã³ããŒãæ©åšã«æ·»ä»ããŠããã(äŸãã°ãåæ±èª¬ææžã«å«ãã) - 36 - 390 é©åå®£èšæžã®ãµã³ãã« - 37 - 391 9 CE ããŒãã³ã°ã®è²Œä» æ©åšãæä»€ã®èŠæ±ã«é©åããŠããããšã瀺ãããã®æ¹æ³ãšããŠãCEããŒãã³ã°è²Œä»ãèŠå®ããŠããã ãããŠãæä»€ã®èŠæ±ãžã®é©åæ§ãéæãããªãã°ãæçµçã«ãæ©åšã«CEããŒãã³ã°ã貌ä»ããããš ã«ãã£ãŠããã®æ©åšãEUå ã§èªç±ã«æµéã§ãããCEããŒãã³ã°ã¯ãèªèšŒããŒã¯ã®ããã«å€éšã®æ©é¢ ããååŸãããã®ã§ãªããæä»€ã®èŠæ±ã«é©åããŠãããšãã宣èšã®èšŒãšããŠãè£œé æ¥è ãèªãã®è²¬ä»» ã®å ã«æ©åšã«è²Œä»ããã CEããŒãã³ã°ã®è²Œä» CEããŒãã³ã°ã¯ãååãšããŠãã®æ©åšèªèº«ã«è²Œä»ãããäœããæ©åšã«ä»ããããšãäžå¯èœãªå Žå(äŸ ãã°ããããå°ãéããããã«) ã«ã¯ããã®å è£ ãæ·»ä»ææžã«ä»ããããšãèªããããã CEããŒãã³ã°ã¯ãé«ãã5mm以äžã§ããããã€ãã®åœ¢ç¶ã®æ¯çãä¿ãããŠããéãã¯ãä»»æã«æ¡å€§ /çž®å°ããããšãã§ããããã®ããŒãã³ã°ã¯ã容æã«èŠãããšãã§ãããã€å®¹æã«å¥ããããæ¶ãã ãããªããããªæ¹æ³ã§è¡ãªãå¿ èŠãããã CEããŒãã³ã°ã¯ããã®æ©åšã«é©çšããããCEããŒãã³ã°ã®è²Œä»ãèŠå®ããŠããå šãŠã®æä»€ãžã®é©å ã瀺ããã®ãšãªããäŸãã°ããã®æ©åšãäœé»å§æä»€ãæ©æ¢°æä»€ã®å¯Ÿè±¡ã«ããªãå Žåããã®æ©åšã«EMC æä»€ãžã®é©åã®ã¿ã«åºã¥ããŠCEããŒãã³ã°ãä»ããããšã¯èªããããªãã - 38 - 392 åèæ å ±ïŒæ¬§å·å§å¡äŒãµã€ã ãã¥ãŒã¢ãããŒãæä»€ http://www.newapproach.org/ http://www.newapproach.org/ProductFamilies/Default.asp âæŽåèŠæ Œææ°æ å ±æ²èŒãµã€ã The New Approach to technical harmonisation and standardisation - Harmonised Standards http://europa.eu.int/comm/enterprise/newapproach/standardization/harmstds/index_en.html âèœåååã蟌ã¿å»çæ©åšæä»€-æŽåèŠæ Œãªã¹ã Active Implantable Medical Devices Directive 90/385/EEC http://europa.eu.int/comm/enterprise/newapproach/standardization/harmstds/reflist/implmedd.html âEMC æä»€-æŽåèŠæ Œãªã¹ã EMC Directive 89/336/EEC http://europa.eu.int/comm/enterprise/electr_equipment/emc/index.htm http://europa.eu.int/comm/enterprise/newapproach/standardization/harmstds/reflist/emc.html âIVD æä»€ In vitro diagnostic medical devices Directive 98/79/EC http://europa.eu.int/comm/enterprise/newapproach/standardization/harmstds/reflist/invimedd.html âäœé»å§æä»€-æŽåèŠæ Œãªã¹ã Low Voltage Directive http://europa.eu.int/comm/enterprise/electr_equipment/lv/index.htm http://europa.eu.int/comm/enterprise/newapproach/standardization/ harmstds/reflist/lvd.html âæ©æ¢°æä»€-æŽåèŠæ Œãªã¹ã Machinery Directive 98/37/EC http://europa.eu.int/comm/enterprise/mechan_equipment/machinery/index.htm http://europa.eu.int/comm/enterprise/newapproach/standardization/harmstds/reflist/machines.html âR&TTE æä»€ Radio and Telecommunications Terminal Equipment R&TTE Directive 1999/5/EC http://europa.eu.int/comm/enterprise/newapproach/standardization/harmstds/reflist/radiotte.html âå»çæ©åšæä»€-æŽåèŠæ Œãªã¹ã Medical Devise Directive 93/42/EEC http://europa.eu.int/comm/enterprise/medical_devices/index.htm http://europa.eu.int/comm/enterprise/newapproach/standardization/harmstds/reflist/meddevic.html âç©å ·æä»€ http://europa.eu.int/comm/enterprise/toys/index_en.htm - 39 - 393 é¡åïŒ èªå·±å®£èšã®ããã® CE ããŒãã³ã°é©å察çå®åã¬ã€ããã㯠èè ïŒ ãã¥ããžã£ãã³æ ªåŒäŒç€Ÿ çºè¡ïŒ 2005 幎 3 æ çºè¡æïŒ æ¥æ¬è²¿ææ¯èæ©æ§(ãžã§ãã) 貿ææè³çžè«ã»ã³ã¿ãŒ 貿ææè³çžè«èª² ã107-6006 æ±äº¬éœæž¯åºèµ€å 1-12-32 TELïŒ(03)3582-6270 äžèš±è€è£œã»çŠç¡æè»¢èŒ - 40 - 394